,study_id,title,type,enrollment_category,enrollment_subcategory,enrollment_value,category,category,group,group_description,value
0,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,milestone,milestone,P1,Placebo,521
1,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,milestone,milestone,P2,Remdesivir,541
2,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,milestone,milestone,P1,Placebo,517
3,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,milestone,milestone,P2,Remdesivir,531
4,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,milestone,milestone,P1,Placebo,508
5,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,milestone,milestone,P2,Remdesivir,517
6,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,milestone,milestone,P1,Placebo,13
7,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,milestone,milestone,P2,Remdesivir,24
8,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Placebo,4
9,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Remdesivir,10
10,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Placebo,1
11,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Remdesivir,0
12,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Placebo,7
13,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Remdesivir,9
14,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Placebo,0
15,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Remdesivir,4
16,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Placebo,1
17,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Remdesivir,1
18,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,age,age,B1,Placebo,0
19,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,age,age,B2,Remdesivir,0
20,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,age,age,B3,Total,0
21,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,age,age,B1,Placebo,324
22,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,age,age,B2,Remdesivir,354
23,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,age,age,B3,Total,678
24,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,age,age,B1,Placebo,197
25,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,age,age,B2,Remdesivir,187
26,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,age,age,B3,Total,384
27,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Placebo,189
28,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Remdesivir,189
29,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,378
30,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Placebo,332
31,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Remdesivir,352
32,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,684
33,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,116
34,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,134
35,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,250
36,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,373
37,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,382
38,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,755
39,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,32
40,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,25
41,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,57
42,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Placebo,3
43,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Remdesivir,4
44,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,7
45,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Placebo,56
46,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Remdesivir,79
47,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,135
48,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Placebo,2
49,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Remdesivir,2
50,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,4
51,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Placebo,117
52,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Remdesivir,109
53,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,226
54,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Placebo,287
55,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Remdesivir,279
56,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,566
57,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Placebo,1
58,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Remdesivir,2
59,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,3
60,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Placebo,55
61,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Remdesivir,66
62,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,121
63,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Placebo,19
64,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Remdesivir,14
65,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Total,33
66,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Placebo,12
67,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Remdesivir,9
68,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Total,21
69,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Placebo,7
70,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Remdesivir,9
71,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Total,16
72,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Placebo,410
73,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Remdesivir,427
74,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Total,837
75,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Placebo,7
76,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Remdesivir,8
77,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Total,15
78,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Placebo,21
79,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Remdesivir,22
80,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Total,43
81,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Placebo,6
82,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Remdesivir,4
83,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Total,10
84,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Placebo,21
85,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Remdesivir,25
86,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Total,46
87,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Placebo,6
88,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Remdesivir,7
89,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Total,13
90,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Placebo,12
91,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Remdesivir,16
92,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Total,28
93,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,Disease severity,Disease severity,B1,Placebo,50
94,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,Disease severity,Disease severity,B2,Remdesivir,55
95,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,Disease severity,Disease severity,B3,Total,105
96,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,Disease severity,Disease severity,B1,Placebo,471
97,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,Disease severity,Disease severity,B2,Remdesivir,486
98,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,gender,All,Disease severity,Disease severity,B3,Total,957
99,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Placebo,521
100,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Remdesivir,541
101,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Placebo,517
102,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Remdesivir,531
103,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Placebo,508
104,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Remdesivir,517
105,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Placebo,13
106,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Remdesivir,24
107,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Placebo,4
108,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Remdesivir,10
109,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Placebo,1
110,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Remdesivir,0
111,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Placebo,7
112,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Remdesivir,9
113,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Placebo,0
114,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Remdesivir,4
115,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Placebo,1
116,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Remdesivir,1
117,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,age,age,B1,Placebo,0
118,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,age,age,B2,Remdesivir,0
119,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,age,age,B3,Total,0
120,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,age,age,B1,Placebo,324
121,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,age,age,B2,Remdesivir,354
122,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,age,age,B3,Total,678
123,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,age,age,B1,Placebo,197
124,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,age,age,B2,Remdesivir,187
125,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,age,age,B3,Total,384
126,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Placebo,189
127,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Remdesivir,189
128,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,378
129,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Placebo,332
130,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Remdesivir,352
131,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,684
132,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,116
133,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,134
134,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,250
135,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,373
136,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,382
137,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,755
138,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,32
139,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,25
140,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,57
141,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Placebo,3
142,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Remdesivir,4
143,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,7
144,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Placebo,56
145,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Remdesivir,79
146,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,135
147,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Placebo,2
148,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Remdesivir,2
149,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,4
150,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Placebo,117
151,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Remdesivir,109
152,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,226
153,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Placebo,287
154,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Remdesivir,279
155,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,566
156,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Placebo,1
157,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Remdesivir,2
158,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,3
159,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Placebo,55
160,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Remdesivir,66
161,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,121
162,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,Placebo,19
163,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B2,Remdesivir,14
164,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B3,Total,33
165,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,Placebo,12
166,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B2,Remdesivir,9
167,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B3,Total,21
168,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,Placebo,7
169,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B2,Remdesivir,9
170,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B3,Total,16
171,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,Placebo,410
172,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B2,Remdesivir,427
173,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B3,Total,837
174,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,Placebo,7
175,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B2,Remdesivir,8
176,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B3,Total,15
177,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,Placebo,21
178,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B2,Remdesivir,22
179,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B3,Total,43
180,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,Placebo,6
181,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B2,Remdesivir,4
182,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B3,Total,10
183,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,Placebo,21
184,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B2,Remdesivir,25
185,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B3,Total,46
186,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,Placebo,6
187,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B2,Remdesivir,7
188,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B3,Total,13
189,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,Placebo,12
190,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B2,Remdesivir,16
191,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B3,Total,28
192,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,Disease severity,Disease severity,B1,Placebo,50
193,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,Disease severity,Disease severity,B2,Remdesivir,55
194,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,Disease severity,Disease severity,B3,Total,105
195,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,Disease severity,Disease severity,B1,Placebo,471
196,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,Disease severity,Disease severity,B2,Remdesivir,486
197,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,minimum_age,18 Years,Disease severity,Disease severity,B3,Total,957
198,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,milestone,milestone,P1,Placebo,521
199,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,milestone,milestone,P2,Remdesivir,541
200,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,milestone,milestone,P1,Placebo,517
201,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,milestone,milestone,P2,Remdesivir,531
202,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,milestone,milestone,P1,Placebo,508
203,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,milestone,milestone,P2,Remdesivir,517
204,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,milestone,milestone,P1,Placebo,13
205,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,milestone,milestone,P2,Remdesivir,24
206,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,withdrawal reason,withdrawal reason,P1,Placebo,4
207,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,withdrawal reason,withdrawal reason,P2,Remdesivir,10
208,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,withdrawal reason,withdrawal reason,P1,Placebo,1
209,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,withdrawal reason,withdrawal reason,P2,Remdesivir,0
210,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,withdrawal reason,withdrawal reason,P1,Placebo,7
211,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,withdrawal reason,withdrawal reason,P2,Remdesivir,9
212,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,withdrawal reason,withdrawal reason,P1,Placebo,0
213,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,withdrawal reason,withdrawal reason,P2,Remdesivir,4
214,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,withdrawal reason,withdrawal reason,P1,Placebo,1
215,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,withdrawal reason,withdrawal reason,P2,Remdesivir,1
216,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,age,age,B1,Placebo,0
217,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,age,age,B2,Remdesivir,0
218,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,age,age,B3,Total,0
219,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,age,age,B1,Placebo,324
220,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,age,age,B2,Remdesivir,354
221,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,age,age,B3,Total,678
222,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,age,age,B1,Placebo,197
223,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,age,age,B2,Remdesivir,187
224,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,age,age,B3,Total,384
225,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,"sex: female, male","sex: female, male",B1,Placebo,189
226,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,"sex: female, male","sex: female, male",B2,Remdesivir,189
227,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,"sex: female, male","sex: female, male",B3,Total,378
228,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,"sex: female, male","sex: female, male",B1,Placebo,332
229,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,"sex: female, male","sex: female, male",B2,Remdesivir,352
230,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,"sex: female, male","sex: female, male",B3,Total,684
231,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,116
232,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,134
233,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,250
234,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,373
235,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,382
236,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,755
237,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,32
238,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,25
239,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,57
240,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,race (nih/omb),race (nih/omb),B1,Placebo,3
241,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,race (nih/omb),race (nih/omb),B2,Remdesivir,4
242,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,race (nih/omb),race (nih/omb),B3,Total,7
243,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,race (nih/omb),race (nih/omb),B1,Placebo,56
244,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,race (nih/omb),race (nih/omb),B2,Remdesivir,79
245,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,race (nih/omb),race (nih/omb),B3,Total,135
246,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,race (nih/omb),race (nih/omb),B1,Placebo,2
247,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,race (nih/omb),race (nih/omb),B2,Remdesivir,2
248,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,race (nih/omb),race (nih/omb),B3,Total,4
249,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,race (nih/omb),race (nih/omb),B1,Placebo,117
250,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,race (nih/omb),race (nih/omb),B2,Remdesivir,109
251,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,race (nih/omb),race (nih/omb),B3,Total,226
252,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,race (nih/omb),race (nih/omb),B1,Placebo,287
253,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,race (nih/omb),race (nih/omb),B2,Remdesivir,279
254,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,race (nih/omb),race (nih/omb),B3,Total,566
255,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,race (nih/omb),race (nih/omb),B1,Placebo,1
256,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,race (nih/omb),race (nih/omb),B2,Remdesivir,2
257,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,race (nih/omb),race (nih/omb),B3,Total,3
258,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,race (nih/omb),race (nih/omb),B1,Placebo,55
259,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,race (nih/omb),race (nih/omb),B2,Remdesivir,66
260,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,race (nih/omb),race (nih/omb),B3,Total,121
261,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B1,Placebo,19
262,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B2,Remdesivir,14
263,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B3,Total,33
264,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B1,Placebo,12
265,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B2,Remdesivir,9
266,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B3,Total,21
267,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B1,Placebo,7
268,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B2,Remdesivir,9
269,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B3,Total,16
270,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B1,Placebo,410
271,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B2,Remdesivir,427
272,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B3,Total,837
273,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B1,Placebo,7
274,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B2,Remdesivir,8
275,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B3,Total,15
276,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B1,Placebo,21
277,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B2,Remdesivir,22
278,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B3,Total,43
279,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B1,Placebo,6
280,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B2,Remdesivir,4
281,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B3,Total,10
282,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B1,Placebo,21
283,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B2,Remdesivir,25
284,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B3,Total,46
285,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B1,Placebo,6
286,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B2,Remdesivir,7
287,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B3,Total,13
288,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B1,Placebo,12
289,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B2,Remdesivir,16
290,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,enrollment region,enrollment region,B3,Total,28
291,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,Disease severity,Disease severity,B1,Placebo,50
292,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,Disease severity,Disease severity,B2,Remdesivir,55
293,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,Disease severity,Disease severity,B3,Total,105
294,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,Disease severity,Disease severity,B1,Placebo,471
295,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,Disease severity,Disease severity,B2,Remdesivir,486
296,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,maximum_age,99 Years,Disease severity,Disease severity,B3,Total,957
297,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Placebo,521
298,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Remdesivir,541
299,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Placebo,517
300,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Remdesivir,531
301,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Placebo,508
302,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Remdesivir,517
303,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Placebo,13
304,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Remdesivir,24
305,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Placebo,4
306,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Remdesivir,10
307,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Placebo,1
308,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Remdesivir,0
309,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Placebo,7
310,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Remdesivir,9
311,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Placebo,0
312,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Remdesivir,4
313,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Placebo,1
314,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Remdesivir,1
315,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,age,age,B1,Placebo,0
316,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,age,age,B2,Remdesivir,0
317,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,age,age,B3,Total,0
318,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,age,age,B1,Placebo,324
319,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,age,age,B2,Remdesivir,354
320,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,age,age,B3,Total,678
321,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,age,age,B1,Placebo,197
322,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,age,age,B2,Remdesivir,187
323,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,age,age,B3,Total,384
324,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Placebo,189
325,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Remdesivir,189
326,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Total,378
327,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Placebo,332
328,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Remdesivir,352
329,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Total,684
330,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,116
331,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,134
332,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,250
333,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,373
334,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,382
335,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,755
336,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,32
337,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,25
338,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,57
339,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Placebo,3
340,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Remdesivir,4
341,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Total,7
342,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Placebo,56
343,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Remdesivir,79
344,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Total,135
345,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Placebo,2
346,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Remdesivir,2
347,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Total,4
348,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Placebo,117
349,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Remdesivir,109
350,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Total,226
351,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Placebo,287
352,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Remdesivir,279
353,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Total,566
354,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Placebo,1
355,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Remdesivir,2
356,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Total,3
357,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Placebo,55
358,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Remdesivir,66
359,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Total,121
360,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Placebo,19
361,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Remdesivir,14
362,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Total,33
363,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Placebo,12
364,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Remdesivir,9
365,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Total,21
366,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Placebo,7
367,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Remdesivir,9
368,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Total,16
369,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Placebo,410
370,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Remdesivir,427
371,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Total,837
372,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Placebo,7
373,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Remdesivir,8
374,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Total,15
375,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Placebo,21
376,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Remdesivir,22
377,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Total,43
378,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Placebo,6
379,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Remdesivir,4
380,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Total,10
381,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Placebo,21
382,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Remdesivir,25
383,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Total,46
384,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Placebo,6
385,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Remdesivir,7
386,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Total,13
387,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Placebo,12
388,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Remdesivir,16
389,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Total,28
390,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,Disease severity,Disease severity,B1,Placebo,50
391,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,Disease severity,Disease severity,B2,Remdesivir,55
392,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,Disease severity,Disease severity,B3,Total,105
393,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,Disease severity,Disease severity,B1,Placebo,471
394,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,Disease severity,Disease severity,B2,Remdesivir,486
395,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,eligibility,healthy_volunteers,No,Disease severity,Disease severity,B3,Total,957
396,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Placebo,521
397,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Remdesivir,541
398,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Placebo,517
399,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Remdesivir,531
400,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Placebo,508
401,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Remdesivir,517
402,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Placebo,13
403,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Remdesivir,24
404,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Placebo,4
405,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Remdesivir,10
406,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Placebo,1
407,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Remdesivir,0
408,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Placebo,7
409,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Remdesivir,9
410,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Placebo,0
411,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Remdesivir,4
412,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Placebo,1
413,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Remdesivir,1
414,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,age,age,B1,Placebo,0
415,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,age,age,B2,Remdesivir,0
416,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,age,age,B3,Total,0
417,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,age,age,B1,Placebo,324
418,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,age,age,B2,Remdesivir,354
419,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,age,age,B3,Total,678
420,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,age,age,B1,Placebo,197
421,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,age,age,B2,Remdesivir,187
422,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,age,age,B3,Total,384
423,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Placebo,189
424,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Remdesivir,189
425,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,378
426,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Placebo,332
427,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Remdesivir,352
428,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,684
429,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,116
430,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,134
431,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,250
432,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,373
433,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,382
434,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,755
435,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,32
436,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,25
437,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,57
438,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Placebo,3
439,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Remdesivir,4
440,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Total,7
441,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Placebo,56
442,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Remdesivir,79
443,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Total,135
444,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Placebo,2
445,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Remdesivir,2
446,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Total,4
447,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Placebo,117
448,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Remdesivir,109
449,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Total,226
450,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Placebo,287
451,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Remdesivir,279
452,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Total,566
453,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Placebo,1
454,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Remdesivir,2
455,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Total,3
456,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Placebo,55
457,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Remdesivir,66
458,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Total,121
459,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Placebo,19
460,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Remdesivir,14
461,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Total,33
462,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Placebo,12
463,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Remdesivir,9
464,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Total,21
465,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Placebo,7
466,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Remdesivir,9
467,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Total,16
468,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Placebo,410
469,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Remdesivir,427
470,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Total,837
471,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Placebo,7
472,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Remdesivir,8
473,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Total,15
474,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Placebo,21
475,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Remdesivir,22
476,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Total,43
477,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Placebo,6
478,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Remdesivir,4
479,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Total,10
480,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Placebo,21
481,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Remdesivir,25
482,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Total,46
483,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Placebo,6
484,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Remdesivir,7
485,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Total,13
486,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Placebo,12
487,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Remdesivir,16
488,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Total,28
489,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,Disease severity,Disease severity,B1,Placebo,50
490,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,Disease severity,Disease severity,B2,Remdesivir,55
491,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,Disease severity,Disease severity,B3,Total,105
492,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,Disease severity,Disease severity,B1,Placebo,471
493,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,Disease severity,Disease severity,B2,Remdesivir,486
494,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,allocation,Randomized,Disease severity,Disease severity,B3,Total,957
495,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Placebo,521
496,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Remdesivir,541
497,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Placebo,517
498,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Remdesivir,531
499,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Placebo,508
500,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Remdesivir,517
501,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Placebo,13
502,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Remdesivir,24
503,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Placebo,4
504,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Remdesivir,10
505,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Placebo,1
506,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Remdesivir,0
507,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Placebo,7
508,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Remdesivir,9
509,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Placebo,0
510,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Remdesivir,4
511,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Placebo,1
512,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Remdesivir,1
513,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B1,Placebo,0
514,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B2,Remdesivir,0
515,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B3,Total,0
516,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B1,Placebo,324
517,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B2,Remdesivir,354
518,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B3,Total,678
519,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B1,Placebo,197
520,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B2,Remdesivir,187
521,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B3,Total,384
522,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Placebo,189
523,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Remdesivir,189
524,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Total,378
525,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Placebo,332
526,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Remdesivir,352
527,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Total,684
528,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,116
529,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,134
530,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,250
531,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,373
532,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,382
533,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,755
534,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,32
535,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,25
536,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,57
537,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Placebo,3
538,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Remdesivir,4
539,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Total,7
540,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Placebo,56
541,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Remdesivir,79
542,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Total,135
543,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Placebo,2
544,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Remdesivir,2
545,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Total,4
546,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Placebo,117
547,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Remdesivir,109
548,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Total,226
549,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Placebo,287
550,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Remdesivir,279
551,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Total,566
552,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Placebo,1
553,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Remdesivir,2
554,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Total,3
555,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Placebo,55
556,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Remdesivir,66
557,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Total,121
558,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Placebo,19
559,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Remdesivir,14
560,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Total,33
561,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Placebo,12
562,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Remdesivir,9
563,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Total,21
564,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Placebo,7
565,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Remdesivir,9
566,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Total,16
567,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Placebo,410
568,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Remdesivir,427
569,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Total,837
570,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Placebo,7
571,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Remdesivir,8
572,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Total,15
573,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Placebo,21
574,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Remdesivir,22
575,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Total,43
576,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Placebo,6
577,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Remdesivir,4
578,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Total,10
579,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Placebo,21
580,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Remdesivir,25
581,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Total,46
582,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Placebo,6
583,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Remdesivir,7
584,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Total,13
585,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Placebo,12
586,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Remdesivir,16
587,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Total,28
588,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,Disease severity,Disease severity,B1,Placebo,50
589,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,Disease severity,Disease severity,B2,Remdesivir,55
590,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,Disease severity,Disease severity,B3,Total,105
591,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,Disease severity,Disease severity,B1,Placebo,471
592,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,Disease severity,Disease severity,B2,Remdesivir,486
593,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,intervention_model,Parallel Assignment,Disease severity,Disease severity,B3,Total,957
594,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Placebo,521
595,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Remdesivir,541
596,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Placebo,517
597,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Remdesivir,531
598,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Placebo,508
599,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Remdesivir,517
600,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Placebo,13
601,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Remdesivir,24
602,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Placebo,4
603,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Remdesivir,10
604,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Placebo,1
605,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Remdesivir,0
606,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Placebo,7
607,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Remdesivir,9
608,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Placebo,0
609,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Remdesivir,4
610,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Placebo,1
611,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Remdesivir,1
612,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,age,age,B1,Placebo,0
613,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,age,age,B2,Remdesivir,0
614,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,age,age,B3,Total,0
615,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,age,age,B1,Placebo,324
616,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,age,age,B2,Remdesivir,354
617,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,age,age,B3,Total,678
618,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,age,age,B1,Placebo,197
619,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,age,age,B2,Remdesivir,187
620,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,age,age,B3,Total,384
621,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Placebo,189
622,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Remdesivir,189
623,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Total,378
624,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Placebo,332
625,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Remdesivir,352
626,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Total,684
627,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,116
628,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,134
629,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,250
630,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,373
631,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,382
632,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,755
633,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,32
634,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,25
635,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,57
636,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Placebo,3
637,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Remdesivir,4
638,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Total,7
639,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Placebo,56
640,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Remdesivir,79
641,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Total,135
642,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Placebo,2
643,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Remdesivir,2
644,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Total,4
645,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Placebo,117
646,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Remdesivir,109
647,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Total,226
648,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Placebo,287
649,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Remdesivir,279
650,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Total,566
651,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Placebo,1
652,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Remdesivir,2
653,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Total,3
654,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Placebo,55
655,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Remdesivir,66
656,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Total,121
657,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Placebo,19
658,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Remdesivir,14
659,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Total,33
660,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Placebo,12
661,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Remdesivir,9
662,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Total,21
663,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Placebo,7
664,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Remdesivir,9
665,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Total,16
666,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Placebo,410
667,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Remdesivir,427
668,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Total,837
669,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Placebo,7
670,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Remdesivir,8
671,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Total,15
672,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Placebo,21
673,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Remdesivir,22
674,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Total,43
675,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Placebo,6
676,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Remdesivir,4
677,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Total,10
678,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Placebo,21
679,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Remdesivir,25
680,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Total,46
681,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Placebo,6
682,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Remdesivir,7
683,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Total,13
684,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Placebo,12
685,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Remdesivir,16
686,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Total,28
687,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,Disease severity,Disease severity,B1,Placebo,50
688,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,Disease severity,Disease severity,B2,Remdesivir,55
689,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,Disease severity,Disease severity,B3,Total,105
690,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,Disease severity,Disease severity,B1,Placebo,471
691,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,Disease severity,Disease severity,B2,Remdesivir,486
692,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,primary_purpose,Treatment,Disease severity,Disease severity,B3,Total,957
693,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P1,Placebo,521
694,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P2,Remdesivir,541
695,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P1,Placebo,517
696,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P2,Remdesivir,531
697,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P1,Placebo,508
698,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P2,Remdesivir,517
699,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P1,Placebo,13
700,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P2,Remdesivir,24
701,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",withdrawal reason,withdrawal reason,P1,Placebo,4
702,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",withdrawal reason,withdrawal reason,P2,Remdesivir,10
703,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",withdrawal reason,withdrawal reason,P1,Placebo,1
704,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",withdrawal reason,withdrawal reason,P2,Remdesivir,0
705,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",withdrawal reason,withdrawal reason,P1,Placebo,7
706,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",withdrawal reason,withdrawal reason,P2,Remdesivir,9
707,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",withdrawal reason,withdrawal reason,P1,Placebo,0
708,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",withdrawal reason,withdrawal reason,P2,Remdesivir,4
709,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",withdrawal reason,withdrawal reason,P1,Placebo,1
710,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",withdrawal reason,withdrawal reason,P2,Remdesivir,1
711,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",age,age,B1,Placebo,0
712,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",age,age,B2,Remdesivir,0
713,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",age,age,B3,Total,0
714,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",age,age,B1,Placebo,324
715,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",age,age,B2,Remdesivir,354
716,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",age,age,B3,Total,678
717,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",age,age,B1,Placebo,197
718,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",age,age,B2,Remdesivir,187
719,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",age,age,B3,Total,384
720,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B1,Placebo,189
721,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B2,Remdesivir,189
722,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B3,Total,378
723,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B1,Placebo,332
724,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B2,Remdesivir,352
725,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B3,Total,684
726,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,116
727,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,134
728,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,250
729,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,373
730,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,382
731,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,755
732,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",ethnicity (nih/omb),ethnicity (nih/omb),B1,Placebo,32
733,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",ethnicity (nih/omb),ethnicity (nih/omb),B2,Remdesivir,25
734,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,57
735,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B1,Placebo,3
736,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B2,Remdesivir,4
737,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B3,Total,7
738,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B1,Placebo,56
739,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B2,Remdesivir,79
740,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B3,Total,135
741,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B1,Placebo,2
742,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B2,Remdesivir,2
743,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B3,Total,4
744,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B1,Placebo,117
745,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B2,Remdesivir,109
746,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B3,Total,226
747,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B1,Placebo,287
748,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B2,Remdesivir,279
749,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B3,Total,566
750,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B1,Placebo,1
751,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B2,Remdesivir,2
752,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B3,Total,3
753,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B1,Placebo,55
754,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B2,Remdesivir,66
755,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B3,Total,121
756,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B1,Placebo,19
757,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B2,Remdesivir,14
758,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B3,Total,33
759,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B1,Placebo,12
760,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B2,Remdesivir,9
761,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B3,Total,21
762,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B1,Placebo,7
763,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B2,Remdesivir,9
764,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B3,Total,16
765,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B1,Placebo,410
766,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B2,Remdesivir,427
767,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B3,Total,837
768,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B1,Placebo,7
769,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B2,Remdesivir,8
770,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B3,Total,15
771,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B1,Placebo,21
772,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B2,Remdesivir,22
773,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B3,Total,43
774,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B1,Placebo,6
775,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B2,Remdesivir,4
776,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B3,Total,10
777,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B1,Placebo,21
778,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B2,Remdesivir,25
779,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B3,Total,46
780,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B1,Placebo,6
781,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B2,Remdesivir,7
782,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B3,Total,13
783,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B1,Placebo,12
784,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B2,Remdesivir,16
785,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B3,Total,28
786,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",Disease severity,Disease severity,B1,Placebo,50
787,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",Disease severity,Disease severity,B2,Remdesivir,55
788,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",Disease severity,Disease severity,B3,Total,105
789,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",Disease severity,Disease severity,B1,Placebo,471
790,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",Disease severity,Disease severity,B2,Remdesivir,486
791,0,Adaptive COVID-19 Treatment Trial (ACTT),Interventional,study_design_info,masking,"Double (Participant, Investigator)",Disease severity,Disease severity,B3,Total,957
792,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,199
793,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,milestone,milestone,P2,Part A: Remdesivir for 10 Days,197
794,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,milestone,milestone,P3,Part A: SOC Therapy,200
795,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",517
796,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,179
797,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,milestone,milestone,P2,Part A: Remdesivir for 10 Days,176
798,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,milestone,milestone,P3,Part A: SOC Therapy,178
799,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",437
800,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,20
801,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,milestone,milestone,P2,Part A: Remdesivir for 10 Days,21
802,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,milestone,milestone,P3,Part A: SOC Therapy,22
803,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",80
804,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
805,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,12
806,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,12
807,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",48
808,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
809,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,2
810,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,4
811,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",12
812,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
813,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,2
814,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,5
815,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",6
816,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
817,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,1
818,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,0
819,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
820,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
821,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
822,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,1
823,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
824,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
825,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,4
826,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,0
827,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",14
828,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"age, customized","age, customized",B1,Part A: Remdesivir for 5 Days,142
829,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,141
830,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"age, customized","age, customized",B3,Part A: SOC Therapy,142
831,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"age, customized","age, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",351
832,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"age, customized","age, customized",B5,Total,776
833,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"age, customized","age, customized",B1,Part A: Remdesivir for 5 Days,49
834,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,52
835,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"age, customized","age, customized",B3,Part A: SOC Therapy,58
836,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"age, customized","age, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",152
837,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"age, customized","age, customized",B5,Total,311
838,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Part A: Remdesivir for 5 Days,77
839,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,75
840,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Part A: SOC Therapy,75
841,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",221
842,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B5,Total,448
843,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Part A: Remdesivir for 5 Days,114
844,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,118
845,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Part A: SOC Therapy,125
846,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",282
847,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B5,Total,639
848,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,2
849,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
850,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
851,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
852,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,6
853,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,34
854,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,31
855,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,37
856,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",61
857,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,163
858,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,35
859,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,37
860,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,27
861,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",107
862,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,206
863,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,1
864,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,1
865,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
866,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
867,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,4
868,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,109
869,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,107
870,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,112
871,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",260
872,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,588
873,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,5
874,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,5
875,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,7
876,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",21
877,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,38
878,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,5
879,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,12
880,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,15
881,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",50
882,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,82
883,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,25
884,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,42
885,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,34
886,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",156
887,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,257
888,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,162
889,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,144
890,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,152
891,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",325
892,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,783
893,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,4
894,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,7
895,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,13
896,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",22
897,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,46
898,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,0
899,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
900,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
901,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
902,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,1
903,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,76
904,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,99
905,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part A: SOC Therapy,85
906,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",318
907,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,578
908,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,37
909,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,28
910,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part A: SOC Therapy,31
911,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",44
912,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,140
913,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,30
914,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,23
915,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part A: SOC Therapy,26
916,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",54
917,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,133
918,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,7
919,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,9
920,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part A: SOC Therapy,17
921,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",27
922,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,60
923,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,7
924,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,4
925,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part A: SOC Therapy,10
926,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",16
927,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,37
928,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,8
929,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
930,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part A: SOC Therapy,8
931,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",13
932,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,35
933,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,3
934,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
935,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part A: SOC Therapy,9
936,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",14
937,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,32
938,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,9
939,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,11
940,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part A: SOC Therapy,7
941,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
942,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,28
943,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,4
944,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,5
945,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part A: SOC Therapy,6
946,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
947,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,18
948,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,2
949,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
950,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
951,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",5
952,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,8
953,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,5
954,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
955,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
956,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
957,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,6
958,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,3
959,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
960,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part A: SOC Therapy,1
961,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
962,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,5
963,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,0
964,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
965,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
966,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",4
967,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,4
968,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,0
969,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
970,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
971,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
972,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,3
973,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,199
974,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P2,Part A: Remdesivir for 10 Days,197
975,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P3,Part A: SOC Therapy,200
976,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",517
977,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,179
978,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P2,Part A: Remdesivir for 10 Days,176
979,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P3,Part A: SOC Therapy,178
980,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",437
981,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,20
982,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P2,Part A: Remdesivir for 10 Days,21
983,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P3,Part A: SOC Therapy,22
984,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",80
985,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
986,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,12
987,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,12
988,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",48
989,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
990,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,2
991,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,4
992,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",12
993,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
994,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,2
995,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,5
996,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",6
997,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
998,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,1
999,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,0
1000,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1001,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
1002,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
1003,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,1
1004,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1005,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
1006,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,4
1007,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,0
1008,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",14
1009,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"age, customized","age, customized",B1,Part A: Remdesivir for 5 Days,142
1010,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,141
1011,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"age, customized","age, customized",B3,Part A: SOC Therapy,142
1012,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"age, customized","age, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",351
1013,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"age, customized","age, customized",B5,Total,776
1014,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"age, customized","age, customized",B1,Part A: Remdesivir for 5 Days,49
1015,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,52
1016,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"age, customized","age, customized",B3,Part A: SOC Therapy,58
1017,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"age, customized","age, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",152
1018,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"age, customized","age, customized",B5,Total,311
1019,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"sex: female, male","sex: female, male",B1,Part A: Remdesivir for 5 Days,77
1020,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,75
1021,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"sex: female, male","sex: female, male",B3,Part A: SOC Therapy,75
1022,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"sex: female, male","sex: female, male",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",221
1023,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"sex: female, male","sex: female, male",B5,Total,448
1024,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"sex: female, male","sex: female, male",B1,Part A: Remdesivir for 5 Days,114
1025,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,118
1026,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"sex: female, male","sex: female, male",B3,Part A: SOC Therapy,125
1027,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"sex: female, male","sex: female, male",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",282
1028,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"sex: female, male","sex: female, male",B5,Total,639
1029,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,2
1030,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
1031,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
1032,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
1033,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,6
1034,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,34
1035,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,31
1036,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,37
1037,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",61
1038,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,163
1039,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,35
1040,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,37
1041,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,27
1042,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",107
1043,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,206
1044,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,1
1045,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,1
1046,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
1047,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
1048,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,4
1049,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,109
1050,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,107
1051,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,112
1052,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",260
1053,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,588
1054,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,5
1055,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,5
1056,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,7
1057,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",21
1058,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,38
1059,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,5
1060,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,12
1061,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,15
1062,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",50
1063,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,82
1064,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,25
1065,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,42
1066,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,34
1067,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",156
1068,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,257
1069,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,162
1070,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,144
1071,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,152
1072,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",325
1073,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,783
1074,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,4
1075,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,7
1076,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,13
1077,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",22
1078,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,46
1079,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,0
1080,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
1081,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
1082,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1083,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,1
1084,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,76
1085,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,99
1086,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part A: SOC Therapy,85
1087,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",318
1088,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,578
1089,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,37
1090,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,28
1091,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part A: SOC Therapy,31
1092,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",44
1093,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,140
1094,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,30
1095,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,23
1096,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part A: SOC Therapy,26
1097,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",54
1098,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,133
1099,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,7
1100,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,9
1101,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part A: SOC Therapy,17
1102,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",27
1103,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,60
1104,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,7
1105,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,4
1106,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part A: SOC Therapy,10
1107,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",16
1108,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,37
1109,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,8
1110,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
1111,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part A: SOC Therapy,8
1112,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",13
1113,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,35
1114,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,3
1115,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
1116,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part A: SOC Therapy,9
1117,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",14
1118,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,32
1119,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,9
1120,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,11
1121,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part A: SOC Therapy,7
1122,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
1123,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,28
1124,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,4
1125,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,5
1126,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part A: SOC Therapy,6
1127,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
1128,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,18
1129,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,2
1130,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
1131,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
1132,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",5
1133,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,8
1134,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,5
1135,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
1136,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
1137,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1138,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,6
1139,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,3
1140,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
1141,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part A: SOC Therapy,1
1142,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
1143,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,5
1144,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,0
1145,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
1146,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
1147,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",4
1148,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,4
1149,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,0
1150,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
1151,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
1152,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
1153,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,3
1154,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,199
1155,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Part A: Remdesivir for 10 Days,197
1156,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P3,Part A: SOC Therapy,200
1157,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",517
1158,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,179
1159,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Part A: Remdesivir for 10 Days,176
1160,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P3,Part A: SOC Therapy,178
1161,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",437
1162,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,20
1163,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Part A: Remdesivir for 10 Days,21
1164,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P3,Part A: SOC Therapy,22
1165,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",80
1166,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
1167,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,12
1168,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,12
1169,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",48
1170,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
1171,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,2
1172,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,4
1173,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",12
1174,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
1175,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,2
1176,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,5
1177,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",6
1178,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
1179,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,1
1180,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,0
1181,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1182,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
1183,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
1184,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,1
1185,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1186,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
1187,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,4
1188,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,0
1189,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",14
1190,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"age, customized","age, customized",B1,Part A: Remdesivir for 5 Days,142
1191,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,141
1192,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"age, customized","age, customized",B3,Part A: SOC Therapy,142
1193,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"age, customized","age, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",351
1194,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"age, customized","age, customized",B5,Total,776
1195,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"age, customized","age, customized",B1,Part A: Remdesivir for 5 Days,49
1196,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,52
1197,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"age, customized","age, customized",B3,Part A: SOC Therapy,58
1198,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"age, customized","age, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",152
1199,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"age, customized","age, customized",B5,Total,311
1200,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Part A: Remdesivir for 5 Days,77
1201,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,75
1202,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Part A: SOC Therapy,75
1203,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",221
1204,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B5,Total,448
1205,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Part A: Remdesivir for 5 Days,114
1206,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,118
1207,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Part A: SOC Therapy,125
1208,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",282
1209,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B5,Total,639
1210,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,2
1211,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
1212,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
1213,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
1214,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,6
1215,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,34
1216,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,31
1217,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,37
1218,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",61
1219,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,163
1220,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,35
1221,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,37
1222,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,27
1223,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",107
1224,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,206
1225,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,1
1226,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,1
1227,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
1228,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
1229,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,4
1230,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,109
1231,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,107
1232,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,112
1233,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",260
1234,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,588
1235,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,5
1236,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,5
1237,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,7
1238,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",21
1239,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,38
1240,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,5
1241,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,12
1242,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,15
1243,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",50
1244,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,82
1245,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,25
1246,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,42
1247,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,34
1248,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",156
1249,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,257
1250,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,162
1251,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,144
1252,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,152
1253,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",325
1254,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,783
1255,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,4
1256,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,7
1257,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,13
1258,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",22
1259,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,46
1260,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,0
1261,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
1262,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
1263,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1264,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,1
1265,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,76
1266,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,99
1267,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part A: SOC Therapy,85
1268,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",318
1269,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,578
1270,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,37
1271,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,28
1272,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part A: SOC Therapy,31
1273,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",44
1274,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,140
1275,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,30
1276,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,23
1277,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part A: SOC Therapy,26
1278,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",54
1279,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,133
1280,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,7
1281,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,9
1282,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part A: SOC Therapy,17
1283,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",27
1284,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,60
1285,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,7
1286,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,4
1287,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part A: SOC Therapy,10
1288,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",16
1289,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,37
1290,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,8
1291,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
1292,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part A: SOC Therapy,8
1293,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",13
1294,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,35
1295,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,3
1296,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
1297,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part A: SOC Therapy,9
1298,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",14
1299,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,32
1300,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,9
1301,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,11
1302,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part A: SOC Therapy,7
1303,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
1304,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,28
1305,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,4
1306,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,5
1307,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part A: SOC Therapy,6
1308,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
1309,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,18
1310,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,2
1311,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
1312,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
1313,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",5
1314,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,8
1315,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,5
1316,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
1317,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
1318,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1319,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,6
1320,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,3
1321,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
1322,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part A: SOC Therapy,1
1323,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
1324,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,5
1325,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,0
1326,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
1327,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
1328,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",4
1329,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,4
1330,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,0
1331,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
1332,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
1333,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
1334,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,3
1335,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,199
1336,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Part A: Remdesivir for 10 Days,197
1337,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P3,Part A: SOC Therapy,200
1338,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",517
1339,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,179
1340,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Part A: Remdesivir for 10 Days,176
1341,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P3,Part A: SOC Therapy,178
1342,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",437
1343,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,20
1344,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Part A: Remdesivir for 10 Days,21
1345,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P3,Part A: SOC Therapy,22
1346,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",80
1347,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
1348,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,12
1349,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,12
1350,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",48
1351,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
1352,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,2
1353,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,4
1354,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",12
1355,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
1356,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,2
1357,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,5
1358,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",6
1359,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
1360,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,1
1361,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,0
1362,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1363,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
1364,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
1365,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,1
1366,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1367,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
1368,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,4
1369,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,0
1370,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",14
1371,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"age, customized","age, customized",B1,Part A: Remdesivir for 5 Days,142
1372,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,141
1373,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"age, customized","age, customized",B3,Part A: SOC Therapy,142
1374,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"age, customized","age, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",351
1375,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"age, customized","age, customized",B5,Total,776
1376,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"age, customized","age, customized",B1,Part A: Remdesivir for 5 Days,49
1377,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,52
1378,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"age, customized","age, customized",B3,Part A: SOC Therapy,58
1379,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"age, customized","age, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",152
1380,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"age, customized","age, customized",B5,Total,311
1381,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Part A: Remdesivir for 5 Days,77
1382,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,75
1383,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Part A: SOC Therapy,75
1384,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",221
1385,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B5,Total,448
1386,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Part A: Remdesivir for 5 Days,114
1387,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,118
1388,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Part A: SOC Therapy,125
1389,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",282
1390,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B5,Total,639
1391,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,2
1392,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
1393,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
1394,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
1395,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,6
1396,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,34
1397,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,31
1398,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,37
1399,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",61
1400,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,163
1401,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,35
1402,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,37
1403,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,27
1404,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",107
1405,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,206
1406,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,1
1407,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,1
1408,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
1409,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
1410,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,4
1411,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,109
1412,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,107
1413,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,112
1414,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",260
1415,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,588
1416,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,5
1417,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,5
1418,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,7
1419,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",21
1420,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,38
1421,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,5
1422,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,12
1423,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,15
1424,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",50
1425,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,82
1426,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,25
1427,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,42
1428,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,34
1429,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",156
1430,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,257
1431,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,162
1432,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,144
1433,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,152
1434,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",325
1435,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,783
1436,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,4
1437,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,7
1438,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,13
1439,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",22
1440,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,46
1441,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,0
1442,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
1443,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
1444,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1445,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,1
1446,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,76
1447,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,99
1448,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part A: SOC Therapy,85
1449,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",318
1450,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,578
1451,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,37
1452,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,28
1453,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part A: SOC Therapy,31
1454,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",44
1455,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,140
1456,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,30
1457,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,23
1458,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part A: SOC Therapy,26
1459,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",54
1460,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,133
1461,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,7
1462,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,9
1463,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part A: SOC Therapy,17
1464,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",27
1465,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,60
1466,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,7
1467,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,4
1468,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part A: SOC Therapy,10
1469,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",16
1470,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,37
1471,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,8
1472,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
1473,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part A: SOC Therapy,8
1474,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",13
1475,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,35
1476,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,3
1477,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
1478,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part A: SOC Therapy,9
1479,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",14
1480,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,32
1481,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,9
1482,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,11
1483,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part A: SOC Therapy,7
1484,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
1485,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,28
1486,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,4
1487,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,5
1488,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part A: SOC Therapy,6
1489,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
1490,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,18
1491,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,2
1492,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
1493,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
1494,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",5
1495,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,8
1496,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,5
1497,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
1498,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
1499,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1500,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,6
1501,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,3
1502,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
1503,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part A: SOC Therapy,1
1504,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
1505,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,5
1506,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,0
1507,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
1508,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
1509,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",4
1510,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,4
1511,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,0
1512,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
1513,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
1514,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
1515,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,3
1516,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,199
1517,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Part A: Remdesivir for 10 Days,197
1518,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P3,Part A: SOC Therapy,200
1519,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",517
1520,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,179
1521,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Part A: Remdesivir for 10 Days,176
1522,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P3,Part A: SOC Therapy,178
1523,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",437
1524,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,20
1525,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Part A: Remdesivir for 10 Days,21
1526,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P3,Part A: SOC Therapy,22
1527,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",80
1528,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
1529,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,12
1530,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,12
1531,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",48
1532,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
1533,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,2
1534,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,4
1535,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",12
1536,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
1537,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,2
1538,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,5
1539,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",6
1540,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
1541,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,1
1542,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,0
1543,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1544,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
1545,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
1546,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,1
1547,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1548,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
1549,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,4
1550,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,0
1551,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",14
1552,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"age, customized","age, customized",B1,Part A: Remdesivir for 5 Days,142
1553,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,141
1554,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"age, customized","age, customized",B3,Part A: SOC Therapy,142
1555,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"age, customized","age, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",351
1556,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"age, customized","age, customized",B5,Total,776
1557,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"age, customized","age, customized",B1,Part A: Remdesivir for 5 Days,49
1558,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,52
1559,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"age, customized","age, customized",B3,Part A: SOC Therapy,58
1560,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"age, customized","age, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",152
1561,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"age, customized","age, customized",B5,Total,311
1562,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Part A: Remdesivir for 5 Days,77
1563,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,75
1564,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Part A: SOC Therapy,75
1565,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",221
1566,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B5,Total,448
1567,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Part A: Remdesivir for 5 Days,114
1568,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,118
1569,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Part A: SOC Therapy,125
1570,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",282
1571,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B5,Total,639
1572,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,2
1573,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
1574,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
1575,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
1576,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,6
1577,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,34
1578,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,31
1579,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,37
1580,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",61
1581,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,163
1582,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,35
1583,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,37
1584,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,27
1585,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",107
1586,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,206
1587,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,1
1588,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,1
1589,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
1590,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
1591,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,4
1592,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,109
1593,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,107
1594,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,112
1595,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",260
1596,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,588
1597,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,5
1598,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,5
1599,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,7
1600,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",21
1601,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,38
1602,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,5
1603,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,12
1604,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,15
1605,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",50
1606,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,82
1607,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,25
1608,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,42
1609,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,34
1610,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",156
1611,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,257
1612,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,162
1613,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,144
1614,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,152
1615,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",325
1616,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,783
1617,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,4
1618,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,7
1619,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,13
1620,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",22
1621,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,46
1622,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,0
1623,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
1624,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
1625,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1626,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,1
1627,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,76
1628,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,99
1629,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part A: SOC Therapy,85
1630,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",318
1631,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,578
1632,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,37
1633,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,28
1634,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part A: SOC Therapy,31
1635,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",44
1636,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,140
1637,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,30
1638,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,23
1639,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part A: SOC Therapy,26
1640,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",54
1641,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,133
1642,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,7
1643,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,9
1644,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part A: SOC Therapy,17
1645,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",27
1646,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,60
1647,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,7
1648,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,4
1649,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part A: SOC Therapy,10
1650,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",16
1651,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,37
1652,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,8
1653,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
1654,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part A: SOC Therapy,8
1655,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",13
1656,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,35
1657,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,3
1658,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
1659,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part A: SOC Therapy,9
1660,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",14
1661,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,32
1662,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,9
1663,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,11
1664,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part A: SOC Therapy,7
1665,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
1666,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,28
1667,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,4
1668,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,5
1669,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part A: SOC Therapy,6
1670,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
1671,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,18
1672,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,2
1673,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
1674,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
1675,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",5
1676,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,8
1677,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,5
1678,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
1679,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
1680,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1681,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,6
1682,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,3
1683,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
1684,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part A: SOC Therapy,1
1685,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
1686,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,5
1687,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,0
1688,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
1689,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
1690,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",4
1691,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,4
1692,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,0
1693,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
1694,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
1695,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
1696,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,3
1697,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,199
1698,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Part A: Remdesivir for 10 Days,197
1699,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P3,Part A: SOC Therapy,200
1700,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",517
1701,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,179
1702,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Part A: Remdesivir for 10 Days,176
1703,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P3,Part A: SOC Therapy,178
1704,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",437
1705,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,20
1706,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Part A: Remdesivir for 10 Days,21
1707,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P3,Part A: SOC Therapy,22
1708,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",80
1709,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
1710,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,12
1711,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,12
1712,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",48
1713,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
1714,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,2
1715,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,4
1716,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",12
1717,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
1718,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,2
1719,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,5
1720,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",6
1721,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
1722,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,1
1723,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,0
1724,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1725,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
1726,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
1727,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,1
1728,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1729,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
1730,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,4
1731,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,0
1732,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",14
1733,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"age, customized","age, customized",B1,Part A: Remdesivir for 5 Days,142
1734,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,141
1735,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"age, customized","age, customized",B3,Part A: SOC Therapy,142
1736,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"age, customized","age, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",351
1737,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"age, customized","age, customized",B5,Total,776
1738,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"age, customized","age, customized",B1,Part A: Remdesivir for 5 Days,49
1739,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,52
1740,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"age, customized","age, customized",B3,Part A: SOC Therapy,58
1741,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"age, customized","age, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",152
1742,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"age, customized","age, customized",B5,Total,311
1743,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Part A: Remdesivir for 5 Days,77
1744,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,75
1745,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Part A: SOC Therapy,75
1746,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",221
1747,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B5,Total,448
1748,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Part A: Remdesivir for 5 Days,114
1749,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,118
1750,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Part A: SOC Therapy,125
1751,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",282
1752,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B5,Total,639
1753,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,2
1754,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
1755,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
1756,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
1757,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,6
1758,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,34
1759,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,31
1760,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,37
1761,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",61
1762,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,163
1763,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,35
1764,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,37
1765,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,27
1766,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",107
1767,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,206
1768,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,1
1769,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,1
1770,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
1771,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
1772,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,4
1773,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,109
1774,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,107
1775,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,112
1776,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",260
1777,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,588
1778,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,5
1779,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,5
1780,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,7
1781,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",21
1782,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,38
1783,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,5
1784,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,12
1785,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,15
1786,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",50
1787,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,82
1788,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,25
1789,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,42
1790,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,34
1791,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",156
1792,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,257
1793,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,162
1794,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,144
1795,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,152
1796,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",325
1797,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,783
1798,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,4
1799,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,7
1800,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,13
1801,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",22
1802,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,46
1803,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,0
1804,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
1805,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
1806,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1807,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,1
1808,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,76
1809,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,99
1810,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part A: SOC Therapy,85
1811,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",318
1812,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,578
1813,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,37
1814,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,28
1815,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part A: SOC Therapy,31
1816,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",44
1817,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,140
1818,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,30
1819,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,23
1820,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part A: SOC Therapy,26
1821,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",54
1822,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,133
1823,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,7
1824,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,9
1825,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part A: SOC Therapy,17
1826,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",27
1827,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,60
1828,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,7
1829,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,4
1830,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part A: SOC Therapy,10
1831,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",16
1832,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,37
1833,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,8
1834,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
1835,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part A: SOC Therapy,8
1836,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",13
1837,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,35
1838,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,3
1839,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
1840,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part A: SOC Therapy,9
1841,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",14
1842,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,32
1843,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,9
1844,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,11
1845,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part A: SOC Therapy,7
1846,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
1847,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,28
1848,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,4
1849,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,5
1850,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part A: SOC Therapy,6
1851,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
1852,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,18
1853,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,2
1854,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
1855,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
1856,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",5
1857,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,8
1858,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,5
1859,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
1860,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
1861,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1862,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,6
1863,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,3
1864,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
1865,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part A: SOC Therapy,1
1866,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
1867,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,5
1868,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,0
1869,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
1870,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
1871,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",4
1872,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,4
1873,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,0
1874,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
1875,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
1876,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
1877,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,3
1878,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,199
1879,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Part A: Remdesivir for 10 Days,197
1880,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P3,Part A: SOC Therapy,200
1881,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",517
1882,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,179
1883,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Part A: Remdesivir for 10 Days,176
1884,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P3,Part A: SOC Therapy,178
1885,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",437
1886,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,20
1887,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Part A: Remdesivir for 10 Days,21
1888,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P3,Part A: SOC Therapy,22
1889,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",80
1890,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
1891,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,12
1892,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,12
1893,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",48
1894,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
1895,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,2
1896,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,4
1897,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",12
1898,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
1899,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,2
1900,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,5
1901,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",6
1902,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
1903,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,1
1904,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,0
1905,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1906,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
1907,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
1908,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,1
1909,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1910,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
1911,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,4
1912,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,0
1913,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",14
1914,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"age, customized","age, customized",B1,Part A: Remdesivir for 5 Days,142
1915,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,141
1916,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"age, customized","age, customized",B3,Part A: SOC Therapy,142
1917,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"age, customized","age, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",351
1918,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"age, customized","age, customized",B5,Total,776
1919,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"age, customized","age, customized",B1,Part A: Remdesivir for 5 Days,49
1920,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,52
1921,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"age, customized","age, customized",B3,Part A: SOC Therapy,58
1922,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"age, customized","age, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",152
1923,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"age, customized","age, customized",B5,Total,311
1924,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Part A: Remdesivir for 5 Days,77
1925,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,75
1926,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Part A: SOC Therapy,75
1927,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",221
1928,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B5,Total,448
1929,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Part A: Remdesivir for 5 Days,114
1930,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,118
1931,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Part A: SOC Therapy,125
1932,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",282
1933,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B5,Total,639
1934,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,2
1935,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
1936,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
1937,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
1938,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,6
1939,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,34
1940,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,31
1941,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,37
1942,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",61
1943,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,163
1944,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,35
1945,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,37
1946,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,27
1947,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",107
1948,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,206
1949,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,1
1950,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,1
1951,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
1952,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
1953,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,4
1954,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,109
1955,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,107
1956,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,112
1957,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",260
1958,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,588
1959,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,5
1960,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,5
1961,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,7
1962,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",21
1963,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,38
1964,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,5
1965,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,12
1966,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,15
1967,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",50
1968,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,82
1969,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,25
1970,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,42
1971,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,34
1972,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",156
1973,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,257
1974,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,162
1975,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,144
1976,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,152
1977,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",325
1978,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,783
1979,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,4
1980,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,7
1981,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,13
1982,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",22
1983,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,46
1984,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,0
1985,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
1986,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
1987,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
1988,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,1
1989,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,76
1990,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,99
1991,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part A: SOC Therapy,85
1992,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",318
1993,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,578
1994,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,37
1995,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,28
1996,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part A: SOC Therapy,31
1997,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",44
1998,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,140
1999,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,30
2000,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,23
2001,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part A: SOC Therapy,26
2002,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",54
2003,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,133
2004,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,7
2005,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,9
2006,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part A: SOC Therapy,17
2007,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",27
2008,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,60
2009,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,7
2010,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,4
2011,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part A: SOC Therapy,10
2012,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",16
2013,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,37
2014,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,8
2015,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
2016,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part A: SOC Therapy,8
2017,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",13
2018,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,35
2019,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,3
2020,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
2021,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part A: SOC Therapy,9
2022,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",14
2023,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,32
2024,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,9
2025,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,11
2026,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part A: SOC Therapy,7
2027,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
2028,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,28
2029,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,4
2030,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,5
2031,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part A: SOC Therapy,6
2032,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
2033,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,18
2034,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,2
2035,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
2036,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
2037,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",5
2038,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,8
2039,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,5
2040,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
2041,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
2042,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
2043,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,6
2044,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,3
2045,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2046,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part A: SOC Therapy,1
2047,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
2048,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,5
2049,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,0
2050,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2051,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
2052,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",4
2053,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,4
2054,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,0
2055,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2056,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part A: SOC Therapy,0
2057,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
2058,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,3
2059,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,199
2060,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,Part A: Remdesivir for 10 Days,197
2061,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P3,Part A: SOC Therapy,200
2062,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",517
2063,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,179
2064,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,Part A: Remdesivir for 10 Days,176
2065,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P3,Part A: SOC Therapy,178
2066,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",437
2067,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,20
2068,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,Part A: Remdesivir for 10 Days,21
2069,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P3,Part A: SOC Therapy,22
2070,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",80
2071,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
2072,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,12
2073,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,12
2074,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",48
2075,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
2076,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,2
2077,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,4
2078,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",12
2079,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
2080,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,2
2081,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,5
2082,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",6
2083,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
2084,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,1
2085,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,0
2086,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
2087,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
2088,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
2089,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,1
2090,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
2091,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
2092,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,4
2093,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P3,Part A: SOC Therapy,0
2094,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P4,"Part B: Extension Treatment, Remdesivir for 10 Days",14
2095,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"age, customized","age, customized",B1,Part A: Remdesivir for 5 Days,142
2096,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,141
2097,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"age, customized","age, customized",B3,Part A: SOC Therapy,142
2098,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"age, customized","age, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",351
2099,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"age, customized","age, customized",B5,Total,776
2100,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"age, customized","age, customized",B1,Part A: Remdesivir for 5 Days,49
2101,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,52
2102,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"age, customized","age, customized",B3,Part A: SOC Therapy,58
2103,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"age, customized","age, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",152
2104,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"age, customized","age, customized",B5,Total,311
2105,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,Part A: Remdesivir for 5 Days,77
2106,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,75
2107,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B3,Part A: SOC Therapy,75
2108,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",221
2109,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B5,Total,448
2110,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,Part A: Remdesivir for 5 Days,114
2111,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,118
2112,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B3,Part A: SOC Therapy,125
2113,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",282
2114,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B5,Total,639
2115,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,2
2116,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
2117,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
2118,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
2119,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,6
2120,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,34
2121,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,31
2122,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,37
2123,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",61
2124,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,163
2125,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,35
2126,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,37
2127,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,27
2128,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",107
2129,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,206
2130,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,1
2131,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,1
2132,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
2133,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
2134,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,4
2135,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,109
2136,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,107
2137,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,112
2138,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",260
2139,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,588
2140,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,5
2141,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,5
2142,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,7
2143,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",21
2144,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,38
2145,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,5
2146,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,12
2147,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,15
2148,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",50
2149,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,82
2150,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,25
2151,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,42
2152,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,34
2153,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",156
2154,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,257
2155,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,162
2156,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,144
2157,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,152
2158,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",325
2159,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,783
2160,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,4
2161,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,7
2162,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,13
2163,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",22
2164,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,46
2165,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir for 5 Days,0
2166,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
2167,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part A: SOC Therapy,1
2168,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
2169,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,1
2170,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,76
2171,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,99
2172,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part A: SOC Therapy,85
2173,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",318
2174,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,578
2175,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,37
2176,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,28
2177,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part A: SOC Therapy,31
2178,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",44
2179,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,140
2180,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,30
2181,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,23
2182,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part A: SOC Therapy,26
2183,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",54
2184,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,133
2185,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,7
2186,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,9
2187,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part A: SOC Therapy,17
2188,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",27
2189,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,60
2190,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,7
2191,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,4
2192,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part A: SOC Therapy,10
2193,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",16
2194,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,37
2195,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,8
2196,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
2197,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part A: SOC Therapy,8
2198,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",13
2199,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,35
2200,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,3
2201,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
2202,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part A: SOC Therapy,9
2203,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",14
2204,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,32
2205,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,9
2206,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,11
2207,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part A: SOC Therapy,7
2208,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
2209,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,28
2210,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,4
2211,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,5
2212,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part A: SOC Therapy,6
2213,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
2214,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,18
2215,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,2
2216,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
2217,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part A: SOC Therapy,0
2218,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",5
2219,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,8
2220,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,5
2221,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
2222,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part A: SOC Therapy,0
2223,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",0
2224,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,6
2225,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,3
2226,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2227,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part A: SOC Therapy,1
2228,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",1
2229,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,5
2230,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,0
2231,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2232,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part A: SOC Therapy,0
2233,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",4
2234,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,4
2235,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir for 5 Days,0
2236,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2237,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part A: SOC Therapy,0
2238,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,"Part B: Extension Treatment, Remdesivir for 10 Days",3
2239,1,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,3
2240,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,200
2241,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,milestone,milestone,P2,Part A: Remdesivir for 10 Days,197
2242,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),844
2243,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),3597
2244,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,168
2245,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,milestone,milestone,P2,Part A: Remdesivir for 10 Days,164
2246,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),621
2247,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),2952
2248,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,32
2249,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,milestone,milestone,P2,Part A: Remdesivir for 10 Days,33
2250,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),223
2251,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),645
2252,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,21
2253,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,28
2254,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),188
2255,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),371
2256,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
2257,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,4
2258,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),22
2259,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),235
2260,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,1
2261,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
2262,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),11
2263,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),32
2264,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
2265,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,1
2266,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
2267,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),2
2268,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
2269,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
2270,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2271,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),3
2272,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
2273,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
2274,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2275,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),1
2276,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
2277,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
2278,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2279,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),1
2280,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"age, customized","age, customized",B1,Part A: Remdesivir (RDV) for 5 Days,116
2281,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,113
2282,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"age, customized","age, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),581
2283,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"age, customized","age, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),2399
2284,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"age, customized","age, customized",B5,Total,3209
2285,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"age, customized","age, customized",B1,Part A: Remdesivir (RDV) for 5 Days,84
2286,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,84
2287,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"age, customized","age, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),263
2288,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"age, customized","age, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1198
2289,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"age, customized","age, customized",B5,Total,1629
2290,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Part A: Remdesivir (RDV) for 5 Days,80
2291,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,64
2292,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),312
2293,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B4,Part B: Remdesivir for 10 Days (Extension Group),1351
2294,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B5,Total,1807
2295,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Part A: Remdesivir (RDV) for 5 Days,120
2296,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,133
2297,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),532
2298,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B4,Part B: Remdesivir for 10 Days (Extension Group),2246
2299,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B5,Total,3031
2300,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,2
2301,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
2302,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),5
2303,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),40
2304,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,47
2305,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,20
2306,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,25
2307,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),88
2308,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),313
2309,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,446
2310,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,21
2311,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,23
2312,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),149
2313,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),611
2314,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,804
2315,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,1
2316,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
2317,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),11
2318,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),29
2319,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,41
2320,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,142
2321,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,134
2322,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),376
2323,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1915
2324,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,2567
2325,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,0
2326,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,5
2327,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),56
2328,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),179
2329,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,240
2330,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,14
2331,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,10
2332,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),159
2333,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),510
2334,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,693
2335,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,47
2336,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,38
2337,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),328
2338,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1341
2339,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,1754
2340,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,152
2341,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,150
2342,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),478
2343,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),2123
2344,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,2903
2345,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,1
2346,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,9
2347,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),37
2348,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),129
2349,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,176
2350,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,0
2351,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
2352,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),1
2353,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),4
2354,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,5
2355,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,118
2356,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,111
2357,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),722
2358,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),2927
2359,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,3878
2360,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,31
2361,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,30
2362,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),27
2363,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),134
2364,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,222
2365,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,39
2366,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,38
2367,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),16
2368,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),108
2369,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,201
2370,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
2371,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2372,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),33
2373,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),144
2374,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,177
2375,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
2376,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2377,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),5
2378,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),83
2379,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,88
2380,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,1
2381,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,8
2382,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),7
2383,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),44
2384,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,60
2385,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
2386,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2387,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),13
2388,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),44
2389,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,57
2390,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
2391,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2392,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
2393,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),45
2394,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,47
2395,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,3
2396,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
2397,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),12
2398,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),27
2399,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,43
2400,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
2401,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2402,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
2403,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),25
2404,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,27
2405,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,6
2406,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
2407,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2408,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),10
2409,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,22
2410,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,2
2411,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,2
2412,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
2413,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),0
2414,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,6
2415,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
2416,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2417,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),1
2418,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),4
2419,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,5
2420,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
2421,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
2422,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
2423,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),2
2424,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,5
2425,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
2426,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
2427,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2428,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
2429,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
2430,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,4
2431,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,9
2432,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),844
2433,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
2434,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,857
2435,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,49
2436,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,59
2437,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2438,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),1069
2439,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,1177
2440,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,113
2441,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,108
2442,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2443,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),2214
2444,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,2435
2445,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,34
2446,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,21
2447,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2448,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),314
2449,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,369
2450,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
2451,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
2452,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2453,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
2454,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
2455,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
2456,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
2457,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2458,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
2459,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,gender,All,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
2460,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,200
2461,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P2,Part A: Remdesivir for 10 Days,197
2462,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),844
2463,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),3597
2464,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,168
2465,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P2,Part A: Remdesivir for 10 Days,164
2466,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),621
2467,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),2952
2468,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,32
2469,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P2,Part A: Remdesivir for 10 Days,33
2470,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),223
2471,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),645
2472,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,21
2473,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,28
2474,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),188
2475,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),371
2476,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
2477,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,4
2478,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),22
2479,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),235
2480,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,1
2481,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
2482,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),11
2483,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),32
2484,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
2485,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,1
2486,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
2487,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),2
2488,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
2489,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
2490,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2491,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),3
2492,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
2493,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
2494,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2495,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),1
2496,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
2497,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
2498,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2499,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),1
2500,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"age, customized","age, customized",B1,Part A: Remdesivir (RDV) for 5 Days,116
2501,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,113
2502,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"age, customized","age, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),581
2503,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"age, customized","age, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),2399
2504,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"age, customized","age, customized",B5,Total,3209
2505,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"age, customized","age, customized",B1,Part A: Remdesivir (RDV) for 5 Days,84
2506,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,84
2507,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"age, customized","age, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),263
2508,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"age, customized","age, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1198
2509,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"age, customized","age, customized",B5,Total,1629
2510,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"sex: female, male","sex: female, male",B1,Part A: Remdesivir (RDV) for 5 Days,80
2511,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,64
2512,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"sex: female, male","sex: female, male",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),312
2513,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"sex: female, male","sex: female, male",B4,Part B: Remdesivir for 10 Days (Extension Group),1351
2514,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"sex: female, male","sex: female, male",B5,Total,1807
2515,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"sex: female, male","sex: female, male",B1,Part A: Remdesivir (RDV) for 5 Days,120
2516,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,133
2517,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"sex: female, male","sex: female, male",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),532
2518,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"sex: female, male","sex: female, male",B4,Part B: Remdesivir for 10 Days (Extension Group),2246
2519,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"sex: female, male","sex: female, male",B5,Total,3031
2520,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,2
2521,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
2522,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),5
2523,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),40
2524,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,47
2525,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,20
2526,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,25
2527,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),88
2528,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),313
2529,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,446
2530,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,21
2531,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,23
2532,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),149
2533,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),611
2534,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,804
2535,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,1
2536,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
2537,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),11
2538,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),29
2539,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,41
2540,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,142
2541,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,134
2542,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),376
2543,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1915
2544,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,2567
2545,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,0
2546,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,5
2547,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),56
2548,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),179
2549,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,240
2550,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,14
2551,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,10
2552,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),159
2553,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),510
2554,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,693
2555,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,47
2556,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,38
2557,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),328
2558,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1341
2559,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,1754
2560,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,152
2561,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,150
2562,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),478
2563,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),2123
2564,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,2903
2565,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,1
2566,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,9
2567,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),37
2568,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),129
2569,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,176
2570,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,0
2571,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
2572,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),1
2573,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),4
2574,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,5
2575,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,118
2576,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,111
2577,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),722
2578,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),2927
2579,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,3878
2580,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,31
2581,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,30
2582,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),27
2583,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),134
2584,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,222
2585,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,39
2586,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,38
2587,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),16
2588,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),108
2589,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,201
2590,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
2591,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2592,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),33
2593,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),144
2594,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,177
2595,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
2596,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2597,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),5
2598,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),83
2599,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,88
2600,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,1
2601,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,8
2602,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),7
2603,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),44
2604,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,60
2605,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
2606,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2607,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),13
2608,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),44
2609,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,57
2610,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
2611,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2612,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
2613,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),45
2614,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,47
2615,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,3
2616,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
2617,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),12
2618,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),27
2619,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,43
2620,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
2621,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2622,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
2623,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),25
2624,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,27
2625,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,6
2626,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
2627,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2628,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),10
2629,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,22
2630,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,2
2631,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,2
2632,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
2633,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),0
2634,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,6
2635,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
2636,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2637,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),1
2638,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),4
2639,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,5
2640,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
2641,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
2642,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
2643,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),2
2644,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,enrollment region,enrollment region,B5,Total,5
2645,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
2646,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
2647,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2648,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
2649,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
2650,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,4
2651,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,9
2652,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),844
2653,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
2654,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,857
2655,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,49
2656,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,59
2657,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2658,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),1069
2659,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,1177
2660,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,113
2661,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,108
2662,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2663,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),2214
2664,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,2435
2665,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,34
2666,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,21
2667,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2668,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),314
2669,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,369
2670,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
2671,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
2672,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2673,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
2674,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
2675,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
2676,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
2677,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2678,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
2679,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,minimum_age,12 Years,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
2680,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,200
2681,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Part A: Remdesivir for 10 Days,197
2682,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),844
2683,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),3597
2684,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,168
2685,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Part A: Remdesivir for 10 Days,164
2686,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),621
2687,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),2952
2688,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,32
2689,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Part A: Remdesivir for 10 Days,33
2690,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),223
2691,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),645
2692,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,21
2693,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,28
2694,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),188
2695,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),371
2696,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
2697,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,4
2698,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),22
2699,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),235
2700,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,1
2701,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
2702,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),11
2703,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),32
2704,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
2705,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,1
2706,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
2707,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),2
2708,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
2709,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
2710,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2711,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),3
2712,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
2713,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
2714,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2715,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),1
2716,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
2717,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
2718,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2719,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),1
2720,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"age, customized","age, customized",B1,Part A: Remdesivir (RDV) for 5 Days,116
2721,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,113
2722,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"age, customized","age, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),581
2723,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"age, customized","age, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),2399
2724,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"age, customized","age, customized",B5,Total,3209
2725,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"age, customized","age, customized",B1,Part A: Remdesivir (RDV) for 5 Days,84
2726,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,84
2727,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"age, customized","age, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),263
2728,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"age, customized","age, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1198
2729,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"age, customized","age, customized",B5,Total,1629
2730,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Part A: Remdesivir (RDV) for 5 Days,80
2731,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,64
2732,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),312
2733,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B4,Part B: Remdesivir for 10 Days (Extension Group),1351
2734,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B5,Total,1807
2735,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Part A: Remdesivir (RDV) for 5 Days,120
2736,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,133
2737,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),532
2738,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B4,Part B: Remdesivir for 10 Days (Extension Group),2246
2739,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B5,Total,3031
2740,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,2
2741,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
2742,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),5
2743,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),40
2744,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,47
2745,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,20
2746,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,25
2747,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),88
2748,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),313
2749,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,446
2750,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,21
2751,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,23
2752,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),149
2753,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),611
2754,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,804
2755,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,1
2756,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
2757,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),11
2758,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),29
2759,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,41
2760,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,142
2761,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,134
2762,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),376
2763,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1915
2764,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,2567
2765,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,0
2766,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,5
2767,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),56
2768,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),179
2769,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,240
2770,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,14
2771,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,10
2772,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),159
2773,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),510
2774,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,693
2775,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,47
2776,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,38
2777,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),328
2778,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1341
2779,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,1754
2780,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,152
2781,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,150
2782,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),478
2783,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),2123
2784,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,2903
2785,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,1
2786,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,9
2787,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),37
2788,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),129
2789,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,176
2790,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,0
2791,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
2792,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),1
2793,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),4
2794,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,5
2795,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,118
2796,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,111
2797,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),722
2798,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),2927
2799,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,3878
2800,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,31
2801,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,30
2802,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),27
2803,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),134
2804,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,222
2805,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,39
2806,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,38
2807,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),16
2808,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),108
2809,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,201
2810,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
2811,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2812,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),33
2813,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),144
2814,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,177
2815,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
2816,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2817,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),5
2818,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),83
2819,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,88
2820,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,1
2821,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,8
2822,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),7
2823,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),44
2824,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,60
2825,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
2826,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2827,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),13
2828,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),44
2829,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,57
2830,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
2831,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2832,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
2833,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),45
2834,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,47
2835,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,3
2836,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
2837,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),12
2838,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),27
2839,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,43
2840,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
2841,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2842,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
2843,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),25
2844,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,27
2845,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,6
2846,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
2847,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2848,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),10
2849,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,22
2850,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,2
2851,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,2
2852,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
2853,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),0
2854,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,6
2855,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
2856,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
2857,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),1
2858,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),4
2859,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,5
2860,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
2861,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
2862,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
2863,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),2
2864,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,5
2865,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
2866,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
2867,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2868,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
2869,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
2870,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,4
2871,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,9
2872,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),844
2873,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
2874,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,857
2875,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,49
2876,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,59
2877,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2878,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),1069
2879,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,1177
2880,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,113
2881,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,108
2882,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2883,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),2214
2884,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,2435
2885,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,34
2886,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,21
2887,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2888,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),314
2889,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,369
2890,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
2891,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
2892,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2893,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
2894,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
2895,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
2896,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
2897,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2898,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
2899,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,maximum_age,N/A,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
2900,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,200
2901,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Part A: Remdesivir for 10 Days,197
2902,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),844
2903,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),3597
2904,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,168
2905,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Part A: Remdesivir for 10 Days,164
2906,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),621
2907,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),2952
2908,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,32
2909,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Part A: Remdesivir for 10 Days,33
2910,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),223
2911,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),645
2912,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,21
2913,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,28
2914,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),188
2915,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),371
2916,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
2917,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,4
2918,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),22
2919,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),235
2920,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,1
2921,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
2922,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),11
2923,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),32
2924,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
2925,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,1
2926,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
2927,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),2
2928,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
2929,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
2930,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2931,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),3
2932,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
2933,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
2934,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2935,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),1
2936,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
2937,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
2938,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
2939,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),1
2940,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"age, customized","age, customized",B1,Part A: Remdesivir (RDV) for 5 Days,116
2941,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,113
2942,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"age, customized","age, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),581
2943,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"age, customized","age, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),2399
2944,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"age, customized","age, customized",B5,Total,3209
2945,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"age, customized","age, customized",B1,Part A: Remdesivir (RDV) for 5 Days,84
2946,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,84
2947,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"age, customized","age, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),263
2948,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"age, customized","age, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1198
2949,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"age, customized","age, customized",B5,Total,1629
2950,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Part A: Remdesivir (RDV) for 5 Days,80
2951,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,64
2952,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),312
2953,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B4,Part B: Remdesivir for 10 Days (Extension Group),1351
2954,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B5,Total,1807
2955,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Part A: Remdesivir (RDV) for 5 Days,120
2956,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,133
2957,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),532
2958,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B4,Part B: Remdesivir for 10 Days (Extension Group),2246
2959,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B5,Total,3031
2960,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,2
2961,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
2962,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),5
2963,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),40
2964,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,47
2965,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,20
2966,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,25
2967,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),88
2968,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),313
2969,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,446
2970,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,21
2971,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,23
2972,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),149
2973,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),611
2974,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,804
2975,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,1
2976,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
2977,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),11
2978,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),29
2979,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,41
2980,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,142
2981,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,134
2982,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),376
2983,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1915
2984,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,2567
2985,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,0
2986,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,5
2987,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),56
2988,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),179
2989,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,240
2990,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,14
2991,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,10
2992,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),159
2993,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),510
2994,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,693
2995,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,47
2996,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,38
2997,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),328
2998,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1341
2999,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,1754
3000,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,152
3001,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,150
3002,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),478
3003,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),2123
3004,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,2903
3005,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,1
3006,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,9
3007,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),37
3008,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),129
3009,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,176
3010,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,0
3011,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
3012,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),1
3013,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),4
3014,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,5
3015,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,118
3016,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,111
3017,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),722
3018,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),2927
3019,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,3878
3020,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,31
3021,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,30
3022,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),27
3023,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),134
3024,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,222
3025,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,39
3026,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,38
3027,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),16
3028,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),108
3029,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,201
3030,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3031,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3032,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),33
3033,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),144
3034,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,177
3035,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3036,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3037,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),5
3038,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),83
3039,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,88
3040,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,1
3041,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,8
3042,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),7
3043,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),44
3044,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,60
3045,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3046,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3047,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),13
3048,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),44
3049,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,57
3050,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3051,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3052,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3053,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),45
3054,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,47
3055,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,3
3056,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
3057,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),12
3058,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),27
3059,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,43
3060,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3061,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3062,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3063,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),25
3064,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,27
3065,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,6
3066,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
3067,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3068,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),10
3069,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,22
3070,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,2
3071,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,2
3072,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3073,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),0
3074,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,6
3075,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3076,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3077,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),1
3078,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),4
3079,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,5
3080,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3081,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
3082,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3083,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),2
3084,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,5
3085,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
3086,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
3087,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3088,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
3089,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
3090,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,4
3091,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,9
3092,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),844
3093,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
3094,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,857
3095,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,49
3096,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,59
3097,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3098,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),1069
3099,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,1177
3100,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,113
3101,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,108
3102,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3103,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),2214
3104,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,2435
3105,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,34
3106,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,21
3107,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3108,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),314
3109,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,369
3110,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
3111,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
3112,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3113,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
3114,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
3115,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
3116,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
3117,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3118,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
3119,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,eligibility,healthy_volunteers,No,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
3120,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,200
3121,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Part A: Remdesivir for 10 Days,197
3122,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),844
3123,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),3597
3124,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,168
3125,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Part A: Remdesivir for 10 Days,164
3126,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),621
3127,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),2952
3128,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,32
3129,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Part A: Remdesivir for 10 Days,33
3130,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),223
3131,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),645
3132,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,21
3133,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,28
3134,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),188
3135,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),371
3136,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
3137,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,4
3138,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),22
3139,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),235
3140,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,1
3141,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
3142,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),11
3143,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),32
3144,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
3145,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,1
3146,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3147,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),2
3148,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
3149,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
3150,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3151,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),3
3152,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
3153,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
3154,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3155,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),1
3156,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
3157,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
3158,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3159,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),1
3160,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"age, customized","age, customized",B1,Part A: Remdesivir (RDV) for 5 Days,116
3161,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,113
3162,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"age, customized","age, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),581
3163,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"age, customized","age, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),2399
3164,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"age, customized","age, customized",B5,Total,3209
3165,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"age, customized","age, customized",B1,Part A: Remdesivir (RDV) for 5 Days,84
3166,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,84
3167,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"age, customized","age, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),263
3168,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"age, customized","age, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1198
3169,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"age, customized","age, customized",B5,Total,1629
3170,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Part A: Remdesivir (RDV) for 5 Days,80
3171,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,64
3172,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),312
3173,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B4,Part B: Remdesivir for 10 Days (Extension Group),1351
3174,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B5,Total,1807
3175,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Part A: Remdesivir (RDV) for 5 Days,120
3176,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,133
3177,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),532
3178,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B4,Part B: Remdesivir for 10 Days (Extension Group),2246
3179,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B5,Total,3031
3180,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,2
3181,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
3182,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),5
3183,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),40
3184,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,47
3185,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,20
3186,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,25
3187,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),88
3188,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),313
3189,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,446
3190,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,21
3191,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,23
3192,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),149
3193,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),611
3194,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,804
3195,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,1
3196,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
3197,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),11
3198,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),29
3199,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,41
3200,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,142
3201,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,134
3202,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),376
3203,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1915
3204,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,2567
3205,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,0
3206,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,5
3207,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),56
3208,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),179
3209,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,240
3210,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,14
3211,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,10
3212,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),159
3213,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),510
3214,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,693
3215,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,47
3216,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,38
3217,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),328
3218,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1341
3219,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,1754
3220,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,152
3221,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,150
3222,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),478
3223,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),2123
3224,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,2903
3225,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,1
3226,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,9
3227,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),37
3228,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),129
3229,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,176
3230,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,0
3231,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
3232,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),1
3233,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),4
3234,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,5
3235,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,118
3236,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,111
3237,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),722
3238,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),2927
3239,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,3878
3240,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,31
3241,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,30
3242,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),27
3243,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),134
3244,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,222
3245,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,39
3246,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,38
3247,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),16
3248,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),108
3249,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,201
3250,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3251,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3252,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),33
3253,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),144
3254,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,177
3255,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3256,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3257,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),5
3258,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),83
3259,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,88
3260,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,1
3261,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,8
3262,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),7
3263,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),44
3264,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,60
3265,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3266,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3267,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),13
3268,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),44
3269,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,57
3270,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3271,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3272,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3273,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),45
3274,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,47
3275,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,3
3276,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
3277,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),12
3278,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),27
3279,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,43
3280,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3281,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3282,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3283,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),25
3284,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,27
3285,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,6
3286,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
3287,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3288,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),10
3289,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,22
3290,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,2
3291,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,2
3292,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3293,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),0
3294,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,6
3295,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3296,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3297,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),1
3298,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),4
3299,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,5
3300,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3301,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
3302,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3303,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),2
3304,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,5
3305,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
3306,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
3307,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3308,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
3309,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
3310,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,4
3311,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,9
3312,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),844
3313,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
3314,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,857
3315,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,49
3316,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,59
3317,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3318,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),1069
3319,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,1177
3320,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,113
3321,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,108
3322,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3323,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),2214
3324,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,2435
3325,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,34
3326,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,21
3327,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3328,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),314
3329,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,369
3330,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
3331,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
3332,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3333,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
3334,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
3335,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
3336,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
3337,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3338,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
3339,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,allocation,Randomized,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
3340,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,200
3341,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Part A: Remdesivir for 10 Days,197
3342,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),844
3343,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),3597
3344,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,168
3345,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Part A: Remdesivir for 10 Days,164
3346,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),621
3347,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),2952
3348,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,32
3349,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Part A: Remdesivir for 10 Days,33
3350,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),223
3351,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),645
3352,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,21
3353,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,28
3354,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),188
3355,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),371
3356,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
3357,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,4
3358,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),22
3359,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),235
3360,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,1
3361,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
3362,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),11
3363,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),32
3364,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
3365,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,1
3366,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3367,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),2
3368,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
3369,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
3370,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3371,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),3
3372,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
3373,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
3374,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3375,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),1
3376,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
3377,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
3378,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3379,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),1
3380,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"age, customized","age, customized",B1,Part A: Remdesivir (RDV) for 5 Days,116
3381,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,113
3382,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"age, customized","age, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),581
3383,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"age, customized","age, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),2399
3384,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"age, customized","age, customized",B5,Total,3209
3385,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"age, customized","age, customized",B1,Part A: Remdesivir (RDV) for 5 Days,84
3386,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,84
3387,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"age, customized","age, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),263
3388,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"age, customized","age, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1198
3389,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"age, customized","age, customized",B5,Total,1629
3390,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Part A: Remdesivir (RDV) for 5 Days,80
3391,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,64
3392,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),312
3393,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B4,Part B: Remdesivir for 10 Days (Extension Group),1351
3394,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B5,Total,1807
3395,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Part A: Remdesivir (RDV) for 5 Days,120
3396,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,133
3397,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),532
3398,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B4,Part B: Remdesivir for 10 Days (Extension Group),2246
3399,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B5,Total,3031
3400,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,2
3401,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
3402,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),5
3403,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),40
3404,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,47
3405,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,20
3406,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,25
3407,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),88
3408,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),313
3409,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,446
3410,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,21
3411,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,23
3412,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),149
3413,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),611
3414,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,804
3415,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,1
3416,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
3417,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),11
3418,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),29
3419,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,41
3420,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,142
3421,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,134
3422,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),376
3423,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1915
3424,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,2567
3425,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,0
3426,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,5
3427,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),56
3428,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),179
3429,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,240
3430,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,14
3431,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,10
3432,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),159
3433,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),510
3434,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,693
3435,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,47
3436,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,38
3437,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),328
3438,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1341
3439,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,1754
3440,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,152
3441,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,150
3442,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),478
3443,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),2123
3444,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,2903
3445,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,1
3446,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,9
3447,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),37
3448,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),129
3449,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,176
3450,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,0
3451,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
3452,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),1
3453,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),4
3454,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,5
3455,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,118
3456,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,111
3457,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),722
3458,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),2927
3459,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,3878
3460,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,31
3461,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,30
3462,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),27
3463,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),134
3464,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,222
3465,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,39
3466,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,38
3467,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),16
3468,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),108
3469,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,201
3470,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3471,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3472,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),33
3473,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),144
3474,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,177
3475,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3476,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3477,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),5
3478,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),83
3479,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,88
3480,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,1
3481,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,8
3482,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),7
3483,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),44
3484,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,60
3485,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3486,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3487,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),13
3488,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),44
3489,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,57
3490,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3491,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3492,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3493,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),45
3494,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,47
3495,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,3
3496,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
3497,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),12
3498,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),27
3499,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,43
3500,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3501,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3502,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3503,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),25
3504,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,27
3505,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,6
3506,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
3507,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3508,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),10
3509,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,22
3510,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,2
3511,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,2
3512,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3513,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),0
3514,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,6
3515,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3516,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3517,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),1
3518,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),4
3519,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,5
3520,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3521,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
3522,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3523,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),2
3524,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,5
3525,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
3526,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
3527,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3528,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
3529,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
3530,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,4
3531,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,9
3532,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),844
3533,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
3534,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,857
3535,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,49
3536,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,59
3537,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3538,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),1069
3539,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,1177
3540,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,113
3541,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,108
3542,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3543,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),2214
3544,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,2435
3545,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,34
3546,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,21
3547,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3548,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),314
3549,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,369
3550,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
3551,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
3552,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3553,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
3554,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
3555,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
3556,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
3557,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3558,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
3559,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,intervention_model,Parallel Assignment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
3560,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,200
3561,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Part A: Remdesivir for 10 Days,197
3562,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),844
3563,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),3597
3564,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,168
3565,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Part A: Remdesivir for 10 Days,164
3566,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),621
3567,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),2952
3568,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,32
3569,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Part A: Remdesivir for 10 Days,33
3570,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),223
3571,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),645
3572,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,21
3573,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,28
3574,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),188
3575,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),371
3576,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
3577,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,4
3578,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),22
3579,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),235
3580,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,1
3581,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
3582,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),11
3583,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),32
3584,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
3585,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,1
3586,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3587,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),2
3588,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
3589,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
3590,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3591,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),3
3592,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
3593,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
3594,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3595,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),1
3596,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
3597,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
3598,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3599,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),1
3600,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"age, customized","age, customized",B1,Part A: Remdesivir (RDV) for 5 Days,116
3601,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,113
3602,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"age, customized","age, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),581
3603,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"age, customized","age, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),2399
3604,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"age, customized","age, customized",B5,Total,3209
3605,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"age, customized","age, customized",B1,Part A: Remdesivir (RDV) for 5 Days,84
3606,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,84
3607,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"age, customized","age, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),263
3608,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"age, customized","age, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1198
3609,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"age, customized","age, customized",B5,Total,1629
3610,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Part A: Remdesivir (RDV) for 5 Days,80
3611,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,64
3612,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),312
3613,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B4,Part B: Remdesivir for 10 Days (Extension Group),1351
3614,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B5,Total,1807
3615,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Part A: Remdesivir (RDV) for 5 Days,120
3616,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,133
3617,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),532
3618,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B4,Part B: Remdesivir for 10 Days (Extension Group),2246
3619,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B5,Total,3031
3620,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,2
3621,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
3622,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),5
3623,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),40
3624,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,47
3625,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,20
3626,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,25
3627,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),88
3628,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),313
3629,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,446
3630,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,21
3631,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,23
3632,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),149
3633,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),611
3634,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,804
3635,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,1
3636,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
3637,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),11
3638,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),29
3639,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,41
3640,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,142
3641,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,134
3642,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),376
3643,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1915
3644,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,2567
3645,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,0
3646,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,5
3647,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),56
3648,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),179
3649,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,240
3650,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,14
3651,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,10
3652,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),159
3653,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),510
3654,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,693
3655,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,47
3656,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,38
3657,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),328
3658,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1341
3659,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,1754
3660,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,152
3661,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,150
3662,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),478
3663,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),2123
3664,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,2903
3665,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,1
3666,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,9
3667,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),37
3668,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),129
3669,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,176
3670,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,0
3671,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
3672,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),1
3673,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),4
3674,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,"race/ethnicity, customized","race/ethnicity, customized",B5,Total,5
3675,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,118
3676,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,111
3677,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),722
3678,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),2927
3679,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,3878
3680,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,31
3681,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,30
3682,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),27
3683,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),134
3684,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,222
3685,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,39
3686,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,38
3687,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),16
3688,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),108
3689,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,201
3690,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3691,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3692,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),33
3693,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),144
3694,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,177
3695,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3696,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3697,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),5
3698,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),83
3699,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,88
3700,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,1
3701,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,8
3702,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),7
3703,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),44
3704,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,60
3705,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3706,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3707,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),13
3708,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),44
3709,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,57
3710,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3711,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3712,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3713,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),45
3714,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,47
3715,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,3
3716,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
3717,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),12
3718,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),27
3719,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,43
3720,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3721,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3722,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3723,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),25
3724,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,27
3725,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,6
3726,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
3727,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3728,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),10
3729,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,22
3730,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,2
3731,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,2
3732,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3733,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),0
3734,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,6
3735,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3736,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3737,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),1
3738,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),4
3739,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,5
3740,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3741,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
3742,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3743,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),2
3744,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,5
3745,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
3746,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
3747,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3748,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
3749,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
3750,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,4
3751,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,9
3752,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),844
3753,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
3754,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,857
3755,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,49
3756,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,59
3757,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3758,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),1069
3759,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,1177
3760,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,113
3761,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,108
3762,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3763,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),2214
3764,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,2435
3765,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,34
3766,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,21
3767,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3768,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),314
3769,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,369
3770,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
3771,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
3772,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3773,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
3774,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
3775,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
3776,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
3777,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3778,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
3779,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,primary_purpose,Treatment,clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
3780,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,200
3781,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,Part A: Remdesivir for 10 Days,197
3782,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),844
3783,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),3597
3784,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,168
3785,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,Part A: Remdesivir for 10 Days,164
3786,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),621
3787,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),2952
3788,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Part A: Remdesivir (RDV) for 5 Days,32
3789,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,Part A: Remdesivir for 10 Days,33
3790,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),223
3791,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P4,Part B: Remdesivir for 10 Days (Extension Group),645
3792,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,21
3793,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,28
3794,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),188
3795,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),371
3796,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,8
3797,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,4
3798,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),22
3799,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),235
3800,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,1
3801,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
3802,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),11
3803,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),32
3804,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,2
3805,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,1
3806,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3807,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),2
3808,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
3809,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
3810,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3811,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),3
3812,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
3813,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
3814,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3815,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),1
3816,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Part A: Remdesivir (RDV) for 5 Days,0
3817,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Part A: Remdesivir for 10 Days,0
3818,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3819,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P4,Part B: Remdesivir for 10 Days (Extension Group),1
3820,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"age, customized","age, customized",B1,Part A: Remdesivir (RDV) for 5 Days,116
3821,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,113
3822,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"age, customized","age, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),581
3823,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"age, customized","age, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),2399
3824,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"age, customized","age, customized",B5,Total,3209
3825,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"age, customized","age, customized",B1,Part A: Remdesivir (RDV) for 5 Days,84
3826,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"age, customized","age, customized",B2,Part A: Remdesivir for 10 Days,84
3827,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"age, customized","age, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),263
3828,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"age, customized","age, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1198
3829,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"age, customized","age, customized",B5,Total,1629
3830,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,Part A: Remdesivir (RDV) for 5 Days,80
3831,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,64
3832,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),312
3833,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B4,Part B: Remdesivir for 10 Days (Extension Group),1351
3834,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B5,Total,1807
3835,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,Part A: Remdesivir (RDV) for 5 Days,120
3836,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B2,Part A: Remdesivir for 10 Days,133
3837,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),532
3838,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B4,Part B: Remdesivir for 10 Days (Extension Group),2246
3839,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B5,Total,3031
3840,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,2
3841,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
3842,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),5
3843,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),40
3844,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,47
3845,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,20
3846,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,25
3847,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),88
3848,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),313
3849,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,446
3850,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,21
3851,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,23
3852,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),149
3853,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),611
3854,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,804
3855,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,1
3856,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
3857,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),11
3858,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),29
3859,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,41
3860,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,142
3861,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,134
3862,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),376
3863,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1915
3864,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,2567
3865,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,0
3866,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,5
3867,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),56
3868,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),179
3869,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,240
3870,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,14
3871,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,10
3872,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),159
3873,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),510
3874,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,693
3875,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,47
3876,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,38
3877,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),328
3878,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),1341
3879,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,1754
3880,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,152
3881,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,150
3882,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),478
3883,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),2123
3884,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,2903
3885,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,1
3886,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,9
3887,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),37
3888,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),129
3889,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,176
3890,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B1,Part A: Remdesivir (RDV) for 5 Days,0
3891,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B2,Part A: Remdesivir for 10 Days,0
3892,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),1
3893,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B4,Part B: Remdesivir for 10 Days (Extension Group),4
3894,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),"race/ethnicity, customized","race/ethnicity, customized",B5,Total,5
3895,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,118
3896,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,111
3897,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),722
3898,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),2927
3899,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,3878
3900,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,31
3901,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,30
3902,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),27
3903,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),134
3904,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,222
3905,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,39
3906,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,38
3907,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),16
3908,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),108
3909,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,201
3910,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3911,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3912,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),33
3913,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),144
3914,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,177
3915,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3916,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3917,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),5
3918,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),83
3919,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,88
3920,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,1
3921,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,8
3922,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),7
3923,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),44
3924,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,60
3925,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3926,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3927,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),13
3928,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),44
3929,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,57
3930,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3931,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3932,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3933,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),45
3934,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,47
3935,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,3
3936,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
3937,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),12
3938,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),27
3939,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,43
3940,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3941,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3942,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3943,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),25
3944,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,27
3945,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,6
3946,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,6
3947,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3948,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),10
3949,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,22
3950,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,2
3951,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,2
3952,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3953,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),0
3954,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,6
3955,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3956,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,0
3957,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),1
3958,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),4
3959,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,5
3960,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Part A: Remdesivir (RDV) for 5 Days,0
3961,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Part A: Remdesivir for 10 Days,1
3962,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),2
3963,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,Part B: Remdesivir for 10 Days (Extension Group),2
3964,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,5
3965,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
3966,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
3967,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3968,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
3969,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
3970,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,4
3971,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,9
3972,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),844
3973,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
3974,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,857
3975,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,49
3976,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,59
3977,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3978,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),1069
3979,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,1177
3980,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,113
3981,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,108
3982,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3983,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),2214
3984,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,2435
3985,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,34
3986,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,21
3987,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3988,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),314
3989,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,369
3990,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
3991,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
3992,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3993,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
3994,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
3995,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B1,Part A: Remdesivir (RDV) for 5 Days,0
3996,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B2,Part A: Remdesivir for 10 Days,0
3997,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B3,Part B: Remdesivir for 10 Days (Mechanically Ventilated Group),0
3998,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B4,Part B: Remdesivir for 10 Days (Extension Group),0
3999,2,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe Coronavirus Disease (COVID-19),Interventional,study_design_info,masking,None (Open Label),clinical status (7-point ordinal scale),clinical status (7-point ordinal scale),B5,Total,0
4000,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ",milestone,milestone,P1,Exposed to Methylprednisolone,83
4001,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ",milestone,milestone,P2,Non-exposed to Methylprednisolone,90
4002,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ",milestone,milestone,P1,Exposed to Methylprednisolone,83
4003,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ",milestone,milestone,P2,Non-exposed to Methylprednisolone,90
4004,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ",milestone,milestone,P1,Exposed to Methylprednisolone,0
4005,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ",milestone,milestone,P2,Non-exposed to Methylprednisolone,0
4006,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ",age,age,B1,Exposed to Methylprednisolone,0
4007,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ",age,age,B2,Non-exposed to Methylprednisolone,0
4008,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ",age,age,B3,Total,0
4009,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ",age,age,B1,Exposed to Methylprednisolone,35
4010,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ",age,age,B2,Non-exposed to Methylprednisolone,34
4011,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ",age,age,B3,Total,69
4012,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ",age,age,B1,Exposed to Methylprednisolone,48
4013,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ",age,age,B2,Non-exposed to Methylprednisolone,56
4014,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ",age,age,B3,Total,104
4015,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B1,Exposed to Methylprednisolone,29
4016,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B2,Non-exposed to Methylprednisolone,24
4017,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B3,Total,53
4018,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B1,Exposed to Methylprednisolone,54
4019,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B2,Non-exposed to Methylprednisolone,66
4020,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B3,Total,120
4021,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ",enrollment region,enrollment region,B1,Exposed to Methylprednisolone,83
4022,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ",enrollment region,enrollment region,B2,Non-exposed to Methylprednisolone,90
4023,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,study_pop,"
      ",enrollment region,enrollment region,B3,Total,173
4024,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P1,Exposed to Methylprednisolone,83
4025,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P2,Non-exposed to Methylprednisolone,90
4026,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P1,Exposed to Methylprednisolone,83
4027,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P2,Non-exposed to Methylprednisolone,90
4028,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P1,Exposed to Methylprednisolone,0
4029,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P2,Non-exposed to Methylprednisolone,0
4030,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,age,age,B1,Exposed to Methylprednisolone,0
4031,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,age,age,B2,Non-exposed to Methylprednisolone,0
4032,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,age,age,B3,Total,0
4033,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,age,age,B1,Exposed to Methylprednisolone,35
4034,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,age,age,B2,Non-exposed to Methylprednisolone,34
4035,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,age,age,B3,Total,69
4036,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,age,age,B1,Exposed to Methylprednisolone,48
4037,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,age,age,B2,Non-exposed to Methylprednisolone,56
4038,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,age,age,B3,Total,104
4039,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B1,Exposed to Methylprednisolone,29
4040,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B2,Non-exposed to Methylprednisolone,24
4041,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B3,Total,53
4042,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B1,Exposed to Methylprednisolone,54
4043,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B2,Non-exposed to Methylprednisolone,66
4044,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B3,Total,120
4045,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,enrollment region,enrollment region,B1,Exposed to Methylprednisolone,83
4046,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,enrollment region,enrollment region,B2,Non-exposed to Methylprednisolone,90
4047,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,sampling_method,Non-Probability Sample,enrollment region,enrollment region,B3,Total,173
4048,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,milestone,milestone,P1,Exposed to Methylprednisolone,83
4049,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,milestone,milestone,P2,Non-exposed to Methylprednisolone,90
4050,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,milestone,milestone,P1,Exposed to Methylprednisolone,83
4051,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,milestone,milestone,P2,Non-exposed to Methylprednisolone,90
4052,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,milestone,milestone,P1,Exposed to Methylprednisolone,0
4053,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,milestone,milestone,P2,Non-exposed to Methylprednisolone,0
4054,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,age,age,B1,Exposed to Methylprednisolone,0
4055,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,age,age,B2,Non-exposed to Methylprednisolone,0
4056,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,age,age,B3,Total,0
4057,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,age,age,B1,Exposed to Methylprednisolone,35
4058,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,age,age,B2,Non-exposed to Methylprednisolone,34
4059,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,age,age,B3,Total,69
4060,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,age,age,B1,Exposed to Methylprednisolone,48
4061,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,age,age,B2,Non-exposed to Methylprednisolone,56
4062,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,age,age,B3,Total,104
4063,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,"sex: female, male","sex: female, male",B1,Exposed to Methylprednisolone,29
4064,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,"sex: female, male","sex: female, male",B2,Non-exposed to Methylprednisolone,24
4065,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,53
4066,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,"sex: female, male","sex: female, male",B1,Exposed to Methylprednisolone,54
4067,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,"sex: female, male","sex: female, male",B2,Non-exposed to Methylprednisolone,66
4068,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,120
4069,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,enrollment region,enrollment region,B1,Exposed to Methylprednisolone,83
4070,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,enrollment region,enrollment region,B2,Non-exposed to Methylprednisolone,90
4071,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,gender,All,enrollment region,enrollment region,B3,Total,173
4072,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,milestone,milestone,P1,Exposed to Methylprednisolone,83
4073,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,milestone,milestone,P2,Non-exposed to Methylprednisolone,90
4074,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,milestone,milestone,P1,Exposed to Methylprednisolone,83
4075,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,milestone,milestone,P2,Non-exposed to Methylprednisolone,90
4076,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,milestone,milestone,P1,Exposed to Methylprednisolone,0
4077,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,milestone,milestone,P2,Non-exposed to Methylprednisolone,0
4078,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,age,age,B1,Exposed to Methylprednisolone,0
4079,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,age,age,B2,Non-exposed to Methylprednisolone,0
4080,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,age,age,B3,Total,0
4081,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,age,age,B1,Exposed to Methylprednisolone,35
4082,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,age,age,B2,Non-exposed to Methylprednisolone,34
4083,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,age,age,B3,Total,69
4084,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,age,age,B1,Exposed to Methylprednisolone,48
4085,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,age,age,B2,Non-exposed to Methylprednisolone,56
4086,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,age,age,B3,Total,104
4087,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Exposed to Methylprednisolone,29
4088,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Non-exposed to Methylprednisolone,24
4089,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,53
4090,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Exposed to Methylprednisolone,54
4091,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Non-exposed to Methylprednisolone,66
4092,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,120
4093,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,Exposed to Methylprednisolone,83
4094,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,enrollment region,enrollment region,B2,Non-exposed to Methylprednisolone,90
4095,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,minimum_age,18 Years,enrollment region,enrollment region,B3,Total,173
4096,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,milestone,milestone,P1,Exposed to Methylprednisolone,83
4097,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,milestone,milestone,P2,Non-exposed to Methylprednisolone,90
4098,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,milestone,milestone,P1,Exposed to Methylprednisolone,83
4099,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,milestone,milestone,P2,Non-exposed to Methylprednisolone,90
4100,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,milestone,milestone,P1,Exposed to Methylprednisolone,0
4101,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,milestone,milestone,P2,Non-exposed to Methylprednisolone,0
4102,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,age,age,B1,Exposed to Methylprednisolone,0
4103,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,age,age,B2,Non-exposed to Methylprednisolone,0
4104,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,age,age,B3,Total,0
4105,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,age,age,B1,Exposed to Methylprednisolone,35
4106,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,age,age,B2,Non-exposed to Methylprednisolone,34
4107,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,age,age,B3,Total,69
4108,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,age,age,B1,Exposed to Methylprednisolone,48
4109,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,age,age,B2,Non-exposed to Methylprednisolone,56
4110,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,age,age,B3,Total,104
4111,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,"sex: female, male","sex: female, male",B1,Exposed to Methylprednisolone,29
4112,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,"sex: female, male","sex: female, male",B2,Non-exposed to Methylprednisolone,24
4113,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,"sex: female, male","sex: female, male",B3,Total,53
4114,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,"sex: female, male","sex: female, male",B1,Exposed to Methylprednisolone,54
4115,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,"sex: female, male","sex: female, male",B2,Non-exposed to Methylprednisolone,66
4116,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,"sex: female, male","sex: female, male",B3,Total,120
4117,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,enrollment region,enrollment region,B1,Exposed to Methylprednisolone,83
4118,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,enrollment region,enrollment region,B2,Non-exposed to Methylprednisolone,90
4119,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,maximum_age,80 Years,enrollment region,enrollment region,B3,Total,173
4120,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,milestone,milestone,P1,Exposed to Methylprednisolone,83
4121,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,milestone,milestone,P2,Non-exposed to Methylprednisolone,90
4122,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,milestone,milestone,P1,Exposed to Methylprednisolone,83
4123,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,milestone,milestone,P2,Non-exposed to Methylprednisolone,90
4124,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,milestone,milestone,P1,Exposed to Methylprednisolone,0
4125,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,milestone,milestone,P2,Non-exposed to Methylprednisolone,0
4126,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,age,age,B1,Exposed to Methylprednisolone,0
4127,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,age,age,B2,Non-exposed to Methylprednisolone,0
4128,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,age,age,B3,Total,0
4129,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,age,age,B1,Exposed to Methylprednisolone,35
4130,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,age,age,B2,Non-exposed to Methylprednisolone,34
4131,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,age,age,B3,Total,69
4132,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,age,age,B1,Exposed to Methylprednisolone,48
4133,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,age,age,B2,Non-exposed to Methylprednisolone,56
4134,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,age,age,B3,Total,104
4135,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Exposed to Methylprednisolone,29
4136,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Non-exposed to Methylprednisolone,24
4137,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Total,53
4138,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Exposed to Methylprednisolone,54
4139,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Non-exposed to Methylprednisolone,66
4140,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Total,120
4141,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Exposed to Methylprednisolone,83
4142,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Non-exposed to Methylprednisolone,90
4143,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Total,173
4144,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,milestone,milestone,P1,Exposed to Methylprednisolone,83
4145,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,milestone,milestone,P2,Non-exposed to Methylprednisolone,90
4146,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,milestone,milestone,P1,Exposed to Methylprednisolone,83
4147,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,milestone,milestone,P2,Non-exposed to Methylprednisolone,90
4148,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,milestone,milestone,P1,Exposed to Methylprednisolone,0
4149,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,milestone,milestone,P2,Non-exposed to Methylprednisolone,0
4150,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,age,age,B1,Exposed to Methylprednisolone,0
4151,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,age,age,B2,Non-exposed to Methylprednisolone,0
4152,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,age,age,B3,Total,0
4153,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,age,age,B1,Exposed to Methylprednisolone,35
4154,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,age,age,B2,Non-exposed to Methylprednisolone,34
4155,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,age,age,B3,Total,69
4156,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,age,age,B1,Exposed to Methylprednisolone,48
4157,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,age,age,B2,Non-exposed to Methylprednisolone,56
4158,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,age,age,B3,Total,104
4159,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B1,Exposed to Methylprednisolone,29
4160,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B2,Non-exposed to Methylprednisolone,24
4161,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B3,Total,53
4162,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B1,Exposed to Methylprednisolone,54
4163,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B2,Non-exposed to Methylprednisolone,66
4164,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B3,Total,120
4165,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,enrollment region,enrollment region,B1,Exposed to Methylprednisolone,83
4166,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,enrollment region,enrollment region,B2,Non-exposed to Methylprednisolone,90
4167,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,observational_model,Cohort,enrollment region,enrollment region,B3,Total,173
4168,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,milestone,milestone,P1,Exposed to Methylprednisolone,83
4169,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,milestone,milestone,P2,Non-exposed to Methylprednisolone,90
4170,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,milestone,milestone,P1,Exposed to Methylprednisolone,83
4171,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,milestone,milestone,P2,Non-exposed to Methylprednisolone,90
4172,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,milestone,milestone,P1,Exposed to Methylprednisolone,0
4173,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,milestone,milestone,P2,Non-exposed to Methylprednisolone,0
4174,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,age,age,B1,Exposed to Methylprednisolone,0
4175,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,age,age,B2,Non-exposed to Methylprednisolone,0
4176,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,age,age,B3,Total,0
4177,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,age,age,B1,Exposed to Methylprednisolone,35
4178,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,age,age,B2,Non-exposed to Methylprednisolone,34
4179,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,age,age,B3,Total,69
4180,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,age,age,B1,Exposed to Methylprednisolone,48
4181,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,age,age,B2,Non-exposed to Methylprednisolone,56
4182,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,age,age,B3,Total,104
4183,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B1,Exposed to Methylprednisolone,29
4184,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B2,Non-exposed to Methylprednisolone,24
4185,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B3,Total,53
4186,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B1,Exposed to Methylprednisolone,54
4187,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B2,Non-exposed to Methylprednisolone,66
4188,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B3,Total,120
4189,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,enrollment region,enrollment region,B1,Exposed to Methylprednisolone,83
4190,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,enrollment region,enrollment region,B2,Non-exposed to Methylprednisolone,90
4191,3,Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome,Observational [Patient Registry],study_design_info,time_perspective,Prospective,enrollment region,enrollment region,B3,Total,173
4192,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,milestone,milestone,P1,Cohort 1 HCQ,17
4193,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,milestone,milestone,P2,Cohort 1 Placebo,17
4194,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,milestone,milestone,P3,Cohort 2 HCQ High Dose,4
4195,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,milestone,milestone,P4,Cohort 2 HCQ Low Dose,3
4196,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,milestone,milestone,P5,Cohort 3 HCQ,66
4197,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,milestone,milestone,P6,Cohort 3 Placebo,66
4198,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,milestone,milestone,P1,Cohort 1 HCQ,16
4199,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,milestone,milestone,P2,Cohort 1 Placebo,13
4200,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,milestone,milestone,P3,Cohort 2 HCQ High Dose,3
4201,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,milestone,milestone,P4,Cohort 2 HCQ Low Dose,2
4202,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,milestone,milestone,P5,Cohort 3 HCQ,64
4203,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,milestone,milestone,P6,Cohort 3 Placebo,61
4204,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,milestone,milestone,P1,Cohort 1 HCQ,1
4205,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,milestone,milestone,P2,Cohort 1 Placebo,4
4206,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,milestone,milestone,P3,Cohort 2 HCQ High Dose,1
4207,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,milestone,milestone,P4,Cohort 2 HCQ Low Dose,1
4208,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,milestone,milestone,P5,Cohort 3 HCQ,2
4209,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,milestone,milestone,P6,Cohort 3 Placebo,5
4210,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,1
4211,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,4
4212,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,1
4213,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,1
4214,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,1
4215,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,1
4216,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,0
4217,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,0
4218,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,0
4219,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,0
4220,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,1
4221,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,2
4222,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,0
4223,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,0
4224,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,0
4225,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,0
4226,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,0
4227,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,2
4228,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Cohort 1 HCQ,12
4229,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Cohort 1 Placebo,9
4230,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Cohort 2 HCQ High Dose,2
4231,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B4,Cohort 2 HCQ Low Dose,3
4232,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B5,Cohort 3 HCQ,54
4233,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B6,Cohort 3 Placebo,33
4234,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B7,Total,113
4235,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Cohort 1 HCQ,5
4236,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Cohort 1 Placebo,8
4237,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Cohort 2 HCQ High Dose,2
4238,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B4,Cohort 2 HCQ Low Dose,0
4239,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B5,Cohort 3 HCQ,12
4240,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B6,Cohort 3 Placebo,33
4241,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B7,Total,60
4242,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4243,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4244,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4245,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4246,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4247,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4248,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B7,Total,0
4249,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4250,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4251,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4252,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4253,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,7
4254,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,7
4255,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B7,Total,14
4256,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4257,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4258,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4259,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4260,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4261,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4262,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B7,Total,0
4263,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,8
4264,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,11
4265,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,3
4266,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,3
4267,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,3
4268,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,1
4269,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B7,Total,29
4270,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,6
4271,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,3
4272,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,1
4273,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4274,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,55
4275,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,56
4276,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B7,Total,121
4277,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4278,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4279,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4280,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4281,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,1
4282,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,2
4283,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B7,Total,3
4284,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,3
4285,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,3
4286,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4287,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4288,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4289,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4290,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B7,Total,6
4291,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Cohort 1 HCQ,17
4292,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Cohort 1 Placebo,17
4293,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P3,Cohort 2 HCQ High Dose,4
4294,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P4,Cohort 2 HCQ Low Dose,3
4295,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P5,Cohort 3 HCQ,66
4296,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P6,Cohort 3 Placebo,66
4297,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Cohort 1 HCQ,16
4298,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Cohort 1 Placebo,13
4299,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P3,Cohort 2 HCQ High Dose,3
4300,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P4,Cohort 2 HCQ Low Dose,2
4301,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P5,Cohort 3 HCQ,64
4302,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P6,Cohort 3 Placebo,61
4303,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Cohort 1 HCQ,1
4304,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Cohort 1 Placebo,4
4305,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P3,Cohort 2 HCQ High Dose,1
4306,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P4,Cohort 2 HCQ Low Dose,1
4307,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P5,Cohort 3 HCQ,2
4308,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P6,Cohort 3 Placebo,5
4309,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,1
4310,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,4
4311,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,1
4312,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,1
4313,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,1
4314,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,1
4315,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,0
4316,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,0
4317,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,0
4318,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,0
4319,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,1
4320,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,2
4321,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,0
4322,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,0
4323,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,0
4324,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,0
4325,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,0
4326,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,2
4327,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Cohort 1 HCQ,12
4328,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Cohort 1 Placebo,9
4329,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Cohort 2 HCQ High Dose,2
4330,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B4,Cohort 2 HCQ Low Dose,3
4331,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B5,Cohort 3 HCQ,54
4332,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B6,Cohort 3 Placebo,33
4333,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B7,Total,113
4334,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Cohort 1 HCQ,5
4335,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Cohort 1 Placebo,8
4336,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Cohort 2 HCQ High Dose,2
4337,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B4,Cohort 2 HCQ Low Dose,0
4338,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B5,Cohort 3 HCQ,12
4339,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B6,Cohort 3 Placebo,33
4340,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B7,Total,60
4341,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4342,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4343,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4344,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4345,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4346,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4347,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B7,Total,0
4348,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4349,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4350,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4351,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4352,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,7
4353,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,7
4354,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B7,Total,14
4355,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4356,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4357,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4358,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4359,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4360,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4361,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B7,Total,0
4362,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,8
4363,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,11
4364,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,3
4365,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,3
4366,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,3
4367,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,1
4368,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B7,Total,29
4369,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,6
4370,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,3
4371,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,1
4372,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4373,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,55
4374,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,56
4375,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B7,Total,121
4376,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4377,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4378,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4379,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4380,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,1
4381,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,2
4382,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B7,Total,3
4383,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,3
4384,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,3
4385,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4386,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4387,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4388,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4389,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B7,Total,6
4390,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Cohort 1 HCQ,17
4391,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Cohort 1 Placebo,17
4392,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P3,Cohort 2 HCQ High Dose,4
4393,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P4,Cohort 2 HCQ Low Dose,3
4394,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P5,Cohort 3 HCQ,66
4395,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P6,Cohort 3 Placebo,66
4396,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Cohort 1 HCQ,16
4397,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Cohort 1 Placebo,13
4398,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P3,Cohort 2 HCQ High Dose,3
4399,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P4,Cohort 2 HCQ Low Dose,2
4400,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P5,Cohort 3 HCQ,64
4401,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P6,Cohort 3 Placebo,61
4402,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Cohort 1 HCQ,1
4403,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Cohort 1 Placebo,4
4404,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P3,Cohort 2 HCQ High Dose,1
4405,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P4,Cohort 2 HCQ Low Dose,1
4406,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P5,Cohort 3 HCQ,2
4407,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,milestone,milestone,P6,Cohort 3 Placebo,5
4408,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,1
4409,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,4
4410,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,1
4411,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,1
4412,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,1
4413,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,1
4414,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,0
4415,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,0
4416,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,0
4417,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,0
4418,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,1
4419,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,2
4420,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,0
4421,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,0
4422,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,0
4423,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,0
4424,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,0
4425,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,2
4426,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Cohort 1 HCQ,12
4427,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Cohort 1 Placebo,9
4428,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Cohort 2 HCQ High Dose,2
4429,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B4,Cohort 2 HCQ Low Dose,3
4430,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B5,Cohort 3 HCQ,54
4431,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B6,Cohort 3 Placebo,33
4432,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B7,Total,113
4433,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Cohort 1 HCQ,5
4434,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Cohort 1 Placebo,8
4435,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Cohort 2 HCQ High Dose,2
4436,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B4,Cohort 2 HCQ Low Dose,0
4437,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B5,Cohort 3 HCQ,12
4438,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B6,Cohort 3 Placebo,33
4439,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B7,Total,60
4440,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4441,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4442,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4443,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4444,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4445,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4446,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B7,Total,0
4447,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4448,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4449,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4450,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4451,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,7
4452,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,7
4453,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B7,Total,14
4454,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4455,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4456,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4457,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4458,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4459,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4460,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B7,Total,0
4461,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,8
4462,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,11
4463,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,3
4464,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,3
4465,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,3
4466,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,1
4467,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B7,Total,29
4468,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,6
4469,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,3
4470,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,1
4471,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4472,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,55
4473,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,56
4474,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B7,Total,121
4475,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4476,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4477,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4478,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4479,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,1
4480,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,2
4481,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B7,Total,3
4482,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,3
4483,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,3
4484,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4485,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4486,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4487,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4488,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B7,Total,6
4489,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,Cohort 1 HCQ,17
4490,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P2,Cohort 1 Placebo,17
4491,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P3,Cohort 2 HCQ High Dose,4
4492,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P4,Cohort 2 HCQ Low Dose,3
4493,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P5,Cohort 3 HCQ,66
4494,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P6,Cohort 3 Placebo,66
4495,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,Cohort 1 HCQ,16
4496,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P2,Cohort 1 Placebo,13
4497,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P3,Cohort 2 HCQ High Dose,3
4498,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P4,Cohort 2 HCQ Low Dose,2
4499,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P5,Cohort 3 HCQ,64
4500,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P6,Cohort 3 Placebo,61
4501,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,Cohort 1 HCQ,1
4502,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P2,Cohort 1 Placebo,4
4503,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P3,Cohort 2 HCQ High Dose,1
4504,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P4,Cohort 2 HCQ Low Dose,1
4505,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P5,Cohort 3 HCQ,2
4506,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P6,Cohort 3 Placebo,5
4507,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,1
4508,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,4
4509,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,1
4510,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,1
4511,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,1
4512,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,1
4513,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,0
4514,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,0
4515,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,0
4516,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,0
4517,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,1
4518,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,2
4519,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,0
4520,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,0
4521,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,0
4522,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,0
4523,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,0
4524,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,2
4525,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B1,Cohort 1 HCQ,12
4526,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B2,Cohort 1 Placebo,9
4527,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B3,Cohort 2 HCQ High Dose,2
4528,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B4,Cohort 2 HCQ Low Dose,3
4529,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B5,Cohort 3 HCQ,54
4530,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B6,Cohort 3 Placebo,33
4531,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B7,Total,113
4532,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B1,Cohort 1 HCQ,5
4533,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B2,Cohort 1 Placebo,8
4534,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B3,Cohort 2 HCQ High Dose,2
4535,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B4,Cohort 2 HCQ Low Dose,0
4536,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B5,Cohort 3 HCQ,12
4537,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B6,Cohort 3 Placebo,33
4538,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B7,Total,60
4539,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4540,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4541,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4542,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4543,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4544,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4545,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B7,Total,0
4546,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4547,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4548,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4549,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4550,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,7
4551,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,7
4552,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B7,Total,14
4553,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4554,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4555,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4556,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4557,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4558,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4559,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B7,Total,0
4560,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,8
4561,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,11
4562,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,3
4563,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,3
4564,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,3
4565,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,1
4566,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B7,Total,29
4567,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,6
4568,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,3
4569,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,1
4570,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4571,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,55
4572,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,56
4573,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B7,Total,121
4574,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4575,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4576,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4577,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4578,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,1
4579,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,2
4580,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B7,Total,3
4581,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,3
4582,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,3
4583,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4584,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4585,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4586,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4587,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B7,Total,6
4588,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Cohort 1 HCQ,17
4589,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Cohort 1 Placebo,17
4590,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P3,Cohort 2 HCQ High Dose,4
4591,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P4,Cohort 2 HCQ Low Dose,3
4592,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P5,Cohort 3 HCQ,66
4593,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P6,Cohort 3 Placebo,66
4594,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Cohort 1 HCQ,16
4595,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Cohort 1 Placebo,13
4596,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P3,Cohort 2 HCQ High Dose,3
4597,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P4,Cohort 2 HCQ Low Dose,2
4598,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P5,Cohort 3 HCQ,64
4599,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P6,Cohort 3 Placebo,61
4600,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Cohort 1 HCQ,1
4601,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Cohort 1 Placebo,4
4602,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P3,Cohort 2 HCQ High Dose,1
4603,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P4,Cohort 2 HCQ Low Dose,1
4604,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P5,Cohort 3 HCQ,2
4605,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,milestone,milestone,P6,Cohort 3 Placebo,5
4606,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,1
4607,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,4
4608,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,1
4609,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,1
4610,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,1
4611,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,1
4612,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,0
4613,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,0
4614,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,0
4615,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,0
4616,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,1
4617,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,2
4618,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,0
4619,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,0
4620,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,0
4621,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,0
4622,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,0
4623,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,2
4624,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Cohort 1 HCQ,12
4625,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Cohort 1 Placebo,9
4626,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Cohort 2 HCQ High Dose,2
4627,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B4,Cohort 2 HCQ Low Dose,3
4628,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B5,Cohort 3 HCQ,54
4629,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B6,Cohort 3 Placebo,33
4630,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B7,Total,113
4631,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Cohort 1 HCQ,5
4632,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Cohort 1 Placebo,8
4633,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Cohort 2 HCQ High Dose,2
4634,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B4,Cohort 2 HCQ Low Dose,0
4635,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B5,Cohort 3 HCQ,12
4636,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B6,Cohort 3 Placebo,33
4637,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B7,Total,60
4638,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4639,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4640,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4641,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4642,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4643,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4644,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B7,Total,0
4645,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4646,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4647,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4648,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4649,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,7
4650,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,7
4651,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B7,Total,14
4652,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4653,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4654,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4655,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4656,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4657,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4658,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B7,Total,0
4659,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,8
4660,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,11
4661,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,3
4662,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,3
4663,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,3
4664,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,1
4665,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B7,Total,29
4666,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,6
4667,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,3
4668,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,1
4669,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4670,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,55
4671,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,56
4672,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B7,Total,121
4673,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4674,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4675,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4676,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4677,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,1
4678,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,2
4679,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B7,Total,3
4680,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,3
4681,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,3
4682,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4683,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4684,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4685,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4686,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B7,Total,6
4687,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Cohort 1 HCQ,17
4688,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Cohort 1 Placebo,17
4689,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P3,Cohort 2 HCQ High Dose,4
4690,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P4,Cohort 2 HCQ Low Dose,3
4691,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P5,Cohort 3 HCQ,66
4692,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P6,Cohort 3 Placebo,66
4693,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Cohort 1 HCQ,16
4694,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Cohort 1 Placebo,13
4695,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P3,Cohort 2 HCQ High Dose,3
4696,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P4,Cohort 2 HCQ Low Dose,2
4697,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P5,Cohort 3 HCQ,64
4698,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P6,Cohort 3 Placebo,61
4699,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Cohort 1 HCQ,1
4700,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Cohort 1 Placebo,4
4701,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P3,Cohort 2 HCQ High Dose,1
4702,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P4,Cohort 2 HCQ Low Dose,1
4703,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P5,Cohort 3 HCQ,2
4704,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P6,Cohort 3 Placebo,5
4705,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,1
4706,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,4
4707,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,1
4708,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,1
4709,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,1
4710,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,1
4711,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,0
4712,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,0
4713,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,0
4714,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,0
4715,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,1
4716,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,2
4717,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,0
4718,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,0
4719,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,0
4720,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,0
4721,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,0
4722,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,2
4723,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Cohort 1 HCQ,12
4724,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Cohort 1 Placebo,9
4725,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Cohort 2 HCQ High Dose,2
4726,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B4,Cohort 2 HCQ Low Dose,3
4727,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B5,Cohort 3 HCQ,54
4728,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B6,Cohort 3 Placebo,33
4729,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B7,Total,113
4730,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Cohort 1 HCQ,5
4731,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Cohort 1 Placebo,8
4732,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Cohort 2 HCQ High Dose,2
4733,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B4,Cohort 2 HCQ Low Dose,0
4734,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B5,Cohort 3 HCQ,12
4735,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B6,Cohort 3 Placebo,33
4736,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B7,Total,60
4737,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4738,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4739,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4740,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4741,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4742,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4743,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B7,Total,0
4744,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4745,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4746,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4747,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4748,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,7
4749,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,7
4750,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B7,Total,14
4751,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4752,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4753,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4754,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4755,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4756,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4757,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B7,Total,0
4758,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,8
4759,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,11
4760,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,3
4761,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,3
4762,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,3
4763,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,1
4764,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B7,Total,29
4765,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,6
4766,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,3
4767,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,1
4768,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4769,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,55
4770,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,56
4771,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B7,Total,121
4772,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4773,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4774,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4775,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4776,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,1
4777,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,2
4778,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B7,Total,3
4779,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,3
4780,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,3
4781,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4782,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4783,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4784,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4785,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B7,Total,6
4786,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,milestone,milestone,P1,Cohort 1 HCQ,17
4787,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,milestone,milestone,P2,Cohort 1 Placebo,17
4788,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,milestone,milestone,P3,Cohort 2 HCQ High Dose,4
4789,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,milestone,milestone,P4,Cohort 2 HCQ Low Dose,3
4790,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,milestone,milestone,P5,Cohort 3 HCQ,66
4791,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,milestone,milestone,P6,Cohort 3 Placebo,66
4792,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,milestone,milestone,P1,Cohort 1 HCQ,16
4793,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,milestone,milestone,P2,Cohort 1 Placebo,13
4794,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,milestone,milestone,P3,Cohort 2 HCQ High Dose,3
4795,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,milestone,milestone,P4,Cohort 2 HCQ Low Dose,2
4796,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,milestone,milestone,P5,Cohort 3 HCQ,64
4797,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,milestone,milestone,P6,Cohort 3 Placebo,61
4798,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,milestone,milestone,P1,Cohort 1 HCQ,1
4799,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,milestone,milestone,P2,Cohort 1 Placebo,4
4800,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,milestone,milestone,P3,Cohort 2 HCQ High Dose,1
4801,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,milestone,milestone,P4,Cohort 2 HCQ Low Dose,1
4802,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,milestone,milestone,P5,Cohort 3 HCQ,2
4803,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,milestone,milestone,P6,Cohort 3 Placebo,5
4804,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,1
4805,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,4
4806,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,1
4807,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,1
4808,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,1
4809,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,1
4810,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,0
4811,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,0
4812,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,0
4813,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,0
4814,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,1
4815,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,2
4816,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,0
4817,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,0
4818,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,0
4819,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,0
4820,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,0
4821,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,2
4822,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,"sex: female, male","sex: female, male",B1,Cohort 1 HCQ,12
4823,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,"sex: female, male","sex: female, male",B2,Cohort 1 Placebo,9
4824,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,"sex: female, male","sex: female, male",B3,Cohort 2 HCQ High Dose,2
4825,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,"sex: female, male","sex: female, male",B4,Cohort 2 HCQ Low Dose,3
4826,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,"sex: female, male","sex: female, male",B5,Cohort 3 HCQ,54
4827,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,"sex: female, male","sex: female, male",B6,Cohort 3 Placebo,33
4828,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,"sex: female, male","sex: female, male",B7,Total,113
4829,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,"sex: female, male","sex: female, male",B1,Cohort 1 HCQ,5
4830,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,"sex: female, male","sex: female, male",B2,Cohort 1 Placebo,8
4831,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,"sex: female, male","sex: female, male",B3,Cohort 2 HCQ High Dose,2
4832,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,"sex: female, male","sex: female, male",B4,Cohort 2 HCQ Low Dose,0
4833,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,"sex: female, male","sex: female, male",B5,Cohort 3 HCQ,12
4834,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,"sex: female, male","sex: female, male",B6,Cohort 3 Placebo,33
4835,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,"sex: female, male","sex: female, male",B7,Total,60
4836,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4837,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4838,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4839,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4840,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4841,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4842,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B7,Total,0
4843,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4844,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4845,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4846,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4847,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,7
4848,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,7
4849,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B7,Total,14
4850,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4851,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4852,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4853,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4854,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4855,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4856,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B7,Total,0
4857,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,8
4858,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,11
4859,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,3
4860,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,3
4861,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,3
4862,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,1
4863,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B7,Total,29
4864,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,6
4865,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,3
4866,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,1
4867,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4868,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,55
4869,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,56
4870,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B7,Total,121
4871,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4872,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4873,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4874,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4875,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,1
4876,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,2
4877,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B7,Total,3
4878,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,3
4879,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,3
4880,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4881,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4882,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4883,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4884,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,intervention_model_description,There are 3 cohorts. All partcipants in of each the cohorts are randomized to one of two arms,race (nih/omb),race (nih/omb),B7,Total,6
4885,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Cohort 1 HCQ,17
4886,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Cohort 1 Placebo,17
4887,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P3,Cohort 2 HCQ High Dose,4
4888,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P4,Cohort 2 HCQ Low Dose,3
4889,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P5,Cohort 3 HCQ,66
4890,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P6,Cohort 3 Placebo,66
4891,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Cohort 1 HCQ,16
4892,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Cohort 1 Placebo,13
4893,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P3,Cohort 2 HCQ High Dose,3
4894,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P4,Cohort 2 HCQ Low Dose,2
4895,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P5,Cohort 3 HCQ,64
4896,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P6,Cohort 3 Placebo,61
4897,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Cohort 1 HCQ,1
4898,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Cohort 1 Placebo,4
4899,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P3,Cohort 2 HCQ High Dose,1
4900,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P4,Cohort 2 HCQ Low Dose,1
4901,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P5,Cohort 3 HCQ,2
4902,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P6,Cohort 3 Placebo,5
4903,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,1
4904,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,4
4905,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,1
4906,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,1
4907,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,1
4908,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,1
4909,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,0
4910,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,0
4911,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,0
4912,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,0
4913,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,1
4914,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,2
4915,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,0
4916,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,0
4917,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,0
4918,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,0
4919,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,0
4920,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,2
4921,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Cohort 1 HCQ,12
4922,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Cohort 1 Placebo,9
4923,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Cohort 2 HCQ High Dose,2
4924,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B4,Cohort 2 HCQ Low Dose,3
4925,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B5,Cohort 3 HCQ,54
4926,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B6,Cohort 3 Placebo,33
4927,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B7,Total,113
4928,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Cohort 1 HCQ,5
4929,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Cohort 1 Placebo,8
4930,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Cohort 2 HCQ High Dose,2
4931,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B4,Cohort 2 HCQ Low Dose,0
4932,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B5,Cohort 3 HCQ,12
4933,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B6,Cohort 3 Placebo,33
4934,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B7,Total,60
4935,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4936,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4937,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4938,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4939,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4940,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4941,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B7,Total,0
4942,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4943,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4944,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4945,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4946,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,7
4947,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,7
4948,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B7,Total,14
4949,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4950,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4951,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4952,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4953,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4954,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4955,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B7,Total,0
4956,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,8
4957,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,11
4958,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,3
4959,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,3
4960,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,3
4961,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,1
4962,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B7,Total,29
4963,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,6
4964,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,3
4965,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,1
4966,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4967,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,55
4968,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,56
4969,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B7,Total,121
4970,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
4971,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
4972,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4973,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4974,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,1
4975,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,2
4976,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B7,Total,3
4977,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,3
4978,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,3
4979,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
4980,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
4981,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
4982,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
4983,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B7,Total,6
4984,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",milestone,milestone,P1,Cohort 1 HCQ,17
4985,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",milestone,milestone,P2,Cohort 1 Placebo,17
4986,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",milestone,milestone,P3,Cohort 2 HCQ High Dose,4
4987,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",milestone,milestone,P4,Cohort 2 HCQ Low Dose,3
4988,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",milestone,milestone,P5,Cohort 3 HCQ,66
4989,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",milestone,milestone,P6,Cohort 3 Placebo,66
4990,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",milestone,milestone,P1,Cohort 1 HCQ,16
4991,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",milestone,milestone,P2,Cohort 1 Placebo,13
4992,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",milestone,milestone,P3,Cohort 2 HCQ High Dose,3
4993,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",milestone,milestone,P4,Cohort 2 HCQ Low Dose,2
4994,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",milestone,milestone,P5,Cohort 3 HCQ,64
4995,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",milestone,milestone,P6,Cohort 3 Placebo,61
4996,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",milestone,milestone,P1,Cohort 1 HCQ,1
4997,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",milestone,milestone,P2,Cohort 1 Placebo,4
4998,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",milestone,milestone,P3,Cohort 2 HCQ High Dose,1
4999,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",milestone,milestone,P4,Cohort 2 HCQ Low Dose,1
5000,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",milestone,milestone,P5,Cohort 3 HCQ,2
5001,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",milestone,milestone,P6,Cohort 3 Placebo,5
5002,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,1
5003,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,4
5004,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,1
5005,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,1
5006,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,1
5007,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,1
5008,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,0
5009,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,0
5010,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,0
5011,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,0
5012,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,1
5013,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,2
5014,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,0
5015,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,0
5016,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,0
5017,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,0
5018,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,0
5019,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,2
5020,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)","sex: female, male","sex: female, male",B1,Cohort 1 HCQ,12
5021,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)","sex: female, male","sex: female, male",B2,Cohort 1 Placebo,9
5022,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)","sex: female, male","sex: female, male",B3,Cohort 2 HCQ High Dose,2
5023,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)","sex: female, male","sex: female, male",B4,Cohort 2 HCQ Low Dose,3
5024,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)","sex: female, male","sex: female, male",B5,Cohort 3 HCQ,54
5025,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)","sex: female, male","sex: female, male",B6,Cohort 3 Placebo,33
5026,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)","sex: female, male","sex: female, male",B7,Total,113
5027,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)","sex: female, male","sex: female, male",B1,Cohort 1 HCQ,5
5028,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)","sex: female, male","sex: female, male",B2,Cohort 1 Placebo,8
5029,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)","sex: female, male","sex: female, male",B3,Cohort 2 HCQ High Dose,2
5030,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)","sex: female, male","sex: female, male",B4,Cohort 2 HCQ Low Dose,0
5031,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)","sex: female, male","sex: female, male",B5,Cohort 3 HCQ,12
5032,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)","sex: female, male","sex: female, male",B6,Cohort 3 Placebo,33
5033,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)","sex: female, male","sex: female, male",B7,Total,60
5034,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
5035,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
5036,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
5037,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
5038,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
5039,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
5040,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B7,Total,0
5041,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
5042,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
5043,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
5044,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
5045,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,7
5046,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,7
5047,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B7,Total,14
5048,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
5049,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
5050,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
5051,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
5052,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
5053,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
5054,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B7,Total,0
5055,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,8
5056,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,11
5057,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,3
5058,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,3
5059,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,3
5060,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,1
5061,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B7,Total,29
5062,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,6
5063,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,3
5064,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,1
5065,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
5066,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,55
5067,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,56
5068,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B7,Total,121
5069,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
5070,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
5071,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
5072,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
5073,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,1
5074,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,2
5075,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B7,Total,3
5076,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,3
5077,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,3
5078,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
5079,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
5080,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
5081,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
5082,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking,"Triple (Participant, Care Provider, Investigator)",race (nih/omb),race (nih/omb),B7,Total,6
5083,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,milestone,milestone,P1,Cohort 1 HCQ,17
5084,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,milestone,milestone,P2,Cohort 1 Placebo,17
5085,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,milestone,milestone,P3,Cohort 2 HCQ High Dose,4
5086,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,milestone,milestone,P4,Cohort 2 HCQ Low Dose,3
5087,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,milestone,milestone,P5,Cohort 3 HCQ,66
5088,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,milestone,milestone,P6,Cohort 3 Placebo,66
5089,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,milestone,milestone,P1,Cohort 1 HCQ,16
5090,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,milestone,milestone,P2,Cohort 1 Placebo,13
5091,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,milestone,milestone,P3,Cohort 2 HCQ High Dose,3
5092,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,milestone,milestone,P4,Cohort 2 HCQ Low Dose,2
5093,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,milestone,milestone,P5,Cohort 3 HCQ,64
5094,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,milestone,milestone,P6,Cohort 3 Placebo,61
5095,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,milestone,milestone,P1,Cohort 1 HCQ,1
5096,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,milestone,milestone,P2,Cohort 1 Placebo,4
5097,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,milestone,milestone,P3,Cohort 2 HCQ High Dose,1
5098,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,milestone,milestone,P4,Cohort 2 HCQ Low Dose,1
5099,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,milestone,milestone,P5,Cohort 3 HCQ,2
5100,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,milestone,milestone,P6,Cohort 3 Placebo,5
5101,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,1
5102,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,4
5103,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,1
5104,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,1
5105,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,1
5106,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,1
5107,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,0
5108,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,0
5109,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,0
5110,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,0
5111,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,1
5112,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,2
5113,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,withdrawal reason,withdrawal reason,P1,Cohort 1 HCQ,0
5114,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,withdrawal reason,withdrawal reason,P2,Cohort 1 Placebo,0
5115,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,withdrawal reason,withdrawal reason,P3,Cohort 2 HCQ High Dose,0
5116,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,withdrawal reason,withdrawal reason,P4,Cohort 2 HCQ Low Dose,0
5117,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,withdrawal reason,withdrawal reason,P5,Cohort 3 HCQ,0
5118,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,withdrawal reason,withdrawal reason,P6,Cohort 3 Placebo,2
5119,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,"sex: female, male","sex: female, male",B1,Cohort 1 HCQ,12
5120,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,"sex: female, male","sex: female, male",B2,Cohort 1 Placebo,9
5121,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,"sex: female, male","sex: female, male",B3,Cohort 2 HCQ High Dose,2
5122,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,"sex: female, male","sex: female, male",B4,Cohort 2 HCQ Low Dose,3
5123,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,"sex: female, male","sex: female, male",B5,Cohort 3 HCQ,54
5124,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,"sex: female, male","sex: female, male",B6,Cohort 3 Placebo,33
5125,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,"sex: female, male","sex: female, male",B7,Total,113
5126,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,"sex: female, male","sex: female, male",B1,Cohort 1 HCQ,5
5127,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,"sex: female, male","sex: female, male",B2,Cohort 1 Placebo,8
5128,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,"sex: female, male","sex: female, male",B3,Cohort 2 HCQ High Dose,2
5129,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,"sex: female, male","sex: female, male",B4,Cohort 2 HCQ Low Dose,0
5130,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,"sex: female, male","sex: female, male",B5,Cohort 3 HCQ,12
5131,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,"sex: female, male","sex: female, male",B6,Cohort 3 Placebo,33
5132,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,"sex: female, male","sex: female, male",B7,Total,60
5133,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
5134,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
5135,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
5136,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
5137,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
5138,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
5139,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B7,Total,0
5140,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
5141,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
5142,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
5143,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
5144,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,7
5145,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,7
5146,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B7,Total,14
5147,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
5148,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
5149,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
5150,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
5151,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
5152,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
5153,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B7,Total,0
5154,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,8
5155,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,11
5156,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,3
5157,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,3
5158,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,3
5159,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,1
5160,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B7,Total,29
5161,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,6
5162,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,3
5163,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,1
5164,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
5165,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,55
5166,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,56
5167,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B7,Total,121
5168,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,0
5169,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,0
5170,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
5171,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
5172,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,1
5173,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,2
5174,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B7,Total,3
5175,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B1,Cohort 1 HCQ,3
5176,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B2,Cohort 1 Placebo,3
5177,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B3,Cohort 2 HCQ High Dose,0
5178,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B4,Cohort 2 HCQ Low Dose,0
5179,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B5,Cohort 3 HCQ,0
5180,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B6,Cohort 3 Placebo,0
5181,4,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Interventional,study_design_info,masking_description,Cohorts 1 and 3 are double-blind placebo control cohorts. Cohort 2 is an open label randomized study,race (nih/omb),race (nih/omb),B7,Total,6
5182,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,gender,All,milestone,milestone,P1,GO2 PEEP MOUTHPIECE,2
5183,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,gender,All,milestone,milestone,P1,GO2 PEEP MOUTHPIECE,2
5184,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,gender,All,milestone,milestone,P1,GO2 PEEP MOUTHPIECE,0
5185,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,GO2 PEEP MOUTHPIECE,0
5186,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,GO2 PEEP MOUTHPIECE,2
5187,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5188,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5189,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5190,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5191,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5192,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5193,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5194,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5195,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5196,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5197,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,GO2 PEEP MOUTHPIECE,2
5198,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,GO2 PEEP MOUTHPIECE,2
5199,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,GO2 PEEP MOUTHPIECE,2
5200,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,GO2 PEEP MOUTHPIECE,0
5201,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,GO2 PEEP MOUTHPIECE,0
5202,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,GO2 PEEP MOUTHPIECE,2
5203,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5204,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5205,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5206,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5207,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5208,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5209,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5210,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5211,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5212,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5213,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,GO2 PEEP MOUTHPIECE,2
5214,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,GO2 PEEP MOUTHPIECE,2
5215,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,GO2 PEEP MOUTHPIECE,2
5216,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,GO2 PEEP MOUTHPIECE,0
5217,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,GO2 PEEP MOUTHPIECE,0
5218,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,GO2 PEEP MOUTHPIECE,2
5219,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5220,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5221,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5222,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5223,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5224,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5225,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5226,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5227,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5228,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5229,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,GO2 PEEP MOUTHPIECE,2
5230,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,GO2 PEEP MOUTHPIECE,2
5231,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,GO2 PEEP MOUTHPIECE,2
5232,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,GO2 PEEP MOUTHPIECE,0
5233,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,GO2 PEEP MOUTHPIECE,0
5234,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,GO2 PEEP MOUTHPIECE,2
5235,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5236,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5237,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5238,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5239,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5240,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5241,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5242,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5243,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5244,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5245,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,GO2 PEEP MOUTHPIECE,2
5246,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,allocation,N/A,milestone,milestone,P1,GO2 PEEP MOUTHPIECE,2
5247,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,allocation,N/A,milestone,milestone,P1,GO2 PEEP MOUTHPIECE,2
5248,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,allocation,N/A,milestone,milestone,P1,GO2 PEEP MOUTHPIECE,0
5249,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,allocation,N/A,"sex: female, male","sex: female, male",B1,GO2 PEEP MOUTHPIECE,0
5250,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,allocation,N/A,"sex: female, male","sex: female, male",B1,GO2 PEEP MOUTHPIECE,2
5251,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,allocation,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5252,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,allocation,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5253,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,allocation,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5254,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,allocation,N/A,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5255,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,allocation,N/A,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5256,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,allocation,N/A,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5257,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,allocation,N/A,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5258,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,allocation,N/A,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5259,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,allocation,N/A,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5260,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,allocation,N/A,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5261,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,allocation,N/A,enrollment region,enrollment region,B1,GO2 PEEP MOUTHPIECE,2
5262,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,intervention_model,Single Group Assignment,milestone,milestone,P1,GO2 PEEP MOUTHPIECE,2
5263,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,intervention_model,Single Group Assignment,milestone,milestone,P1,GO2 PEEP MOUTHPIECE,2
5264,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,intervention_model,Single Group Assignment,milestone,milestone,P1,GO2 PEEP MOUTHPIECE,0
5265,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,intervention_model,Single Group Assignment,"sex: female, male","sex: female, male",B1,GO2 PEEP MOUTHPIECE,0
5266,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,intervention_model,Single Group Assignment,"sex: female, male","sex: female, male",B1,GO2 PEEP MOUTHPIECE,2
5267,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,intervention_model,Single Group Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5268,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,intervention_model,Single Group Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5269,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,intervention_model,Single Group Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5270,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,intervention_model,Single Group Assignment,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5271,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,intervention_model,Single Group Assignment,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5272,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,intervention_model,Single Group Assignment,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5273,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,intervention_model,Single Group Assignment,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5274,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,intervention_model,Single Group Assignment,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5275,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,intervention_model,Single Group Assignment,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5276,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,intervention_model,Single Group Assignment,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5277,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,intervention_model,Single Group Assignment,enrollment region,enrollment region,B1,GO2 PEEP MOUTHPIECE,2
5278,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,primary_purpose,Supportive Care,milestone,milestone,P1,GO2 PEEP MOUTHPIECE,2
5279,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,primary_purpose,Supportive Care,milestone,milestone,P1,GO2 PEEP MOUTHPIECE,2
5280,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,primary_purpose,Supportive Care,milestone,milestone,P1,GO2 PEEP MOUTHPIECE,0
5281,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,primary_purpose,Supportive Care,"sex: female, male","sex: female, male",B1,GO2 PEEP MOUTHPIECE,0
5282,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,primary_purpose,Supportive Care,"sex: female, male","sex: female, male",B1,GO2 PEEP MOUTHPIECE,2
5283,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,primary_purpose,Supportive Care,ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5284,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,primary_purpose,Supportive Care,ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5285,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,primary_purpose,Supportive Care,ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5286,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,primary_purpose,Supportive Care,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5287,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,primary_purpose,Supportive Care,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5288,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,primary_purpose,Supportive Care,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5289,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,primary_purpose,Supportive Care,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5290,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,primary_purpose,Supportive Care,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5291,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,primary_purpose,Supportive Care,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5292,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,primary_purpose,Supportive Care,race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5293,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,primary_purpose,Supportive Care,enrollment region,enrollment region,B1,GO2 PEEP MOUTHPIECE,2
5294,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,GO2 PEEP MOUTHPIECE,2
5295,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,GO2 PEEP MOUTHPIECE,2
5296,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,GO2 PEEP MOUTHPIECE,0
5297,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,GO2 PEEP MOUTHPIECE,0
5298,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,GO2 PEEP MOUTHPIECE,2
5299,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,masking,None (Open Label),ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5300,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,masking,None (Open Label),ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5301,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,masking,None (Open Label),ethnicity (nih/omb),ethnicity (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5302,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5303,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5304,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5305,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5306,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5307,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,0
5308,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,GO2 PEEP MOUTHPIECE,1
5309,5,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,GO2 PEEP MOUTHPIECE,2
5310,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,milestone,milestone,P1,Hydroxychloroquine,242
5311,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,milestone,milestone,P2,Placebo,237
5312,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,milestone,milestone,P1,Hydroxychloroquine,242
5313,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,milestone,milestone,P2,Placebo,237
5314,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,milestone,milestone,P1,Hydroxychloroquine,0
5315,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,milestone,milestone,P2,Placebo,0
5316,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Hydroxychloroquine,107
5317,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Placebo,105
5318,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,212
5319,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Hydroxychloroquine,135
5320,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Placebo,132
5321,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,267
5322,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,13
5323,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,19
5324,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,32
5325,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,28
5326,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,27
5327,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,55
5328,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,116
5329,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,108
5330,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,224
5331,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,85
5332,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,83
5333,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,gender,All,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,168
5334,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Hydroxychloroquine,242
5335,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Placebo,237
5336,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Hydroxychloroquine,242
5337,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Placebo,237
5338,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Hydroxychloroquine,0
5339,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Placebo,0
5340,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Hydroxychloroquine,107
5341,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Placebo,105
5342,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,212
5343,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Hydroxychloroquine,135
5344,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Placebo,132
5345,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,267
5346,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,13
5347,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,19
5348,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,32
5349,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,28
5350,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,27
5351,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,55
5352,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,116
5353,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,108
5354,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,224
5355,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,85
5356,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,83
5357,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,minimum_age,18 Years,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,168
5358,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Hydroxychloroquine,242
5359,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Placebo,237
5360,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Hydroxychloroquine,242
5361,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Placebo,237
5362,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Hydroxychloroquine,0
5363,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Placebo,0
5364,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Hydroxychloroquine,107
5365,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Placebo,105
5366,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Total,212
5367,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Hydroxychloroquine,135
5368,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Placebo,132
5369,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Total,267
5370,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,13
5371,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,19
5372,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,32
5373,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,28
5374,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,27
5375,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,55
5376,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,116
5377,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,108
5378,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,224
5379,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,85
5380,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,83
5381,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,maximum_age,N/A,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,168
5382,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Hydroxychloroquine,242
5383,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Placebo,237
5384,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Hydroxychloroquine,242
5385,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Placebo,237
5386,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Hydroxychloroquine,0
5387,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Placebo,0
5388,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Hydroxychloroquine,107
5389,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Placebo,105
5390,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Total,212
5391,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Hydroxychloroquine,135
5392,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Placebo,132
5393,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Total,267
5394,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,13
5395,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,19
5396,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,32
5397,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,28
5398,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,27
5399,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,55
5400,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,116
5401,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,108
5402,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,224
5403,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,85
5404,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,83
5405,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,eligibility,healthy_volunteers,No,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,168
5406,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Hydroxychloroquine,242
5407,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Placebo,237
5408,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Hydroxychloroquine,242
5409,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Placebo,237
5410,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Hydroxychloroquine,0
5411,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Placebo,0
5412,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Hydroxychloroquine,107
5413,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Placebo,105
5414,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,212
5415,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Hydroxychloroquine,135
5416,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Placebo,132
5417,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,267
5418,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,13
5419,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,19
5420,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,32
5421,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,28
5422,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,27
5423,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,55
5424,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,116
5425,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,108
5426,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,224
5427,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,85
5428,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,83
5429,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,allocation,Randomized,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,168
5430,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Hydroxychloroquine,242
5431,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Placebo,237
5432,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Hydroxychloroquine,242
5433,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Placebo,237
5434,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Hydroxychloroquine,0
5435,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Placebo,0
5436,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Hydroxychloroquine,107
5437,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Placebo,105
5438,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Total,212
5439,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Hydroxychloroquine,135
5440,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Placebo,132
5441,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Total,267
5442,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,13
5443,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,19
5444,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,32
5445,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,28
5446,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,27
5447,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,55
5448,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,116
5449,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,108
5450,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,224
5451,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,85
5452,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,83
5453,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,168
5454,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,milestone,milestone,P1,Hydroxychloroquine,242
5455,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,milestone,milestone,P2,Placebo,237
5456,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,milestone,milestone,P1,Hydroxychloroquine,242
5457,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,milestone,milestone,P2,Placebo,237
5458,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,milestone,milestone,P1,Hydroxychloroquine,0
5459,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,milestone,milestone,P2,Placebo,0
5460,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,"sex: female, male","sex: female, male",B1,Hydroxychloroquine,107
5461,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,"sex: female, male","sex: female, male",B2,Placebo,105
5462,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,"sex: female, male","sex: female, male",B3,Total,212
5463,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,"sex: female, male","sex: female, male",B1,Hydroxychloroquine,135
5464,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,"sex: female, male","sex: female, male",B2,Placebo,132
5465,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,"sex: female, male","sex: female, male",B3,Total,267
5466,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,13
5467,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,19
5468,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,32
5469,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,28
5470,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,27
5471,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,55
5472,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,116
5473,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,108
5474,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,224
5475,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,85
5476,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,83
5477,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,intervention_model_description,Eligible participants will be randomized 1:1 to hydroxychloroquine versus placebo. Randomization will be stratified by site and be in permuted blocks of variable size.,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,168
5478,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Hydroxychloroquine,242
5479,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Placebo,237
5480,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Hydroxychloroquine,242
5481,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Placebo,237
5482,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Hydroxychloroquine,0
5483,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Placebo,0
5484,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Hydroxychloroquine,107
5485,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Placebo,105
5486,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Total,212
5487,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Hydroxychloroquine,135
5488,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Placebo,132
5489,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Total,267
5490,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,13
5491,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,19
5492,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,32
5493,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,28
5494,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,27
5495,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,55
5496,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,116
5497,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,108
5498,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,224
5499,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,85
5500,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,83
5501,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,primary_purpose,Treatment,covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,168
5502,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",milestone,milestone,P1,Hydroxychloroquine,242
5503,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",milestone,milestone,P2,Placebo,237
5504,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",milestone,milestone,P1,Hydroxychloroquine,242
5505,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",milestone,milestone,P2,Placebo,237
5506,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",milestone,milestone,P1,Hydroxychloroquine,0
5507,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",milestone,milestone,P2,Placebo,0
5508,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","sex: female, male","sex: female, male",B1,Hydroxychloroquine,107
5509,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","sex: female, male","sex: female, male",B2,Placebo,105
5510,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","sex: female, male","sex: female, male",B3,Total,212
5511,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","sex: female, male","sex: female, male",B1,Hydroxychloroquine,135
5512,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","sex: female, male","sex: female, male",B2,Placebo,132
5513,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","sex: female, male","sex: female, male",B3,Total,267
5514,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,13
5515,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,19
5516,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,32
5517,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,28
5518,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,27
5519,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,55
5520,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,116
5521,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,108
5522,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,224
5523,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,85
5524,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,83
5525,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,168
5526,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.",milestone,milestone,P1,Hydroxychloroquine,242
5527,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.",milestone,milestone,P2,Placebo,237
5528,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.",milestone,milestone,P1,Hydroxychloroquine,242
5529,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.",milestone,milestone,P2,Placebo,237
5530,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.",milestone,milestone,P1,Hydroxychloroquine,0
5531,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.",milestone,milestone,P2,Placebo,0
5532,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.","sex: female, male","sex: female, male",B1,Hydroxychloroquine,107
5533,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.","sex: female, male","sex: female, male",B2,Placebo,105
5534,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.","sex: female, male","sex: female, male",B3,Total,212
5535,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.","sex: female, male","sex: female, male",B1,Hydroxychloroquine,135
5536,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.","sex: female, male","sex: female, male",B2,Placebo,132
5537,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.","sex: female, male","sex: female, male",B3,Total,267
5538,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,13
5539,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,19
5540,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,32
5541,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,28
5542,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,27
5543,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,55
5544,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,116
5545,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,108
5546,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,224
5547,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B1,Hydroxychloroquine,85
5548,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B2,Placebo,83
5549,6,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Interventional,study_design_info,masking_description,"Patients, treating clinicians, trial personnel, and outcome assessors will be blinded to group assignment.",covid outcomes scale category at randomization,covid outcomes scale category at randomization,B3,Total,168
5550,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,gender,All,milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5551,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,gender,All,milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5552,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,gender,All,milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),0
5553,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),5
5554,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),11
5555,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5556,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5557,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5558,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),0
5559,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),5
5560,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),11
5561,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5562,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5563,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5564,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),0
5565,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),5
5566,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),11
5567,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5568,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5569,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5570,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),0
5571,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),5
5572,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),11
5573,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5574,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,allocation,N/A,milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5575,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,allocation,N/A,milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5576,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,allocation,N/A,milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),0
5577,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,allocation,N/A,"sex: female, male","sex: female, male",B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),5
5578,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,allocation,N/A,"sex: female, male","sex: female, male",B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),11
5579,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,allocation,N/A,enrollment region,enrollment region,B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5580,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,intervention_model,Single Group Assignment,milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5581,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,intervention_model,Single Group Assignment,milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5582,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,intervention_model,Single Group Assignment,milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),0
5583,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,intervention_model,Single Group Assignment,"sex: female, male","sex: female, male",B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),5
5584,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,intervention_model,Single Group Assignment,"sex: female, male","sex: female, male",B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),11
5585,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,intervention_model,Single Group Assignment,enrollment region,enrollment region,B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5586,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5587,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5588,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),0
5589,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),5
5590,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),11
5591,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5592,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5593,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5594,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),0
5595,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),5
5596,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),11
5597,7,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Ivermectin (IVM)+ Hydroxychloroquin (HCQ)+ Azithromycin (AZT),16
5598,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,gender,All,milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,48
5599,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,gender,All,milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,40
5600,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,gender,All,milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,8
5601,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,COVID-19 Patients Treated With Convalescent Plasma,1
5602,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,COVID-19 Patients Treated With Convalescent Plasma,7
5603,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,gender,All,age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,0
5604,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,gender,All,age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,24
5605,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,gender,All,age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,24
5606,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,COVID-19 Patients Treated With Convalescent Plasma,21
5607,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,COVID-19 Patients Treated With Convalescent Plasma,27
5608,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,12
5609,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,34
5610,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,2
5611,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5612,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5613,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5614,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,16
5615,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,17
5616,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,12
5617,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,3
5618,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,COVID-19 Patients Treated With Convalescent Plasma,48
5619,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,48
5620,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,40
5621,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,8
5622,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,COVID-19 Patients Treated With Convalescent Plasma,1
5623,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,COVID-19 Patients Treated With Convalescent Plasma,7
5624,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,minimum_age,18 Years,age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,0
5625,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,minimum_age,18 Years,age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,24
5626,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,minimum_age,18 Years,age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,24
5627,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,COVID-19 Patients Treated With Convalescent Plasma,21
5628,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,COVID-19 Patients Treated With Convalescent Plasma,27
5629,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,12
5630,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,34
5631,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,2
5632,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5633,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5634,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5635,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,16
5636,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,17
5637,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,12
5638,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,3
5639,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,COVID-19 Patients Treated With Convalescent Plasma,48
5640,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,maximum_age,90 Years,milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,48
5641,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,maximum_age,90 Years,milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,40
5642,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,maximum_age,90 Years,milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,8
5643,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,maximum_age,90 Years,withdrawal reason,withdrawal reason,P1,COVID-19 Patients Treated With Convalescent Plasma,1
5644,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,maximum_age,90 Years,withdrawal reason,withdrawal reason,P1,COVID-19 Patients Treated With Convalescent Plasma,7
5645,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,maximum_age,90 Years,age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,0
5646,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,maximum_age,90 Years,age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,24
5647,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,maximum_age,90 Years,age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,24
5648,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,maximum_age,90 Years,"sex: female, male","sex: female, male",B1,COVID-19 Patients Treated With Convalescent Plasma,21
5649,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,maximum_age,90 Years,"sex: female, male","sex: female, male",B1,COVID-19 Patients Treated With Convalescent Plasma,27
5650,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,maximum_age,90 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,12
5651,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,maximum_age,90 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,34
5652,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,maximum_age,90 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,2
5653,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,maximum_age,90 Years,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5654,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,maximum_age,90 Years,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5655,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,maximum_age,90 Years,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5656,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,maximum_age,90 Years,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,16
5657,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,maximum_age,90 Years,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,17
5658,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,maximum_age,90 Years,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,12
5659,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,maximum_age,90 Years,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,3
5660,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,maximum_age,90 Years,enrollment region,enrollment region,B1,COVID-19 Patients Treated With Convalescent Plasma,48
5661,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,48
5662,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,40
5663,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,8
5664,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,COVID-19 Patients Treated With Convalescent Plasma,1
5665,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,COVID-19 Patients Treated With Convalescent Plasma,7
5666,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,healthy_volunteers,No,age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,0
5667,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,healthy_volunteers,No,age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,24
5668,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,healthy_volunteers,No,age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,24
5669,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,COVID-19 Patients Treated With Convalescent Plasma,21
5670,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,COVID-19 Patients Treated With Convalescent Plasma,27
5671,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,12
5672,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,34
5673,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,2
5674,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5675,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5676,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5677,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,16
5678,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,17
5679,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,12
5680,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,3
5681,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,COVID-19 Patients Treated With Convalescent Plasma,48
5682,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,allocation,N/A,milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,48
5683,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,allocation,N/A,milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,40
5684,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,allocation,N/A,milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,8
5685,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,allocation,N/A,withdrawal reason,withdrawal reason,P1,COVID-19 Patients Treated With Convalescent Plasma,1
5686,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,allocation,N/A,withdrawal reason,withdrawal reason,P1,COVID-19 Patients Treated With Convalescent Plasma,7
5687,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,allocation,N/A,age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,0
5688,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,allocation,N/A,age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,24
5689,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,allocation,N/A,age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,24
5690,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,allocation,N/A,"sex: female, male","sex: female, male",B1,COVID-19 Patients Treated With Convalescent Plasma,21
5691,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,allocation,N/A,"sex: female, male","sex: female, male",B1,COVID-19 Patients Treated With Convalescent Plasma,27
5692,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,allocation,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,12
5693,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,allocation,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,34
5694,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,allocation,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,2
5695,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,allocation,N/A,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5696,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,allocation,N/A,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5697,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,allocation,N/A,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5698,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,allocation,N/A,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,16
5699,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,allocation,N/A,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,17
5700,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,allocation,N/A,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,12
5701,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,allocation,N/A,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,3
5702,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,allocation,N/A,enrollment region,enrollment region,B1,COVID-19 Patients Treated With Convalescent Plasma,48
5703,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,intervention_model,Single Group Assignment,milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,48
5704,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,intervention_model,Single Group Assignment,milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,40
5705,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,intervention_model,Single Group Assignment,milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,8
5706,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,intervention_model,Single Group Assignment,withdrawal reason,withdrawal reason,P1,COVID-19 Patients Treated With Convalescent Plasma,1
5707,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,intervention_model,Single Group Assignment,withdrawal reason,withdrawal reason,P1,COVID-19 Patients Treated With Convalescent Plasma,7
5708,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,intervention_model,Single Group Assignment,age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,0
5709,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,intervention_model,Single Group Assignment,age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,24
5710,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,intervention_model,Single Group Assignment,age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,24
5711,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,intervention_model,Single Group Assignment,"sex: female, male","sex: female, male",B1,COVID-19 Patients Treated With Convalescent Plasma,21
5712,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,intervention_model,Single Group Assignment,"sex: female, male","sex: female, male",B1,COVID-19 Patients Treated With Convalescent Plasma,27
5713,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,intervention_model,Single Group Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,12
5714,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,intervention_model,Single Group Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,34
5715,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,intervention_model,Single Group Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,2
5716,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,intervention_model,Single Group Assignment,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5717,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,intervention_model,Single Group Assignment,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5718,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,intervention_model,Single Group Assignment,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5719,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,intervention_model,Single Group Assignment,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,16
5720,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,intervention_model,Single Group Assignment,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,17
5721,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,intervention_model,Single Group Assignment,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,12
5722,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,intervention_model,Single Group Assignment,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,3
5723,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,intervention_model,Single Group Assignment,enrollment region,enrollment region,B1,COVID-19 Patients Treated With Convalescent Plasma,48
5724,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,48
5725,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,40
5726,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,8
5727,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,COVID-19 Patients Treated With Convalescent Plasma,1
5728,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,COVID-19 Patients Treated With Convalescent Plasma,7
5729,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,primary_purpose,Treatment,age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,0
5730,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,primary_purpose,Treatment,age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,24
5731,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,primary_purpose,Treatment,age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,24
5732,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,COVID-19 Patients Treated With Convalescent Plasma,21
5733,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,COVID-19 Patients Treated With Convalescent Plasma,27
5734,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,primary_purpose,Treatment,ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,12
5735,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,primary_purpose,Treatment,ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,34
5736,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,primary_purpose,Treatment,ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,2
5737,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5738,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5739,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5740,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,16
5741,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,17
5742,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,12
5743,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,3
5744,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,COVID-19 Patients Treated With Convalescent Plasma,48
5745,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,48
5746,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,40
5747,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,COVID-19 Patients Treated With Convalescent Plasma,8
5748,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,COVID-19 Patients Treated With Convalescent Plasma,1
5749,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,COVID-19 Patients Treated With Convalescent Plasma,7
5750,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,masking,None (Open Label),age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,0
5751,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,masking,None (Open Label),age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,24
5752,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,masking,None (Open Label),age,age,B1,COVID-19 Patients Treated With Convalescent Plasma,24
5753,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,COVID-19 Patients Treated With Convalescent Plasma,21
5754,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,COVID-19 Patients Treated With Convalescent Plasma,27
5755,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,masking,None (Open Label),ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,12
5756,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,masking,None (Open Label),ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,34
5757,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,masking,None (Open Label),ethnicity (nih/omb),ethnicity (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,2
5758,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5759,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5760,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,0
5761,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,16
5762,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,17
5763,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,12
5764,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,COVID-19 Patients Treated With Convalescent Plasma,3
5765,8,Convalescent Plasma in the Treatment of COVID 19,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,COVID-19 Patients Treated With Convalescent Plasma,48
5766,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),9
5767,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,11
5768,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
5769,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,9
5770,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
5771,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
5772,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
5773,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
5774,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
5775,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,4
5776,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,11
5777,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5778,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,5
5779,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,5
5780,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
5781,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
5782,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,4
5783,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),5
5784,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,6
5785,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,11
5786,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5787,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,1
5788,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,1
5789,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5790,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5791,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,0
5792,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5793,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5794,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,0
5795,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5796,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5797,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,0
5798,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),1
5799,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5800,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,1
5801,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),6
5802,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,8
5803,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,14
5804,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5805,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5806,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,0
5807,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5808,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,1
5809,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,1
5810,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
5811,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,9
5812,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Total,16
5813,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),9
5814,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,11
5815,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
5816,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,9
5817,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
5818,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
5819,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
5820,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
5821,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
5822,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,4
5823,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,11
5824,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5825,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,5
5826,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,5
5827,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
5828,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
5829,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,4
5830,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),5
5831,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,6
5832,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,11
5833,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5834,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,1
5835,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,1
5836,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5837,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5838,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,0
5839,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5840,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5841,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,0
5842,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5843,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5844,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,0
5845,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),1
5846,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5847,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,1
5848,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),6
5849,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,8
5850,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,14
5851,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5852,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5853,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,0
5854,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5855,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,1
5856,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,1
5857,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
5858,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,9
5859,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B3,Total,16
5860,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),9
5861,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,11
5862,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
5863,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,9
5864,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
5865,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
5866,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
5867,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
5868,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
5869,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,4
5870,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Total,11
5871,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5872,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,5
5873,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Total,5
5874,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
5875,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
5876,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,4
5877,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),5
5878,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,6
5879,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,11
5880,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5881,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,1
5882,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,1
5883,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5884,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5885,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Total,0
5886,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5887,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5888,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Total,0
5889,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5890,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5891,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Total,0
5892,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),1
5893,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5894,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Total,1
5895,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),6
5896,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,8
5897,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Total,14
5898,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5899,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5900,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Total,0
5901,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5902,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,1
5903,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Total,1
5904,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
5905,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,9
5906,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Total,16
5907,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),9
5908,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,11
5909,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
5910,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,9
5911,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
5912,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
5913,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
5914,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
5915,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
5916,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,4
5917,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Total,11
5918,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5919,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,5
5920,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Total,5
5921,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
5922,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
5923,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,4
5924,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),5
5925,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,6
5926,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,11
5927,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5928,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,1
5929,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,1
5930,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5931,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5932,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Total,0
5933,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5934,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5935,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Total,0
5936,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5937,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5938,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Total,0
5939,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),1
5940,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5941,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Total,1
5942,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),6
5943,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,8
5944,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Total,14
5945,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5946,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5947,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Total,0
5948,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5949,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,1
5950,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Total,1
5951,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
5952,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,9
5953,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Total,16
5954,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),9
5955,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,11
5956,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
5957,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,9
5958,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
5959,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
5960,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
5961,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
5962,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
5963,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,4
5964,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,11
5965,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5966,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,5
5967,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,5
5968,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
5969,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
5970,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,4
5971,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),5
5972,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,6
5973,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,11
5974,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5975,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,1
5976,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,1
5977,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5978,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5979,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Total,0
5980,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5981,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5982,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Total,0
5983,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5984,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5985,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Total,0
5986,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),1
5987,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5988,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Total,1
5989,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),6
5990,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,8
5991,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Total,14
5992,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5993,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
5994,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Total,0
5995,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
5996,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,1
5997,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Total,1
5998,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
5999,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,9
6000,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Total,16
6001,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),9
6002,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,11
6003,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
6004,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,9
6005,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
6006,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
6007,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
6008,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
6009,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
6010,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,4
6011,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Total,11
6012,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
6013,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,5
6014,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Total,5
6015,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
6016,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
6017,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,4
6018,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),5
6019,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,6
6020,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,11
6021,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
6022,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,1
6023,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,1
6024,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
6025,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
6026,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Total,0
6027,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
6028,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
6029,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Total,0
6030,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
6031,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
6032,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Total,0
6033,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),1
6034,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
6035,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Total,1
6036,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),6
6037,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,8
6038,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Total,14
6039,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
6040,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
6041,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Total,0
6042,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
6043,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,1
6044,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Total,1
6045,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
6046,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,9
6047,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Total,16
6048,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),9
6049,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,11
6050,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
6051,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,9
6052,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
6053,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
6054,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
6055,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
6056,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
6057,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,4
6058,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Total,11
6059,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
6060,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,5
6061,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Total,5
6062,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
6063,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
6064,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,4
6065,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),5
6066,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,6
6067,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,11
6068,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
6069,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,1
6070,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,1
6071,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
6072,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
6073,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Total,0
6074,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
6075,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
6076,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Total,0
6077,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
6078,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
6079,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Total,0
6080,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),1
6081,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
6082,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Total,1
6083,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),6
6084,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,8
6085,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Total,14
6086,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
6087,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
6088,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Total,0
6089,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
6090,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,1
6091,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Total,1
6092,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
6093,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,9
6094,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Total,16
6095,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),9
6096,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,11
6097,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
6098,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,9
6099,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
6100,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
6101,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",withdrawal reason,withdrawal reason,P1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
6102,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",withdrawal reason,withdrawal reason,P2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
6103,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
6104,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,4
6105,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B3,Total,11
6106,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
6107,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,5
6108,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B3,Total,5
6109,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),2
6110,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,2
6111,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,4
6112,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),5
6113,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,6
6114,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,11
6115,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",ethnicity (nih/omb),ethnicity (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
6116,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",ethnicity (nih/omb),ethnicity (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,1
6117,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,1
6118,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
6119,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
6120,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B3,Total,0
6121,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
6122,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
6123,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B3,Total,0
6124,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
6125,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
6126,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B3,Total,0
6127,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),1
6128,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
6129,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B3,Total,1
6130,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),6
6131,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,8
6132,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B3,Total,14
6133,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
6134,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,0
6135,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B3,Total,0
6136,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),0
6137,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,1
6138,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",race (nih/omb),race (nih/omb),B3,Total,1
6139,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B1,Arm A: Hydroxychloroquine (HCQ) and Azithromycin (Azithro),7
6140,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B2,Arm B: Placebo for Hydroxychloroquine and Azithromycin,9
6141,9,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Interventional,study_design_info,masking,"Double (Participant, Investigator)",enrollment region,enrollment region,B3,Total,16
6142,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,7
6143,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,7
6144,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,5
6145,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,3
6146,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,6
6147,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,2
6148,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,4
6149,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,1
6150,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,3
6151,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6152,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,1
6153,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6154,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,1
6155,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6156,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6157,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,2
6158,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6159,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6160,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,1
6161,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6162,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6163,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6164,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,0
6165,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6166,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,age,age,B4,Total,0
6167,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,7
6168,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,4
6169,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,5
6170,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,age,age,B4,Total,16
6171,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6172,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,3
6173,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6174,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,age,age,B4,Total,3
6175,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,3
6176,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Arm 2: Hydroxychloroquine + Azithromycin,1
6177,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,3
6178,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B4,Total,7
6179,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,4
6180,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Arm 2: Hydroxychloroquine + Azithromycin,6
6181,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,2
6182,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B4,Total,12
6183,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,7
6184,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,7
6185,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,5
6186,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,3
6187,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,6
6188,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,2
6189,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,4
6190,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,1
6191,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,3
6192,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6193,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,1
6194,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6195,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,1
6196,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6197,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6198,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,2
6199,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6200,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6201,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,1
6202,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6203,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6204,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6205,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,0
6206,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6207,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,age,age,B4,Total,0
6208,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,7
6209,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,4
6210,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,5
6211,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,age,age,B4,Total,16
6212,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6213,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,3
6214,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6215,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,age,age,B4,Total,3
6216,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,3
6217,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Arm 2: Hydroxychloroquine + Azithromycin,1
6218,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,3
6219,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B4,Total,7
6220,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,4
6221,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Arm 2: Hydroxychloroquine + Azithromycin,6
6222,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,2
6223,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B4,Total,12
6224,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,7
6225,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,7
6226,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,5
6227,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,3
6228,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,6
6229,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,2
6230,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,4
6231,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,1
6232,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,3
6233,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6234,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,1
6235,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6236,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,1
6237,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6238,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6239,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,2
6240,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6241,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6242,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,1
6243,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6244,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6245,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6246,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,0
6247,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6248,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,age,age,B4,Total,0
6249,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,7
6250,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,4
6251,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,5
6252,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,age,age,B4,Total,16
6253,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6254,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,3
6255,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6256,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,age,age,B4,Total,3
6257,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,3
6258,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Arm 2: Hydroxychloroquine + Azithromycin,1
6259,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,3
6260,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B4,Total,7
6261,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,4
6262,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Arm 2: Hydroxychloroquine + Azithromycin,6
6263,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,2
6264,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B4,Total,12
6265,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,7
6266,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,7
6267,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,5
6268,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,3
6269,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,6
6270,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,2
6271,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,4
6272,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,1
6273,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,3
6274,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6275,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,1
6276,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6277,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,1
6278,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6279,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6280,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,2
6281,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6282,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6283,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,1
6284,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6285,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6286,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6287,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,0
6288,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6289,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,age,age,B4,Total,0
6290,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,7
6291,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,4
6292,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,5
6293,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,age,age,B4,Total,16
6294,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6295,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,3
6296,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6297,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,age,age,B4,Total,3
6298,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,3
6299,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Arm 2: Hydroxychloroquine + Azithromycin,1
6300,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,3
6301,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B4,Total,7
6302,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,4
6303,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Arm 2: Hydroxychloroquine + Azithromycin,6
6304,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,2
6305,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B4,Total,12
6306,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,7
6307,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,7
6308,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,5
6309,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,3
6310,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,6
6311,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,2
6312,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,4
6313,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,1
6314,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,3
6315,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6316,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,1
6317,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6318,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,1
6319,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6320,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6321,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,2
6322,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6323,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6324,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,1
6325,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6326,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6327,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6328,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,0
6329,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6330,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,age,age,B4,Total,0
6331,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,7
6332,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,4
6333,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,5
6334,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,age,age,B4,Total,16
6335,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6336,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,3
6337,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6338,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,age,age,B4,Total,3
6339,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,3
6340,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Arm 2: Hydroxychloroquine + Azithromycin,1
6341,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,3
6342,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B4,Total,7
6343,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,4
6344,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Arm 2: Hydroxychloroquine + Azithromycin,6
6345,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,2
6346,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B4,Total,12
6347,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,7
6348,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,7
6349,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,5
6350,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,3
6351,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,6
6352,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,2
6353,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,4
6354,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,1
6355,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,3
6356,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6357,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,1
6358,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6359,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,1
6360,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6361,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6362,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,2
6363,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6364,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6365,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,1
6366,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6367,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6368,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6369,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,0
6370,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6371,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B4,Total,0
6372,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,7
6373,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,4
6374,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,5
6375,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B4,Total,16
6376,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6377,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,3
6378,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6379,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B4,Total,3
6380,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,3
6381,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Arm 2: Hydroxychloroquine + Azithromycin,1
6382,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,3
6383,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B4,Total,7
6384,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,4
6385,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Arm 2: Hydroxychloroquine + Azithromycin,6
6386,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,2
6387,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B4,Total,12
6388,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,7
6389,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,7
6390,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,5
6391,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,3
6392,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,6
6393,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,2
6394,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,4
6395,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,1
6396,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,3
6397,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6398,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,1
6399,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6400,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,1
6401,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6402,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6403,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,2
6404,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6405,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6406,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,1
6407,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6408,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6409,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6410,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,0
6411,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6412,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,age,age,B4,Total,0
6413,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,7
6414,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,4
6415,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,5
6416,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,age,age,B4,Total,16
6417,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6418,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,3
6419,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6420,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,age,age,B4,Total,3
6421,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,3
6422,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Arm 2: Hydroxychloroquine + Azithromycin,1
6423,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,3
6424,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B4,Total,7
6425,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,4
6426,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Arm 2: Hydroxychloroquine + Azithromycin,6
6427,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,2
6428,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B4,Total,12
6429,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,7
6430,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,7
6431,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,5
6432,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,3
6433,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,6
6434,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,2
6435,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",milestone,milestone,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,4
6436,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",milestone,milestone,P2,Arm 2: Hydroxychloroquine + Azithromycin,1
6437,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",milestone,milestone,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,3
6438,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6439,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,1
6440,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6441,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,1
6442,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6443,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6444,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,2
6445,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6446,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,1
6447,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",withdrawal reason,withdrawal reason,P1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,1
6448,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",withdrawal reason,withdrawal reason,P2,Arm 2: Hydroxychloroquine + Azithromycin,0
6449,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",withdrawal reason,withdrawal reason,P3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6450,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6451,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,0
6452,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6453,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",age,age,B4,Total,0
6454,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,7
6455,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,4
6456,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,5
6457,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",age,age,B4,Total,16
6458,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",age,age,B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,0
6459,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",age,age,B2,Arm 2: Hydroxychloroquine + Azithromycin,3
6460,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",age,age,B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,0
6461,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",age,age,B4,Total,3
6462,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","sex: female, male","sex: female, male",B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,3
6463,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","sex: female, male","sex: female, male",B2,Arm 2: Hydroxychloroquine + Azithromycin,1
6464,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","sex: female, male","sex: female, male",B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,3
6465,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","sex: female, male","sex: female, male",B4,Total,7
6466,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","sex: female, male","sex: female, male",B1,Arm 1: Hydroxychloroquine + Aithromycin Placebo,4
6467,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","sex: female, male","sex: female, male",B2,Arm 2: Hydroxychloroquine + Azithromycin,6
6468,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","sex: female, male","sex: female, male",B3,Arm 3: Hydroxychloroquine Placebo + Azithromycin Placebo,2
6469,10,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","sex: female, male","sex: female, male",B4,Total,12
6470,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,study_pop,"
      ",milestone,milestone,P1,Pregnant Women,5712
6471,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,study_pop,"
      ",milestone,milestone,P2,Post-partum Women,1182
6472,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,study_pop,"
      ",milestone,milestone,P1,Pregnant Women,5712
6473,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,study_pop,"
      ",milestone,milestone,P2,Post-partum Women,1182
6474,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,study_pop,"
      ",milestone,milestone,P1,Pregnant Women,0
6475,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,study_pop,"
      ",milestone,milestone,P2,Post-partum Women,0
6476,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B1,Pregnant Women,5712
6477,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B2,Post-partum Women,1182
6478,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B3,Total,6894
6479,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B1,Pregnant Women,0
6480,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B2,Post-partum Women,0
6481,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B3,Total,0
6482,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,1288
6483,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,131
6484,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,1419
6485,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,4424
6486,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,1051
6487,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,5475
6488,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,0
6489,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,0
6490,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
6491,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P1,Pregnant Women,5712
6492,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P2,Post-partum Women,1182
6493,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P1,Pregnant Women,5712
6494,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P2,Post-partum Women,1182
6495,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P1,Pregnant Women,0
6496,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P2,Post-partum Women,0
6497,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B1,Pregnant Women,5712
6498,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B2,Post-partum Women,1182
6499,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B3,Total,6894
6500,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B1,Pregnant Women,0
6501,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B2,Post-partum Women,0
6502,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B3,Total,0
6503,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,1288
6504,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,131
6505,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,1419
6506,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,4424
6507,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,1051
6508,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,5475
6509,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,0
6510,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,0
6511,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
6512,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender,Female,milestone,milestone,P1,Pregnant Women,5712
6513,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender,Female,milestone,milestone,P2,Post-partum Women,1182
6514,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender,Female,milestone,milestone,P1,Pregnant Women,5712
6515,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender,Female,milestone,milestone,P2,Post-partum Women,1182
6516,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender,Female,milestone,milestone,P1,Pregnant Women,0
6517,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender,Female,milestone,milestone,P2,Post-partum Women,0
6518,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender,Female,"sex: female, male","sex: female, male",B1,Pregnant Women,5712
6519,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender,Female,"sex: female, male","sex: female, male",B2,Post-partum Women,1182
6520,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender,Female,"sex: female, male","sex: female, male",B3,Total,6894
6521,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender,Female,"sex: female, male","sex: female, male",B1,Pregnant Women,0
6522,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender,Female,"sex: female, male","sex: female, male",B2,Post-partum Women,0
6523,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender,Female,"sex: female, male","sex: female, male",B3,Total,0
6524,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender,Female,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,1288
6525,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender,Female,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,131
6526,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender,Female,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,1419
6527,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender,Female,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,4424
6528,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender,Female,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,1051
6529,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender,Female,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,5475
6530,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender,Female,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,0
6531,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender,Female,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,0
6532,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender,Female,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
6533,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_based,Yes,milestone,milestone,P1,Pregnant Women,5712
6534,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_based,Yes,milestone,milestone,P2,Post-partum Women,1182
6535,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_based,Yes,milestone,milestone,P1,Pregnant Women,5712
6536,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_based,Yes,milestone,milestone,P2,Post-partum Women,1182
6537,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_based,Yes,milestone,milestone,P1,Pregnant Women,0
6538,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_based,Yes,milestone,milestone,P2,Post-partum Women,0
6539,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_based,Yes,"sex: female, male","sex: female, male",B1,Pregnant Women,5712
6540,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_based,Yes,"sex: female, male","sex: female, male",B2,Post-partum Women,1182
6541,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_based,Yes,"sex: female, male","sex: female, male",B3,Total,6894
6542,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_based,Yes,"sex: female, male","sex: female, male",B1,Pregnant Women,0
6543,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_based,Yes,"sex: female, male","sex: female, male",B2,Post-partum Women,0
6544,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_based,Yes,"sex: female, male","sex: female, male",B3,Total,0
6545,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_based,Yes,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,1288
6546,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_based,Yes,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,131
6547,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_based,Yes,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,1419
6548,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_based,Yes,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,4424
6549,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_based,Yes,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,1051
6550,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_based,Yes,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,5475
6551,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_based,Yes,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,0
6552,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_based,Yes,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,0
6553,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_based,Yes,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
6554,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_description,Persons assigned gender female at birth.,milestone,milestone,P1,Pregnant Women,5712
6555,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_description,Persons assigned gender female at birth.,milestone,milestone,P2,Post-partum Women,1182
6556,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_description,Persons assigned gender female at birth.,milestone,milestone,P1,Pregnant Women,5712
6557,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_description,Persons assigned gender female at birth.,milestone,milestone,P2,Post-partum Women,1182
6558,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_description,Persons assigned gender female at birth.,milestone,milestone,P1,Pregnant Women,0
6559,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_description,Persons assigned gender female at birth.,milestone,milestone,P2,Post-partum Women,0
6560,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_description,Persons assigned gender female at birth.,"sex: female, male","sex: female, male",B1,Pregnant Women,5712
6561,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_description,Persons assigned gender female at birth.,"sex: female, male","sex: female, male",B2,Post-partum Women,1182
6562,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_description,Persons assigned gender female at birth.,"sex: female, male","sex: female, male",B3,Total,6894
6563,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_description,Persons assigned gender female at birth.,"sex: female, male","sex: female, male",B1,Pregnant Women,0
6564,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_description,Persons assigned gender female at birth.,"sex: female, male","sex: female, male",B2,Post-partum Women,0
6565,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_description,Persons assigned gender female at birth.,"sex: female, male","sex: female, male",B3,Total,0
6566,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_description,Persons assigned gender female at birth.,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,1288
6567,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_description,Persons assigned gender female at birth.,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,131
6568,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_description,Persons assigned gender female at birth.,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,1419
6569,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_description,Persons assigned gender female at birth.,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,4424
6570,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_description,Persons assigned gender female at birth.,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,1051
6571,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_description,Persons assigned gender female at birth.,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,5475
6572,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_description,Persons assigned gender female at birth.,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,0
6573,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_description,Persons assigned gender female at birth.,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,0
6574,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,gender_description,Persons assigned gender female at birth.,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
6575,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,minimum_age,18 Years,milestone,milestone,P1,Pregnant Women,5712
6576,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,minimum_age,18 Years,milestone,milestone,P2,Post-partum Women,1182
6577,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,minimum_age,18 Years,milestone,milestone,P1,Pregnant Women,5712
6578,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,minimum_age,18 Years,milestone,milestone,P2,Post-partum Women,1182
6579,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,minimum_age,18 Years,milestone,milestone,P1,Pregnant Women,0
6580,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,minimum_age,18 Years,milestone,milestone,P2,Post-partum Women,0
6581,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Pregnant Women,5712
6582,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Post-partum Women,1182
6583,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,6894
6584,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Pregnant Women,0
6585,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Post-partum Women,0
6586,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,0
6587,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,1288
6588,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,131
6589,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,1419
6590,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,4424
6591,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,1051
6592,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,5475
6593,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,0
6594,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,0
6595,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
6596,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,maximum_age,N/A,milestone,milestone,P1,Pregnant Women,5712
6597,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,maximum_age,N/A,milestone,milestone,P2,Post-partum Women,1182
6598,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,maximum_age,N/A,milestone,milestone,P1,Pregnant Women,5712
6599,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,maximum_age,N/A,milestone,milestone,P2,Post-partum Women,1182
6600,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,maximum_age,N/A,milestone,milestone,P1,Pregnant Women,0
6601,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,maximum_age,N/A,milestone,milestone,P2,Post-partum Women,0
6602,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Pregnant Women,5712
6603,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Post-partum Women,1182
6604,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Total,6894
6605,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Pregnant Women,0
6606,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Post-partum Women,0
6607,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Total,0
6608,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,1288
6609,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,131
6610,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,1419
6611,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,4424
6612,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,1051
6613,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,5475
6614,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,0
6615,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,0
6616,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
6617,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,healthy_volunteers,No,milestone,milestone,P1,Pregnant Women,5712
6618,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,healthy_volunteers,No,milestone,milestone,P2,Post-partum Women,1182
6619,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,healthy_volunteers,No,milestone,milestone,P1,Pregnant Women,5712
6620,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,healthy_volunteers,No,milestone,milestone,P2,Post-partum Women,1182
6621,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,healthy_volunteers,No,milestone,milestone,P1,Pregnant Women,0
6622,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,healthy_volunteers,No,milestone,milestone,P2,Post-partum Women,0
6623,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Pregnant Women,5712
6624,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Post-partum Women,1182
6625,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Total,6894
6626,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Pregnant Women,0
6627,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Post-partum Women,0
6628,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Total,0
6629,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,1288
6630,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,131
6631,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,1419
6632,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,4424
6633,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,1051
6634,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,5475
6635,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,0
6636,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,0
6637,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
6638,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,observational_model,Case-Only,milestone,milestone,P1,Pregnant Women,5712
6639,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,observational_model,Case-Only,milestone,milestone,P2,Post-partum Women,1182
6640,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,observational_model,Case-Only,milestone,milestone,P1,Pregnant Women,5712
6641,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,observational_model,Case-Only,milestone,milestone,P2,Post-partum Women,1182
6642,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,observational_model,Case-Only,milestone,milestone,P1,Pregnant Women,0
6643,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,observational_model,Case-Only,milestone,milestone,P2,Post-partum Women,0
6644,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,observational_model,Case-Only,"sex: female, male","sex: female, male",B1,Pregnant Women,5712
6645,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,observational_model,Case-Only,"sex: female, male","sex: female, male",B2,Post-partum Women,1182
6646,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,observational_model,Case-Only,"sex: female, male","sex: female, male",B3,Total,6894
6647,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,observational_model,Case-Only,"sex: female, male","sex: female, male",B1,Pregnant Women,0
6648,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,observational_model,Case-Only,"sex: female, male","sex: female, male",B2,Post-partum Women,0
6649,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,observational_model,Case-Only,"sex: female, male","sex: female, male",B3,Total,0
6650,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,observational_model,Case-Only,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,1288
6651,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,observational_model,Case-Only,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,131
6652,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,observational_model,Case-Only,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,1419
6653,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,observational_model,Case-Only,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,4424
6654,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,observational_model,Case-Only,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,1051
6655,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,observational_model,Case-Only,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,5475
6656,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,observational_model,Case-Only,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,0
6657,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,observational_model,Case-Only,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,0
6658,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,observational_model,Case-Only,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
6659,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,time_perspective,Cross-Sectional,milestone,milestone,P1,Pregnant Women,5712
6660,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,time_perspective,Cross-Sectional,milestone,milestone,P2,Post-partum Women,1182
6661,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,time_perspective,Cross-Sectional,milestone,milestone,P1,Pregnant Women,5712
6662,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,time_perspective,Cross-Sectional,milestone,milestone,P2,Post-partum Women,1182
6663,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,time_perspective,Cross-Sectional,milestone,milestone,P1,Pregnant Women,0
6664,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,time_perspective,Cross-Sectional,milestone,milestone,P2,Post-partum Women,0
6665,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,time_perspective,Cross-Sectional,"sex: female, male","sex: female, male",B1,Pregnant Women,5712
6666,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,time_perspective,Cross-Sectional,"sex: female, male","sex: female, male",B2,Post-partum Women,1182
6667,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,time_perspective,Cross-Sectional,"sex: female, male","sex: female, male",B3,Total,6894
6668,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,time_perspective,Cross-Sectional,"sex: female, male","sex: female, male",B1,Pregnant Women,0
6669,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,time_perspective,Cross-Sectional,"sex: female, male","sex: female, male",B2,Post-partum Women,0
6670,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,time_perspective,Cross-Sectional,"sex: female, male","sex: female, male",B3,Total,0
6671,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,time_perspective,Cross-Sectional,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,1288
6672,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,time_perspective,Cross-Sectional,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,131
6673,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,time_perspective,Cross-Sectional,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,1419
6674,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,time_perspective,Cross-Sectional,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,4424
6675,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,time_perspective,Cross-Sectional,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,1051
6676,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,time_perspective,Cross-Sectional,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,5475
6677,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,time_perspective,Cross-Sectional,ethnicity (nih/omb),ethnicity (nih/omb),B1,Pregnant Women,0
6678,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,time_perspective,Cross-Sectional,ethnicity (nih/omb),ethnicity (nih/omb),B2,Post-partum Women,0
6679,11,Health and Wellbeing of Pregnant and Post-Partum Women During the COVID-19 Pandemic,Observational,study_design_info,time_perspective,Cross-Sectional,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
6680,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,gender,All,milestone,milestone,P1,Ivermectin,12
6681,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,gender,All,milestone,milestone,P2,Placebo,12
6682,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,gender,All,milestone,milestone,P1,Ivermectin,12
6683,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,gender,All,milestone,milestone,P2,Placebo,12
6684,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,gender,All,milestone,milestone,P1,Ivermectin,0
6685,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,gender,All,milestone,milestone,P2,Placebo,0
6686,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Ivermectin,5
6687,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Placebo,7
6688,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,12
6689,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Ivermectin,7
6690,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Placebo,5
6691,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,12
6692,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Ivermectin,12
6693,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Placebo,12
6694,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Ivermectin,12
6695,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Placebo,12
6696,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Ivermectin,0
6697,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Placebo,0
6698,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Ivermectin,5
6699,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Placebo,7
6700,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,12
6701,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Ivermectin,7
6702,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Placebo,5
6703,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,12
6704,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,maximum_age,59 Years,milestone,milestone,P1,Ivermectin,12
6705,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,maximum_age,59 Years,milestone,milestone,P2,Placebo,12
6706,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,maximum_age,59 Years,milestone,milestone,P1,Ivermectin,12
6707,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,maximum_age,59 Years,milestone,milestone,P2,Placebo,12
6708,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,maximum_age,59 Years,milestone,milestone,P1,Ivermectin,0
6709,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,maximum_age,59 Years,milestone,milestone,P2,Placebo,0
6710,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,maximum_age,59 Years,"sex: female, male","sex: female, male",B1,Ivermectin,5
6711,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,maximum_age,59 Years,"sex: female, male","sex: female, male",B2,Placebo,7
6712,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,maximum_age,59 Years,"sex: female, male","sex: female, male",B3,Total,12
6713,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,maximum_age,59 Years,"sex: female, male","sex: female, male",B1,Ivermectin,7
6714,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,maximum_age,59 Years,"sex: female, male","sex: female, male",B2,Placebo,5
6715,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,maximum_age,59 Years,"sex: female, male","sex: female, male",B3,Total,12
6716,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Ivermectin,12
6717,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Placebo,12
6718,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Ivermectin,12
6719,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Placebo,12
6720,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Ivermectin,0
6721,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Placebo,0
6722,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Ivermectin,5
6723,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Placebo,7
6724,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Total,12
6725,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Ivermectin,7
6726,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Placebo,5
6727,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Total,12
6728,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Ivermectin,12
6729,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Placebo,12
6730,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Ivermectin,12
6731,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Placebo,12
6732,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Ivermectin,0
6733,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Placebo,0
6734,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Ivermectin,5
6735,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Placebo,7
6736,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,12
6737,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Ivermectin,7
6738,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Placebo,5
6739,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,12
6740,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Ivermectin,12
6741,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Placebo,12
6742,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Ivermectin,12
6743,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Placebo,12
6744,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Ivermectin,0
6745,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Placebo,0
6746,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Ivermectin,5
6747,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Placebo,7
6748,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Total,12
6749,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Ivermectin,7
6750,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Placebo,5
6751,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Total,12
6752,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model_description,"SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease.",milestone,milestone,P1,Ivermectin,12
6753,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model_description,"SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease.",milestone,milestone,P2,Placebo,12
6754,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model_description,"SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease.",milestone,milestone,P1,Ivermectin,12
6755,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model_description,"SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease.",milestone,milestone,P2,Placebo,12
6756,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model_description,"SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease.",milestone,milestone,P1,Ivermectin,0
6757,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model_description,"SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease.",milestone,milestone,P2,Placebo,0
6758,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model_description,"SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease.","sex: female, male","sex: female, male",B1,Ivermectin,5
6759,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model_description,"SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease.","sex: female, male","sex: female, male",B2,Placebo,7
6760,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model_description,"SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease.","sex: female, male","sex: female, male",B3,Total,12
6761,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model_description,"SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease.","sex: female, male","sex: female, male",B1,Ivermectin,7
6762,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model_description,"SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease.","sex: female, male","sex: female, male",B2,Placebo,5
6763,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,intervention_model_description,"SAINT is a double-blind, randomized controlled trial with two parallel groups that evaluates the efficacy of ivermectin in reducing nasal viral carriage at seven days after treatment in SARS-CoV-2 infected patients who are at low risk of progression to severe disease.","sex: female, male","sex: female, male",B3,Total,12
6764,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Ivermectin,12
6765,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Placebo,12
6766,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Ivermectin,12
6767,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Placebo,12
6768,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Ivermectin,0
6769,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Placebo,0
6770,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Ivermectin,5
6771,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Placebo,7
6772,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Total,12
6773,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Ivermectin,7
6774,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Placebo,5
6775,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Total,12
6776,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P1,Ivermectin,12
6777,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P2,Placebo,12
6778,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P1,Ivermectin,12
6779,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P2,Placebo,12
6780,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P1,Ivermectin,0
6781,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P2,Placebo,0
6782,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B1,Ivermectin,5
6783,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B2,Placebo,7
6784,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B3,Total,12
6785,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B1,Ivermectin,7
6786,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B2,Placebo,5
6787,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B3,Total,12
6788,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking_description,Double blind,milestone,milestone,P1,Ivermectin,12
6789,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking_description,Double blind,milestone,milestone,P2,Placebo,12
6790,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking_description,Double blind,milestone,milestone,P1,Ivermectin,12
6791,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking_description,Double blind,milestone,milestone,P2,Placebo,12
6792,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking_description,Double blind,milestone,milestone,P1,Ivermectin,0
6793,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking_description,Double blind,milestone,milestone,P2,Placebo,0
6794,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking_description,Double blind,"sex: female, male","sex: female, male",B1,Ivermectin,5
6795,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking_description,Double blind,"sex: female, male","sex: female, male",B2,Placebo,7
6796,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking_description,Double blind,"sex: female, male","sex: female, male",B3,Total,12
6797,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking_description,Double blind,"sex: female, male","sex: female, male",B1,Ivermectin,7
6798,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking_description,Double blind,"sex: female, male","sex: female, male",B2,Placebo,5
6799,12,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Interventional,study_design_info,masking_description,Double blind,"sex: female, male","sex: female, male",B3,Total,12
6800,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,milestone,milestone,P1,FAVIRA Then AVIGAN,15
6801,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,milestone,milestone,P2,AVIGAN Then FAVIRA,15
6802,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,milestone,milestone,P1,FAVIRA Then AVIGAN,14
6803,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,milestone,milestone,P2,AVIGAN Then FAVIRA,11
6804,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,milestone,milestone,P1,FAVIRA Then AVIGAN,1
6805,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,milestone,milestone,P2,AVIGAN Then FAVIRA,4
6806,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,withdrawal reason,withdrawal reason,P1,FAVIRA Then AVIGAN,1
6807,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,withdrawal reason,withdrawal reason,P2,AVIGAN Then FAVIRA,4
6808,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,"sex: female, male","sex: female, male",B1,FAVIRA Then AVIGAN,0
6809,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVIRA,0
6810,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,"sex: female, male","sex: female, male",B3,Total,0
6811,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,"sex: female, male","sex: female, male",B1,FAVIRA Then AVIGAN,15
6812,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVIRA,15
6813,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,"sex: female, male","sex: female, male",B3,Total,30
6814,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,milestone,milestone,P1,FAVIRA Then AVIGAN,15
6815,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,milestone,milestone,P2,AVIGAN Then FAVIRA,15
6816,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,milestone,milestone,P1,FAVIRA Then AVIGAN,14
6817,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,milestone,milestone,P2,AVIGAN Then FAVIRA,11
6818,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,milestone,milestone,P1,FAVIRA Then AVIGAN,1
6819,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,milestone,milestone,P2,AVIGAN Then FAVIRA,4
6820,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,withdrawal reason,withdrawal reason,P1,FAVIRA Then AVIGAN,1
6821,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,withdrawal reason,withdrawal reason,P2,AVIGAN Then FAVIRA,4
6822,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,"sex: female, male","sex: female, male",B1,FAVIRA Then AVIGAN,0
6823,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVIRA,0
6824,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,"sex: female, male","sex: female, male",B3,Total,0
6825,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,"sex: female, male","sex: female, male",B1,FAVIRA Then AVIGAN,15
6826,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVIRA,15
6827,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,"sex: female, male","sex: female, male",B3,Total,30
6828,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,milestone,milestone,P1,FAVIRA Then AVIGAN,15
6829,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,milestone,milestone,P2,AVIGAN Then FAVIRA,15
6830,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,milestone,milestone,P1,FAVIRA Then AVIGAN,14
6831,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,milestone,milestone,P2,AVIGAN Then FAVIRA,11
6832,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,milestone,milestone,P1,FAVIRA Then AVIGAN,1
6833,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,milestone,milestone,P2,AVIGAN Then FAVIRA,4
6834,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,withdrawal reason,withdrawal reason,P1,FAVIRA Then AVIGAN,1
6835,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,withdrawal reason,withdrawal reason,P2,AVIGAN Then FAVIRA,4
6836,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,"sex: female, male","sex: female, male",B1,FAVIRA Then AVIGAN,0
6837,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVIRA,0
6838,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,"sex: female, male","sex: female, male",B3,Total,0
6839,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,"sex: female, male","sex: female, male",B1,FAVIRA Then AVIGAN,15
6840,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVIRA,15
6841,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,"sex: female, male","sex: female, male",B3,Total,30
6842,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,FAVIRA Then AVIGAN,15
6843,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P2,AVIGAN Then FAVIRA,15
6844,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,FAVIRA Then AVIGAN,14
6845,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P2,AVIGAN Then FAVIRA,11
6846,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,FAVIRA Then AVIGAN,1
6847,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P2,AVIGAN Then FAVIRA,4
6848,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P1,FAVIRA Then AVIGAN,1
6849,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P2,AVIGAN Then FAVIRA,4
6850,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B1,FAVIRA Then AVIGAN,0
6851,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVIRA,0
6852,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B3,Total,0
6853,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B1,FAVIRA Then AVIGAN,15
6854,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVIRA,15
6855,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B3,Total,30
6856,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,FAVIRA Then AVIGAN,15
6857,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,AVIGAN Then FAVIRA,15
6858,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,FAVIRA Then AVIGAN,14
6859,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,AVIGAN Then FAVIRA,11
6860,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,FAVIRA Then AVIGAN,1
6861,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,AVIGAN Then FAVIRA,4
6862,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,FAVIRA Then AVIGAN,1
6863,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,AVIGAN Then FAVIRA,4
6864,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,FAVIRA Then AVIGAN,0
6865,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVIRA,0
6866,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,0
6867,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,FAVIRA Then AVIGAN,15
6868,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVIRA,15
6869,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,30
6870,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,milestone,milestone,P1,FAVIRA Then AVIGAN,15
6871,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,milestone,milestone,P2,AVIGAN Then FAVIRA,15
6872,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,milestone,milestone,P1,FAVIRA Then AVIGAN,14
6873,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,milestone,milestone,P2,AVIGAN Then FAVIRA,11
6874,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,milestone,milestone,P1,FAVIRA Then AVIGAN,1
6875,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,milestone,milestone,P2,AVIGAN Then FAVIRA,4
6876,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,withdrawal reason,withdrawal reason,P1,FAVIRA Then AVIGAN,1
6877,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,withdrawal reason,withdrawal reason,P2,AVIGAN Then FAVIRA,4
6878,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,"sex: female, male","sex: female, male",B1,FAVIRA Then AVIGAN,0
6879,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVIRA,0
6880,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,"sex: female, male","sex: female, male",B3,Total,0
6881,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,"sex: female, male","sex: female, male",B1,FAVIRA Then AVIGAN,15
6882,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVIRA,15
6883,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,"sex: female, male","sex: female, male",B3,Total,30
6884,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P1,FAVIRA Then AVIGAN,15
6885,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P2,AVIGAN Then FAVIRA,15
6886,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P1,FAVIRA Then AVIGAN,14
6887,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P2,AVIGAN Then FAVIRA,11
6888,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P1,FAVIRA Then AVIGAN,1
6889,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P2,AVIGAN Then FAVIRA,4
6890,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,withdrawal reason,withdrawal reason,P1,FAVIRA Then AVIGAN,1
6891,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,withdrawal reason,withdrawal reason,P2,AVIGAN Then FAVIRA,4
6892,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B1,FAVIRA Then AVIGAN,0
6893,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVIRA,0
6894,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B3,Total,0
6895,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B1,FAVIRA Then AVIGAN,15
6896,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVIRA,15
6897,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B3,Total,30
6898,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,FAVIRA Then AVIGAN,15
6899,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,AVIGAN Then FAVIRA,15
6900,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,FAVIRA Then AVIGAN,14
6901,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,AVIGAN Then FAVIRA,11
6902,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,FAVIRA Then AVIGAN,1
6903,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,AVIGAN Then FAVIRA,4
6904,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,FAVIRA Then AVIGAN,1
6905,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,AVIGAN Then FAVIRA,4
6906,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,FAVIRA Then AVIGAN,0
6907,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B2,AVIGAN Then FAVIRA,0
6908,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B3,Total,0
6909,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,FAVIRA Then AVIGAN,15
6910,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B2,AVIGAN Then FAVIRA,15
6911,13,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (Novelfarma, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B3,Total,30
6912,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,15
6913,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,milestone,milestone,P2,AVIGAN Then FAVICOVIR,15
6914,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,15
6915,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,milestone,milestone,P2,AVIGAN Then FAVICOVIR,14
6916,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,0
6917,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,milestone,milestone,P2,AVIGAN Then FAVICOVIR,1
6918,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,withdrawal reason,withdrawal reason,P1,Experimental: FAVICOVIR Then AVIGAN,0
6919,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,withdrawal reason,withdrawal reason,P2,AVIGAN Then FAVICOVIR,1
6920,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,"sex: female, male","sex: female, male",B1,FAVICOVIR Then AVIGAN,0
6921,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVICOVIR,0
6922,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,"sex: female, male","sex: female, male",B3,Total,0
6923,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,"sex: female, male","sex: female, male",B1,FAVICOVIR Then AVIGAN,15
6924,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVICOVIR,15
6925,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,gender,Male,"sex: female, male","sex: female, male",B3,Total,30
6926,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,15
6927,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,milestone,milestone,P2,AVIGAN Then FAVICOVIR,15
6928,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,15
6929,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,milestone,milestone,P2,AVIGAN Then FAVICOVIR,14
6930,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,0
6931,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,milestone,milestone,P2,AVIGAN Then FAVICOVIR,1
6932,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,withdrawal reason,withdrawal reason,P1,Experimental: FAVICOVIR Then AVIGAN,0
6933,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,withdrawal reason,withdrawal reason,P2,AVIGAN Then FAVICOVIR,1
6934,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,"sex: female, male","sex: female, male",B1,FAVICOVIR Then AVIGAN,0
6935,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVICOVIR,0
6936,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,"sex: female, male","sex: female, male",B3,Total,0
6937,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,"sex: female, male","sex: female, male",B1,FAVICOVIR Then AVIGAN,15
6938,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVICOVIR,15
6939,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,minimum_age,20 Years,"sex: female, male","sex: female, male",B3,Total,30
6940,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,15
6941,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,milestone,milestone,P2,AVIGAN Then FAVICOVIR,15
6942,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,15
6943,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,milestone,milestone,P2,AVIGAN Then FAVICOVIR,14
6944,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,0
6945,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,milestone,milestone,P2,AVIGAN Then FAVICOVIR,1
6946,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,withdrawal reason,withdrawal reason,P1,Experimental: FAVICOVIR Then AVIGAN,0
6947,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,withdrawal reason,withdrawal reason,P2,AVIGAN Then FAVICOVIR,1
6948,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,"sex: female, male","sex: female, male",B1,FAVICOVIR Then AVIGAN,0
6949,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVICOVIR,0
6950,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,"sex: female, male","sex: female, male",B3,Total,0
6951,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,"sex: female, male","sex: female, male",B1,FAVICOVIR Then AVIGAN,15
6952,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVICOVIR,15
6953,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,maximum_age,40 Years,"sex: female, male","sex: female, male",B3,Total,30
6954,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,15
6955,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P2,AVIGAN Then FAVICOVIR,15
6956,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,15
6957,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P2,AVIGAN Then FAVICOVIR,14
6958,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,0
6959,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P2,AVIGAN Then FAVICOVIR,1
6960,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P1,Experimental: FAVICOVIR Then AVIGAN,0
6961,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P2,AVIGAN Then FAVICOVIR,1
6962,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B1,FAVICOVIR Then AVIGAN,0
6963,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVICOVIR,0
6964,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B3,Total,0
6965,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B1,FAVICOVIR Then AVIGAN,15
6966,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVICOVIR,15
6967,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B3,Total,30
6968,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,15
6969,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,AVIGAN Then FAVICOVIR,15
6970,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,15
6971,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,AVIGAN Then FAVICOVIR,14
6972,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,0
6973,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,AVIGAN Then FAVICOVIR,1
6974,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Experimental: FAVICOVIR Then AVIGAN,0
6975,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,AVIGAN Then FAVICOVIR,1
6976,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,FAVICOVIR Then AVIGAN,0
6977,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVICOVIR,0
6978,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,0
6979,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,FAVICOVIR Then AVIGAN,15
6980,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVICOVIR,15
6981,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,30
6982,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,15
6983,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,milestone,milestone,P2,AVIGAN Then FAVICOVIR,15
6984,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,15
6985,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,milestone,milestone,P2,AVIGAN Then FAVICOVIR,14
6986,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,0
6987,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,milestone,milestone,P2,AVIGAN Then FAVICOVIR,1
6988,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,withdrawal reason,withdrawal reason,P1,Experimental: FAVICOVIR Then AVIGAN,0
6989,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,withdrawal reason,withdrawal reason,P2,AVIGAN Then FAVICOVIR,1
6990,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,"sex: female, male","sex: female, male",B1,FAVICOVIR Then AVIGAN,0
6991,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVICOVIR,0
6992,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,"sex: female, male","sex: female, male",B3,Total,0
6993,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,"sex: female, male","sex: female, male",B1,FAVICOVIR Then AVIGAN,15
6994,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVICOVIR,15
6995,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,intervention_model,Crossover Assignment,"sex: female, male","sex: female, male",B3,Total,30
6996,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,15
6997,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P2,AVIGAN Then FAVICOVIR,15
6998,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,15
6999,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P2,AVIGAN Then FAVICOVIR,14
7000,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,0
7001,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P2,AVIGAN Then FAVICOVIR,1
7002,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,withdrawal reason,withdrawal reason,P1,Experimental: FAVICOVIR Then AVIGAN,0
7003,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,withdrawal reason,withdrawal reason,P2,AVIGAN Then FAVICOVIR,1
7004,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B1,FAVICOVIR Then AVIGAN,0
7005,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVICOVIR,0
7006,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B3,Total,0
7007,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B1,FAVICOVIR Then AVIGAN,15
7008,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B2,AVIGAN Then FAVICOVIR,15
7009,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B3,Total,30
7010,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,15
7011,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,AVIGAN Then FAVICOVIR,15
7012,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,15
7013,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,AVIGAN Then FAVICOVIR,14
7014,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Experimental: FAVICOVIR Then AVIGAN,0
7015,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,AVIGAN Then FAVICOVIR,1
7016,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Experimental: FAVICOVIR Then AVIGAN,0
7017,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,AVIGAN Then FAVICOVIR,1
7018,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,FAVICOVIR Then AVIGAN,0
7019,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B2,AVIGAN Then FAVICOVIR,0
7020,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B3,Total,0
7021,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,FAVICOVIR Then AVIGAN,15
7022,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B2,AVIGAN Then FAVICOVIR,15
7023,14,"Bioequivalence Study of Favipiravir 200 mg Film Tablet (ATABAY, Turkey) Under Fasting Conditions",Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B3,Total,30
7024,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,milestone,milestone,P1,Povidone-iodine,5
7025,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,milestone,milestone,P2,Essential Oils,5
7026,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,milestone,milestone,P3,Tap Water,5
7027,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,milestone,milestone,P4,Control,5
7028,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,milestone,milestone,P1,Povidone-iodine,5
7029,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,milestone,milestone,P2,Essential Oils,5
7030,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,milestone,milestone,P3,Tap Water,5
7031,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,milestone,milestone,P4,Control,5
7032,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,milestone,milestone,P1,Povidone-iodine,0
7033,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,milestone,milestone,P2,Essential Oils,0
7034,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,milestone,milestone,P3,Tap Water,0
7035,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,milestone,milestone,P4,Control,0
7036,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,age,age,B1,Povidone-iodine,0
7037,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,age,age,B2,Essential Oils,0
7038,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,age,age,B3,Tap Water,0
7039,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,age,age,B4,Control,0
7040,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,age,age,B5,Total,0
7041,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,age,age,B1,Povidone-iodine,5
7042,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,age,age,B2,Essential Oils,5
7043,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,age,age,B3,Tap Water,5
7044,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,age,age,B4,Control,5
7045,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,age,age,B5,Total,20
7046,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,age,age,B1,Povidone-iodine,0
7047,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,age,age,B2,Essential Oils,0
7048,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,age,age,B3,Tap Water,0
7049,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,age,age,B4,Control,0
7050,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,age,age,B5,Total,0
7051,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Povidone-iodine,3
7052,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Essential Oils,1
7053,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Tap Water,0
7054,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B4,Control,0
7055,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B5,Total,4
7056,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Povidone-iodine,2
7057,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Essential Oils,4
7058,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Tap Water,5
7059,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B4,Control,5
7060,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B5,Total,16
7061,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7062,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7063,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Tap Water,0
7064,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B4,Control,0
7065,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B5,Total,0
7066,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Povidone-iodine,5
7067,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Essential Oils,5
7068,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Tap Water,5
7069,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B4,Control,5
7070,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B5,Total,20
7071,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7072,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7073,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Tap Water,0
7074,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B4,Control,0
7075,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B5,Total,0
7076,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7077,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7078,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Tap Water,0
7079,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B4,Control,0
7080,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B5,Total,0
7081,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7082,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7083,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Tap Water,0
7084,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B4,Control,0
7085,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B5,Total,0
7086,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7087,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7088,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Tap Water,0
7089,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B4,Control,0
7090,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B5,Total,0
7091,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7092,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7093,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Tap Water,0
7094,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B4,Control,0
7095,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B5,Total,0
7096,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Povidone-iodine,5
7097,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Essential Oils,5
7098,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Tap Water,5
7099,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,Control,5
7100,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,gender,All,enrollment region,enrollment region,B5,Total,20
7101,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Povidone-iodine,5
7102,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Essential Oils,5
7103,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P3,Tap Water,5
7104,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P4,Control,5
7105,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Povidone-iodine,5
7106,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Essential Oils,5
7107,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P3,Tap Water,5
7108,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P4,Control,5
7109,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Povidone-iodine,0
7110,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Essential Oils,0
7111,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P3,Tap Water,0
7112,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P4,Control,0
7113,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,age,age,B1,Povidone-iodine,0
7114,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,age,age,B2,Essential Oils,0
7115,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,age,age,B3,Tap Water,0
7116,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,age,age,B4,Control,0
7117,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,age,age,B5,Total,0
7118,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,age,age,B1,Povidone-iodine,5
7119,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,age,age,B2,Essential Oils,5
7120,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,age,age,B3,Tap Water,5
7121,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,age,age,B4,Control,5
7122,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,age,age,B5,Total,20
7123,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,age,age,B1,Povidone-iodine,0
7124,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,age,age,B2,Essential Oils,0
7125,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,age,age,B3,Tap Water,0
7126,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,age,age,B4,Control,0
7127,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,age,age,B5,Total,0
7128,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Povidone-iodine,3
7129,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Essential Oils,1
7130,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Tap Water,0
7131,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B4,Control,0
7132,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B5,Total,4
7133,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Povidone-iodine,2
7134,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Essential Oils,4
7135,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Tap Water,5
7136,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B4,Control,5
7137,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B5,Total,16
7138,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7139,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7140,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Tap Water,0
7141,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B4,Control,0
7142,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B5,Total,0
7143,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Povidone-iodine,5
7144,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Essential Oils,5
7145,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Tap Water,5
7146,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B4,Control,5
7147,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B5,Total,20
7148,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7149,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7150,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Tap Water,0
7151,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B4,Control,0
7152,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B5,Total,0
7153,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7154,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7155,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Tap Water,0
7156,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B4,Control,0
7157,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B5,Total,0
7158,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7159,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7160,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Tap Water,0
7161,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B4,Control,0
7162,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B5,Total,0
7163,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7164,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7165,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Tap Water,0
7166,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B4,Control,0
7167,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B5,Total,0
7168,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7169,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7170,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Tap Water,0
7171,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B4,Control,0
7172,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B5,Total,0
7173,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,Povidone-iodine,5
7174,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B2,Essential Oils,5
7175,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B3,Tap Water,5
7176,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B4,Control,5
7177,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B5,Total,20
7178,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Povidone-iodine,5
7179,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Essential Oils,5
7180,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P3,Tap Water,5
7181,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P4,Control,5
7182,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Povidone-iodine,5
7183,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Essential Oils,5
7184,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P3,Tap Water,5
7185,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P4,Control,5
7186,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Povidone-iodine,0
7187,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Essential Oils,0
7188,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P3,Tap Water,0
7189,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P4,Control,0
7190,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,age,age,B1,Povidone-iodine,0
7191,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,age,age,B2,Essential Oils,0
7192,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,age,age,B3,Tap Water,0
7193,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,age,age,B4,Control,0
7194,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,age,age,B5,Total,0
7195,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,age,age,B1,Povidone-iodine,5
7196,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,age,age,B2,Essential Oils,5
7197,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,age,age,B3,Tap Water,5
7198,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,age,age,B4,Control,5
7199,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,age,age,B5,Total,20
7200,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,age,age,B1,Povidone-iodine,0
7201,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,age,age,B2,Essential Oils,0
7202,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,age,age,B3,Tap Water,0
7203,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,age,age,B4,Control,0
7204,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,age,age,B5,Total,0
7205,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Povidone-iodine,3
7206,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Essential Oils,1
7207,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Tap Water,0
7208,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B4,Control,0
7209,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B5,Total,4
7210,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Povidone-iodine,2
7211,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Essential Oils,4
7212,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Tap Water,5
7213,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B4,Control,5
7214,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B5,Total,16
7215,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7216,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7217,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Tap Water,0
7218,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B4,Control,0
7219,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B5,Total,0
7220,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Povidone-iodine,5
7221,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Essential Oils,5
7222,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Tap Water,5
7223,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B4,Control,5
7224,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B5,Total,20
7225,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7226,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7227,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Tap Water,0
7228,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B4,Control,0
7229,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B5,Total,0
7230,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7231,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7232,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Tap Water,0
7233,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B4,Control,0
7234,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B5,Total,0
7235,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7236,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7237,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Tap Water,0
7238,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B4,Control,0
7239,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B5,Total,0
7240,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7241,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7242,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Tap Water,0
7243,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B4,Control,0
7244,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B5,Total,0
7245,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7246,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7247,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Tap Water,0
7248,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B4,Control,0
7249,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B5,Total,0
7250,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Povidone-iodine,5
7251,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Essential Oils,5
7252,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Tap Water,5
7253,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,Control,5
7254,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B5,Total,20
7255,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Povidone-iodine,5
7256,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Essential Oils,5
7257,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P3,Tap Water,5
7258,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P4,Control,5
7259,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Povidone-iodine,5
7260,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Essential Oils,5
7261,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P3,Tap Water,5
7262,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P4,Control,5
7263,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Povidone-iodine,0
7264,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Essential Oils,0
7265,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P3,Tap Water,0
7266,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P4,Control,0
7267,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,age,age,B1,Povidone-iodine,0
7268,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,age,age,B2,Essential Oils,0
7269,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,age,age,B3,Tap Water,0
7270,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,age,age,B4,Control,0
7271,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,age,age,B5,Total,0
7272,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,age,age,B1,Povidone-iodine,5
7273,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,age,age,B2,Essential Oils,5
7274,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,age,age,B3,Tap Water,5
7275,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,age,age,B4,Control,5
7276,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,age,age,B5,Total,20
7277,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,age,age,B1,Povidone-iodine,0
7278,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,age,age,B2,Essential Oils,0
7279,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,age,age,B3,Tap Water,0
7280,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,age,age,B4,Control,0
7281,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,age,age,B5,Total,0
7282,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Povidone-iodine,3
7283,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Essential Oils,1
7284,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Tap Water,0
7285,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B4,Control,0
7286,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B5,Total,4
7287,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Povidone-iodine,2
7288,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Essential Oils,4
7289,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Tap Water,5
7290,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B4,Control,5
7291,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B5,Total,16
7292,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7293,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7294,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Tap Water,0
7295,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B4,Control,0
7296,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B5,Total,0
7297,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Povidone-iodine,5
7298,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Essential Oils,5
7299,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Tap Water,5
7300,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B4,Control,5
7301,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B5,Total,20
7302,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7303,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7304,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Tap Water,0
7305,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B4,Control,0
7306,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B5,Total,0
7307,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7308,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7309,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Tap Water,0
7310,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B4,Control,0
7311,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B5,Total,0
7312,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7313,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7314,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Tap Water,0
7315,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B4,Control,0
7316,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B5,Total,0
7317,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7318,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7319,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Tap Water,0
7320,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B4,Control,0
7321,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B5,Total,0
7322,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7323,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7324,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Tap Water,0
7325,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B4,Control,0
7326,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B5,Total,0
7327,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Povidone-iodine,5
7328,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Essential Oils,5
7329,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Tap Water,5
7330,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,Control,5
7331,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B5,Total,20
7332,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Povidone-iodine,5
7333,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Essential Oils,5
7334,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P3,Tap Water,5
7335,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P4,Control,5
7336,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Povidone-iodine,5
7337,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Essential Oils,5
7338,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P3,Tap Water,5
7339,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P4,Control,5
7340,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Povidone-iodine,0
7341,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Essential Oils,0
7342,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P3,Tap Water,0
7343,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P4,Control,0
7344,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,age,age,B1,Povidone-iodine,0
7345,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,age,age,B2,Essential Oils,0
7346,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,age,age,B3,Tap Water,0
7347,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,age,age,B4,Control,0
7348,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,age,age,B5,Total,0
7349,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,age,age,B1,Povidone-iodine,5
7350,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,age,age,B2,Essential Oils,5
7351,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,age,age,B3,Tap Water,5
7352,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,age,age,B4,Control,5
7353,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,age,age,B5,Total,20
7354,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,age,age,B1,Povidone-iodine,0
7355,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,age,age,B2,Essential Oils,0
7356,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,age,age,B3,Tap Water,0
7357,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,age,age,B4,Control,0
7358,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,age,age,B5,Total,0
7359,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Povidone-iodine,3
7360,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Essential Oils,1
7361,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Tap Water,0
7362,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B4,Control,0
7363,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B5,Total,4
7364,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Povidone-iodine,2
7365,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Essential Oils,4
7366,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Tap Water,5
7367,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B4,Control,5
7368,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B5,Total,16
7369,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7370,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7371,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Tap Water,0
7372,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B4,Control,0
7373,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B5,Total,0
7374,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Povidone-iodine,5
7375,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Essential Oils,5
7376,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Tap Water,5
7377,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B4,Control,5
7378,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B5,Total,20
7379,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7380,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7381,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Tap Water,0
7382,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B4,Control,0
7383,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B5,Total,0
7384,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7385,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7386,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Tap Water,0
7387,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B4,Control,0
7388,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B5,Total,0
7389,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7390,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7391,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Tap Water,0
7392,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B4,Control,0
7393,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B5,Total,0
7394,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7395,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7396,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Tap Water,0
7397,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B4,Control,0
7398,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B5,Total,0
7399,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7400,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7401,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Tap Water,0
7402,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B4,Control,0
7403,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B5,Total,0
7404,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Povidone-iodine,5
7405,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Essential Oils,5
7406,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Tap Water,5
7407,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,Control,5
7408,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B5,Total,20
7409,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Povidone-iodine,5
7410,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Essential Oils,5
7411,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P3,Tap Water,5
7412,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P4,Control,5
7413,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Povidone-iodine,5
7414,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Essential Oils,5
7415,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P3,Tap Water,5
7416,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P4,Control,5
7417,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Povidone-iodine,0
7418,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Essential Oils,0
7419,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P3,Tap Water,0
7420,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P4,Control,0
7421,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B1,Povidone-iodine,0
7422,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B2,Essential Oils,0
7423,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B3,Tap Water,0
7424,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B4,Control,0
7425,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B5,Total,0
7426,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B1,Povidone-iodine,5
7427,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B2,Essential Oils,5
7428,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B3,Tap Water,5
7429,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B4,Control,5
7430,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B5,Total,20
7431,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B1,Povidone-iodine,0
7432,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B2,Essential Oils,0
7433,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B3,Tap Water,0
7434,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B4,Control,0
7435,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B5,Total,0
7436,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Povidone-iodine,3
7437,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Essential Oils,1
7438,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Tap Water,0
7439,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B4,Control,0
7440,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B5,Total,4
7441,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Povidone-iodine,2
7442,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Essential Oils,4
7443,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Tap Water,5
7444,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B4,Control,5
7445,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B5,Total,16
7446,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7447,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7448,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Tap Water,0
7449,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B4,Control,0
7450,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B5,Total,0
7451,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Povidone-iodine,5
7452,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Essential Oils,5
7453,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Tap Water,5
7454,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B4,Control,5
7455,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B5,Total,20
7456,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7457,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7458,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Tap Water,0
7459,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B4,Control,0
7460,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B5,Total,0
7461,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7462,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7463,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Tap Water,0
7464,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B4,Control,0
7465,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B5,Total,0
7466,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7467,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7468,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Tap Water,0
7469,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B4,Control,0
7470,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B5,Total,0
7471,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7472,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7473,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Tap Water,0
7474,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B4,Control,0
7475,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B5,Total,0
7476,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7477,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7478,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Tap Water,0
7479,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B4,Control,0
7480,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B5,Total,0
7481,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Povidone-iodine,5
7482,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Essential Oils,5
7483,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Tap Water,5
7484,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,Control,5
7485,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B5,Total,20
7486,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",milestone,milestone,P1,Povidone-iodine,5
7487,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",milestone,milestone,P2,Essential Oils,5
7488,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",milestone,milestone,P3,Tap Water,5
7489,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",milestone,milestone,P4,Control,5
7490,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",milestone,milestone,P1,Povidone-iodine,5
7491,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",milestone,milestone,P2,Essential Oils,5
7492,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",milestone,milestone,P3,Tap Water,5
7493,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",milestone,milestone,P4,Control,5
7494,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",milestone,milestone,P1,Povidone-iodine,0
7495,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",milestone,milestone,P2,Essential Oils,0
7496,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",milestone,milestone,P3,Tap Water,0
7497,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",milestone,milestone,P4,Control,0
7498,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",age,age,B1,Povidone-iodine,0
7499,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",age,age,B2,Essential Oils,0
7500,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",age,age,B3,Tap Water,0
7501,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",age,age,B4,Control,0
7502,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",age,age,B5,Total,0
7503,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",age,age,B1,Povidone-iodine,5
7504,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",age,age,B2,Essential Oils,5
7505,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",age,age,B3,Tap Water,5
7506,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",age,age,B4,Control,5
7507,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",age,age,B5,Total,20
7508,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",age,age,B1,Povidone-iodine,0
7509,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",age,age,B2,Essential Oils,0
7510,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",age,age,B3,Tap Water,0
7511,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",age,age,B4,Control,0
7512,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",age,age,B5,Total,0
7513,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control","sex: female, male","sex: female, male",B1,Povidone-iodine,3
7514,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control","sex: female, male","sex: female, male",B2,Essential Oils,1
7515,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control","sex: female, male","sex: female, male",B3,Tap Water,0
7516,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control","sex: female, male","sex: female, male",B4,Control,0
7517,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control","sex: female, male","sex: female, male",B5,Total,4
7518,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control","sex: female, male","sex: female, male",B1,Povidone-iodine,2
7519,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control","sex: female, male","sex: female, male",B2,Essential Oils,4
7520,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control","sex: female, male","sex: female, male",B3,Tap Water,5
7521,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control","sex: female, male","sex: female, male",B4,Control,5
7522,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control","sex: female, male","sex: female, male",B5,Total,16
7523,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7524,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B2,Essential Oils,0
7525,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B3,Tap Water,0
7526,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B4,Control,0
7527,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B5,Total,0
7528,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B1,Povidone-iodine,5
7529,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B2,Essential Oils,5
7530,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B3,Tap Water,5
7531,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B4,Control,5
7532,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B5,Total,20
7533,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7534,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B2,Essential Oils,0
7535,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B3,Tap Water,0
7536,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B4,Control,0
7537,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B5,Total,0
7538,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7539,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B2,Essential Oils,0
7540,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B3,Tap Water,0
7541,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B4,Control,0
7542,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B5,Total,0
7543,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7544,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B2,Essential Oils,0
7545,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B3,Tap Water,0
7546,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B4,Control,0
7547,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B5,Total,0
7548,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7549,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B2,Essential Oils,0
7550,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B3,Tap Water,0
7551,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B4,Control,0
7552,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B5,Total,0
7553,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7554,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B2,Essential Oils,0
7555,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B3,Tap Water,0
7556,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B4,Control,0
7557,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",race (nih/omb),race (nih/omb),B5,Total,0
7558,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",enrollment region,enrollment region,B1,Povidone-iodine,5
7559,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",enrollment region,enrollment region,B2,Essential Oils,5
7560,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",enrollment region,enrollment region,B3,Tap Water,5
7561,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",enrollment region,enrollment region,B4,Control,5
7562,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,intervention_model_description,"4 arms
Gargle with povidone-iodine
Gargle with essential oils
Gargle with tap water
Control",enrollment region,enrollment region,B5,Total,20
7563,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Povidone-iodine,5
7564,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Essential Oils,5
7565,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P3,Tap Water,5
7566,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P4,Control,5
7567,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Povidone-iodine,5
7568,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Essential Oils,5
7569,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P3,Tap Water,5
7570,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P4,Control,5
7571,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Povidone-iodine,0
7572,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Essential Oils,0
7573,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P3,Tap Water,0
7574,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P4,Control,0
7575,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,age,age,B1,Povidone-iodine,0
7576,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,age,age,B2,Essential Oils,0
7577,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,age,age,B3,Tap Water,0
7578,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,age,age,B4,Control,0
7579,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,age,age,B5,Total,0
7580,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,age,age,B1,Povidone-iodine,5
7581,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,age,age,B2,Essential Oils,5
7582,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,age,age,B3,Tap Water,5
7583,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,age,age,B4,Control,5
7584,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,age,age,B5,Total,20
7585,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,age,age,B1,Povidone-iodine,0
7586,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,age,age,B2,Essential Oils,0
7587,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,age,age,B3,Tap Water,0
7588,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,age,age,B4,Control,0
7589,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,age,age,B5,Total,0
7590,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Povidone-iodine,3
7591,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Essential Oils,1
7592,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Tap Water,0
7593,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B4,Control,0
7594,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B5,Total,4
7595,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Povidone-iodine,2
7596,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Essential Oils,4
7597,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Tap Water,5
7598,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B4,Control,5
7599,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B5,Total,16
7600,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7601,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7602,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Tap Water,0
7603,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B4,Control,0
7604,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B5,Total,0
7605,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Povidone-iodine,5
7606,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Essential Oils,5
7607,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Tap Water,5
7608,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B4,Control,5
7609,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B5,Total,20
7610,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7611,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7612,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Tap Water,0
7613,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B4,Control,0
7614,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B5,Total,0
7615,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7616,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7617,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Tap Water,0
7618,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B4,Control,0
7619,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B5,Total,0
7620,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7621,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7622,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Tap Water,0
7623,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B4,Control,0
7624,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B5,Total,0
7625,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7626,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7627,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Tap Water,0
7628,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B4,Control,0
7629,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B5,Total,0
7630,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7631,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Essential Oils,0
7632,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Tap Water,0
7633,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B4,Control,0
7634,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B5,Total,0
7635,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Povidone-iodine,5
7636,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Essential Oils,5
7637,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Tap Water,5
7638,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B4,Control,5
7639,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B5,Total,20
7640,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Povidone-iodine,5
7641,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,Essential Oils,5
7642,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P3,Tap Water,5
7643,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P4,Control,5
7644,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Povidone-iodine,5
7645,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,Essential Oils,5
7646,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P3,Tap Water,5
7647,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P4,Control,5
7648,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Povidone-iodine,0
7649,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,Essential Oils,0
7650,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P3,Tap Water,0
7651,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P4,Control,0
7652,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),age,age,B1,Povidone-iodine,0
7653,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),age,age,B2,Essential Oils,0
7654,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),age,age,B3,Tap Water,0
7655,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),age,age,B4,Control,0
7656,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),age,age,B5,Total,0
7657,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),age,age,B1,Povidone-iodine,5
7658,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),age,age,B2,Essential Oils,5
7659,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),age,age,B3,Tap Water,5
7660,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),age,age,B4,Control,5
7661,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),age,age,B5,Total,20
7662,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),age,age,B1,Povidone-iodine,0
7663,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),age,age,B2,Essential Oils,0
7664,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),age,age,B3,Tap Water,0
7665,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),age,age,B4,Control,0
7666,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),age,age,B5,Total,0
7667,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,Povidone-iodine,3
7668,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B2,Essential Oils,1
7669,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B3,Tap Water,0
7670,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B4,Control,0
7671,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B5,Total,4
7672,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,Povidone-iodine,2
7673,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B2,Essential Oils,4
7674,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B3,Tap Water,5
7675,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B4,Control,5
7676,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B5,Total,16
7677,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7678,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B2,Essential Oils,0
7679,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B3,Tap Water,0
7680,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B4,Control,0
7681,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B5,Total,0
7682,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,Povidone-iodine,5
7683,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B2,Essential Oils,5
7684,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B3,Tap Water,5
7685,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B4,Control,5
7686,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B5,Total,20
7687,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7688,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B2,Essential Oils,0
7689,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B3,Tap Water,0
7690,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B4,Control,0
7691,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B5,Total,0
7692,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7693,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B2,Essential Oils,0
7694,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B3,Tap Water,0
7695,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B4,Control,0
7696,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B5,Total,0
7697,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7698,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B2,Essential Oils,0
7699,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B3,Tap Water,0
7700,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B4,Control,0
7701,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B5,Total,0
7702,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7703,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B2,Essential Oils,0
7704,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B3,Tap Water,0
7705,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B4,Control,0
7706,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B5,Total,0
7707,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,Povidone-iodine,0
7708,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B2,Essential Oils,0
7709,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B3,Tap Water,0
7710,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B4,Control,0
7711,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B5,Total,0
7712,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Povidone-iodine,5
7713,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Essential Oils,5
7714,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Tap Water,5
7715,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B4,Control,5
7716,15,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B5,Total,20
7717,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,gender,All,milestone,milestone,P1,Ivermectin Group,228
7718,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,gender,All,milestone,milestone,P2,Control Group,112
7719,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,gender,All,milestone,milestone,P1,Ivermectin Group,203
7720,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,gender,All,milestone,milestone,P2,Control Group,101
7721,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,gender,All,milestone,milestone,P1,Ivermectin Group,25
7722,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,gender,All,milestone,milestone,P2,Control Group,11
7723,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Ivermectin Group,25
7724,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Control Group,11
7725,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Ivermectin Group,97
7726,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Control Group,51
7727,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,148
7728,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Ivermectin Group,106
7729,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Control Group,50
7730,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,156
7731,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,minimum_age,16 Years,milestone,milestone,P1,Ivermectin Group,228
7732,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,minimum_age,16 Years,milestone,milestone,P2,Control Group,112
7733,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,minimum_age,16 Years,milestone,milestone,P1,Ivermectin Group,203
7734,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,minimum_age,16 Years,milestone,milestone,P2,Control Group,101
7735,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,minimum_age,16 Years,milestone,milestone,P1,Ivermectin Group,25
7736,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,minimum_age,16 Years,milestone,milestone,P2,Control Group,11
7737,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,minimum_age,16 Years,withdrawal reason,withdrawal reason,P1,Ivermectin Group,25
7738,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,minimum_age,16 Years,withdrawal reason,withdrawal reason,P2,Control Group,11
7739,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,minimum_age,16 Years,"sex: female, male","sex: female, male",B1,Ivermectin Group,97
7740,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,minimum_age,16 Years,"sex: female, male","sex: female, male",B2,Control Group,51
7741,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,minimum_age,16 Years,"sex: female, male","sex: female, male",B3,Total,148
7742,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,minimum_age,16 Years,"sex: female, male","sex: female, male",B1,Ivermectin Group,106
7743,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,minimum_age,16 Years,"sex: female, male","sex: female, male",B2,Control Group,50
7744,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,minimum_age,16 Years,"sex: female, male","sex: female, male",B3,Total,156
7745,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,maximum_age,70 Years,milestone,milestone,P1,Ivermectin Group,228
7746,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,maximum_age,70 Years,milestone,milestone,P2,Control Group,112
7747,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,maximum_age,70 Years,milestone,milestone,P1,Ivermectin Group,203
7748,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,maximum_age,70 Years,milestone,milestone,P2,Control Group,101
7749,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,maximum_age,70 Years,milestone,milestone,P1,Ivermectin Group,25
7750,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,maximum_age,70 Years,milestone,milestone,P2,Control Group,11
7751,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,maximum_age,70 Years,withdrawal reason,withdrawal reason,P1,Ivermectin Group,25
7752,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,maximum_age,70 Years,withdrawal reason,withdrawal reason,P2,Control Group,11
7753,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,maximum_age,70 Years,"sex: female, male","sex: female, male",B1,Ivermectin Group,97
7754,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,maximum_age,70 Years,"sex: female, male","sex: female, male",B2,Control Group,51
7755,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,maximum_age,70 Years,"sex: female, male","sex: female, male",B3,Total,148
7756,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,maximum_age,70 Years,"sex: female, male","sex: female, male",B1,Ivermectin Group,106
7757,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,maximum_age,70 Years,"sex: female, male","sex: female, male",B2,Control Group,50
7758,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,maximum_age,70 Years,"sex: female, male","sex: female, male",B3,Total,156
7759,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,Ivermectin Group,228
7760,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P2,Control Group,112
7761,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,Ivermectin Group,203
7762,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P2,Control Group,101
7763,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,Ivermectin Group,25
7764,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P2,Control Group,11
7765,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P1,Ivermectin Group,25
7766,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P2,Control Group,11
7767,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B1,Ivermectin Group,97
7768,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B2,Control Group,51
7769,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B3,Total,148
7770,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B1,Ivermectin Group,106
7771,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B2,Control Group,50
7772,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B3,Total,156
7773,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Ivermectin Group,228
7774,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Control Group,112
7775,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Ivermectin Group,203
7776,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Control Group,101
7777,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Ivermectin Group,25
7778,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Control Group,11
7779,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Ivermectin Group,25
7780,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Control Group,11
7781,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Ivermectin Group,97
7782,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Control Group,51
7783,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,148
7784,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Ivermectin Group,106
7785,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Control Group,50
7786,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,156
7787,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,intervention_model,Sequential Assignment,milestone,milestone,P1,Ivermectin Group,228
7788,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,intervention_model,Sequential Assignment,milestone,milestone,P2,Control Group,112
7789,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,intervention_model,Sequential Assignment,milestone,milestone,P1,Ivermectin Group,203
7790,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,intervention_model,Sequential Assignment,milestone,milestone,P2,Control Group,101
7791,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,intervention_model,Sequential Assignment,milestone,milestone,P1,Ivermectin Group,25
7792,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,intervention_model,Sequential Assignment,milestone,milestone,P2,Control Group,11
7793,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,intervention_model,Sequential Assignment,withdrawal reason,withdrawal reason,P1,Ivermectin Group,25
7794,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,intervention_model,Sequential Assignment,withdrawal reason,withdrawal reason,P2,Control Group,11
7795,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,intervention_model,Sequential Assignment,"sex: female, male","sex: female, male",B1,Ivermectin Group,97
7796,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,intervention_model,Sequential Assignment,"sex: female, male","sex: female, male",B2,Control Group,51
7797,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,intervention_model,Sequential Assignment,"sex: female, male","sex: female, male",B3,Total,148
7798,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,intervention_model,Sequential Assignment,"sex: female, male","sex: female, male",B1,Ivermectin Group,106
7799,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,intervention_model,Sequential Assignment,"sex: female, male","sex: female, male",B2,Control Group,50
7800,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,intervention_model,Sequential Assignment,"sex: female, male","sex: female, male",B3,Total,156
7801,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,primary_purpose,Prevention,milestone,milestone,P1,Ivermectin Group,228
7802,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,primary_purpose,Prevention,milestone,milestone,P2,Control Group,112
7803,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,primary_purpose,Prevention,milestone,milestone,P1,Ivermectin Group,203
7804,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,primary_purpose,Prevention,milestone,milestone,P2,Control Group,101
7805,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,primary_purpose,Prevention,milestone,milestone,P1,Ivermectin Group,25
7806,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,primary_purpose,Prevention,milestone,milestone,P2,Control Group,11
7807,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,primary_purpose,Prevention,withdrawal reason,withdrawal reason,P1,Ivermectin Group,25
7808,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,primary_purpose,Prevention,withdrawal reason,withdrawal reason,P2,Control Group,11
7809,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,primary_purpose,Prevention,"sex: female, male","sex: female, male",B1,Ivermectin Group,97
7810,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,primary_purpose,Prevention,"sex: female, male","sex: female, male",B2,Control Group,51
7811,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,primary_purpose,Prevention,"sex: female, male","sex: female, male",B3,Total,148
7812,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,primary_purpose,Prevention,"sex: female, male","sex: female, male",B1,Ivermectin Group,106
7813,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,primary_purpose,Prevention,"sex: female, male","sex: female, male",B2,Control Group,50
7814,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,primary_purpose,Prevention,"sex: female, male","sex: female, male",B3,Total,156
7815,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Ivermectin Group,228
7816,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,Control Group,112
7817,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Ivermectin Group,203
7818,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,Control Group,101
7819,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Ivermectin Group,25
7820,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,Control Group,11
7821,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Ivermectin Group,25
7822,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Control Group,11
7823,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,Ivermectin Group,97
7824,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B2,Control Group,51
7825,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B3,Total,148
7826,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,Ivermectin Group,106
7827,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B2,Control Group,50
7828,16,Prophylactic Ivermectin in COVID-19 Contacts,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B3,Total,156
7829,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",milestone,milestone,P1,IVER+,131
7830,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",milestone,milestone,P2,IVER-,98
7831,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",milestone,milestone,P1,IVER+,131
7832,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",milestone,milestone,P2,IVER-,98
7833,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",milestone,milestone,P1,IVER+,0
7834,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",milestone,milestone,P2,IVER-,0
7835,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B1,IVER+,70
7836,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B2,IVER-,72
7837,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B3,Total,142
7838,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B1,IVER+,61
7839,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B2,IVER-,26
7840,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B3,Total,87
7841,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,131
7842,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,98
7843,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,229
7844,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,0
7845,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,0
7846,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
7847,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,0
7848,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,0
7849,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
7850,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B1,IVER+,0
7851,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B2,IVER-,0
7852,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B3,Total,0
7853,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B1,IVER+,0
7854,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B2,IVER-,0
7855,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B3,Total,0
7856,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B1,IVER+,0
7857,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B2,IVER-,0
7858,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B3,Total,0
7859,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B1,IVER+,0
7860,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B2,IVER-,0
7861,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B3,Total,0
7862,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B1,IVER+,0
7863,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B2,IVER-,0
7864,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B3,Total,0
7865,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B1,IVER+,131
7866,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B2,IVER-,98
7867,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B3,Total,229
7868,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B1,IVER+,0
7869,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B2,IVER-,0
7870,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B3,Total,0
7871,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",enrollment region,enrollment region,B1,IVER+,131
7872,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",enrollment region,enrollment region,B2,IVER-,98
7873,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,study_pop,"
      ",enrollment region,enrollment region,B3,Total,229
7874,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P1,IVER+,131
7875,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P2,IVER-,98
7876,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P1,IVER+,131
7877,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P2,IVER-,98
7878,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P1,IVER+,0
7879,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P2,IVER-,0
7880,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B1,IVER+,70
7881,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B2,IVER-,72
7882,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B3,Total,142
7883,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B1,IVER+,61
7884,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B2,IVER-,26
7885,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B3,Total,87
7886,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,131
7887,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,98
7888,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,229
7889,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,0
7890,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,0
7891,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
7892,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,0
7893,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,0
7894,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
7895,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B1,IVER+,0
7896,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B2,IVER-,0
7897,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B3,Total,0
7898,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B1,IVER+,0
7899,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B2,IVER-,0
7900,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B3,Total,0
7901,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B1,IVER+,0
7902,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B2,IVER-,0
7903,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B3,Total,0
7904,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B1,IVER+,0
7905,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B2,IVER-,0
7906,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B3,Total,0
7907,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B1,IVER+,0
7908,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B2,IVER-,0
7909,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B3,Total,0
7910,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B1,IVER+,131
7911,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B2,IVER-,98
7912,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B3,Total,229
7913,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B1,IVER+,0
7914,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B2,IVER-,0
7915,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B3,Total,0
7916,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,enrollment region,enrollment region,B1,IVER+,131
7917,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,enrollment region,enrollment region,B2,IVER-,98
7918,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,sampling_method,Non-Probability Sample,enrollment region,enrollment region,B3,Total,229
7919,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,milestone,milestone,P1,IVER+,131
7920,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,milestone,milestone,P2,IVER-,98
7921,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,milestone,milestone,P1,IVER+,131
7922,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,milestone,milestone,P2,IVER-,98
7923,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,milestone,milestone,P1,IVER+,0
7924,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,milestone,milestone,P2,IVER-,0
7925,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,"sex: female, male","sex: female, male",B1,IVER+,70
7926,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,"sex: female, male","sex: female, male",B2,IVER-,72
7927,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,142
7928,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,"sex: female, male","sex: female, male",B1,IVER+,61
7929,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,"sex: female, male","sex: female, male",B2,IVER-,26
7930,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,87
7931,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,131
7932,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,98
7933,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,229
7934,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,0
7935,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,0
7936,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
7937,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,0
7938,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,0
7939,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
7940,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,IVER+,0
7941,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,IVER-,0
7942,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,0
7943,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,IVER+,0
7944,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,IVER-,0
7945,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,0
7946,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,IVER+,0
7947,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,IVER-,0
7948,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,0
7949,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,IVER+,0
7950,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,IVER-,0
7951,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,0
7952,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,IVER+,0
7953,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,IVER-,0
7954,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,0
7955,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,IVER+,131
7956,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,IVER-,98
7957,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,229
7958,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,IVER+,0
7959,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,IVER-,0
7960,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,0
7961,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,enrollment region,enrollment region,B1,IVER+,131
7962,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,enrollment region,enrollment region,B2,IVER-,98
7963,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,gender,All,enrollment region,enrollment region,B3,Total,229
7964,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,milestone,milestone,P1,IVER+,131
7965,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,milestone,milestone,P2,IVER-,98
7966,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,milestone,milestone,P1,IVER+,131
7967,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,milestone,milestone,P2,IVER-,98
7968,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,milestone,milestone,P1,IVER+,0
7969,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,milestone,milestone,P2,IVER-,0
7970,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,IVER+,70
7971,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,IVER-,72
7972,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,142
7973,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,IVER+,61
7974,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,IVER-,26
7975,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,87
7976,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,131
7977,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,98
7978,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,229
7979,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,0
7980,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,0
7981,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
7982,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,0
7983,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,0
7984,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
7985,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,IVER+,0
7986,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,IVER-,0
7987,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,0
7988,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,IVER+,0
7989,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,IVER-,0
7990,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,0
7991,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,IVER+,0
7992,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,IVER-,0
7993,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,0
7994,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,IVER+,0
7995,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,IVER-,0
7996,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,0
7997,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,IVER+,0
7998,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,IVER-,0
7999,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,0
8000,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,IVER+,131
8001,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,IVER-,98
8002,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,229
8003,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,IVER+,0
8004,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,IVER-,0
8005,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,0
8006,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,IVER+,131
8007,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B2,IVER-,98
8008,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B3,Total,229
8009,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,milestone,milestone,P1,IVER+,131
8010,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,milestone,milestone,P2,IVER-,98
8011,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,milestone,milestone,P1,IVER+,131
8012,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,milestone,milestone,P2,IVER-,98
8013,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,milestone,milestone,P1,IVER+,0
8014,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,milestone,milestone,P2,IVER-,0
8015,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,IVER+,70
8016,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,IVER-,72
8017,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Total,142
8018,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,IVER+,61
8019,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,IVER-,26
8020,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Total,87
8021,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,131
8022,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,98
8023,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,229
8024,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,0
8025,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,0
8026,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
8027,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,0
8028,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,0
8029,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
8030,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,IVER+,0
8031,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,IVER-,0
8032,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Total,0
8033,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,IVER+,0
8034,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,IVER-,0
8035,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Total,0
8036,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,IVER+,0
8037,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,IVER-,0
8038,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Total,0
8039,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,IVER+,0
8040,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,IVER-,0
8041,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Total,0
8042,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,IVER+,0
8043,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,IVER-,0
8044,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Total,0
8045,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,IVER+,131
8046,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,IVER-,98
8047,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Total,229
8048,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,IVER+,0
8049,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,IVER-,0
8050,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Total,0
8051,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,IVER+,131
8052,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,IVER-,98
8053,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Total,229
8054,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,IVER+,131
8055,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P2,IVER-,98
8056,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,IVER+,131
8057,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P2,IVER-,98
8058,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,IVER+,0
8059,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P2,IVER-,0
8060,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B1,IVER+,70
8061,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B2,IVER-,72
8062,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B3,Total,142
8063,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B1,IVER+,61
8064,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B2,IVER-,26
8065,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B3,Total,87
8066,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,131
8067,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,98
8068,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,229
8069,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,0
8070,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,0
8071,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
8072,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,0
8073,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,0
8074,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
8075,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,IVER+,0
8076,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B2,IVER-,0
8077,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B3,Total,0
8078,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,IVER+,0
8079,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B2,IVER-,0
8080,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B3,Total,0
8081,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,IVER+,0
8082,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B2,IVER-,0
8083,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B3,Total,0
8084,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,IVER+,0
8085,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B2,IVER-,0
8086,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B3,Total,0
8087,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,IVER+,0
8088,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B2,IVER-,0
8089,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B3,Total,0
8090,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,IVER+,131
8091,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B2,IVER-,98
8092,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B3,Total,229
8093,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,IVER+,0
8094,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B2,IVER-,0
8095,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B3,Total,0
8096,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,enrollment region,enrollment region,B1,IVER+,131
8097,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,enrollment region,enrollment region,B2,IVER-,98
8098,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,eligibility,healthy_volunteers,Accepts Healthy Volunteers,enrollment region,enrollment region,B3,Total,229
8099,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,milestone,milestone,P1,IVER+,131
8100,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,milestone,milestone,P2,IVER-,98
8101,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,milestone,milestone,P1,IVER+,131
8102,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,milestone,milestone,P2,IVER-,98
8103,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,milestone,milestone,P1,IVER+,0
8104,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,milestone,milestone,P2,IVER-,0
8105,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B1,IVER+,70
8106,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B2,IVER-,72
8107,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B3,Total,142
8108,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B1,IVER+,61
8109,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B2,IVER-,26
8110,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B3,Total,87
8111,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,131
8112,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,98
8113,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,229
8114,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,0
8115,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,0
8116,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
8117,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,0
8118,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,0
8119,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
8120,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B1,IVER+,0
8121,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B2,IVER-,0
8122,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B3,Total,0
8123,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B1,IVER+,0
8124,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B2,IVER-,0
8125,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B3,Total,0
8126,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B1,IVER+,0
8127,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B2,IVER-,0
8128,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B3,Total,0
8129,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B1,IVER+,0
8130,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B2,IVER-,0
8131,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B3,Total,0
8132,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B1,IVER+,0
8133,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B2,IVER-,0
8134,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B3,Total,0
8135,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B1,IVER+,131
8136,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B2,IVER-,98
8137,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B3,Total,229
8138,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B1,IVER+,0
8139,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B2,IVER-,0
8140,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B3,Total,0
8141,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,enrollment region,enrollment region,B1,IVER+,131
8142,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,enrollment region,enrollment region,B2,IVER-,98
8143,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,observational_model,Cohort,enrollment region,enrollment region,B3,Total,229
8144,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,milestone,milestone,P1,IVER+,131
8145,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,milestone,milestone,P2,IVER-,98
8146,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,milestone,milestone,P1,IVER+,131
8147,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,milestone,milestone,P2,IVER-,98
8148,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,milestone,milestone,P1,IVER+,0
8149,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,milestone,milestone,P2,IVER-,0
8150,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B1,IVER+,70
8151,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B2,IVER-,72
8152,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B3,Total,142
8153,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B1,IVER+,61
8154,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B2,IVER-,26
8155,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B3,Total,87
8156,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,131
8157,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,98
8158,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,229
8159,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,0
8160,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,0
8161,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
8162,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,ethnicity (nih/omb),ethnicity (nih/omb),B1,IVER+,0
8163,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,ethnicity (nih/omb),ethnicity (nih/omb),B2,IVER-,0
8164,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,ethnicity (nih/omb),ethnicity (nih/omb),B3,Total,0
8165,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B1,IVER+,0
8166,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B2,IVER-,0
8167,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B3,Total,0
8168,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B1,IVER+,0
8169,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B2,IVER-,0
8170,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B3,Total,0
8171,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B1,IVER+,0
8172,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B2,IVER-,0
8173,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B3,Total,0
8174,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B1,IVER+,0
8175,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B2,IVER-,0
8176,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B3,Total,0
8177,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B1,IVER+,0
8178,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B2,IVER-,0
8179,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B3,Total,0
8180,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B1,IVER+,131
8181,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B2,IVER-,98
8182,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B3,Total,229
8183,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B1,IVER+,0
8184,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B2,IVER-,0
8185,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B3,Total,0
8186,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,enrollment region,enrollment region,B1,IVER+,131
8187,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,enrollment region,enrollment region,B2,IVER-,98
8188,17,USEFULNESS of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19,Observational,study_design_info,time_perspective,Prospective,enrollment region,enrollment region,B3,Total,229
8189,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",milestone,milestone,P1,Mild Cases,135
8190,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",milestone,milestone,P2,Moderate Cases,12
8191,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",milestone,milestone,P3,Severe Cases,20
8192,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",milestone,milestone,P1,Mild Cases,135
8193,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",milestone,milestone,P2,Moderate Cases,12
8194,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",milestone,milestone,P3,Severe Cases,19
8195,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",milestone,milestone,P1,Mild Cases,0
8196,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",milestone,milestone,P2,Moderate Cases,0
8197,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",milestone,milestone,P3,Severe Cases,1
8198,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",withdrawal reason,withdrawal reason,P1,Mild Cases,0
8199,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",withdrawal reason,withdrawal reason,P2,Moderate Cases,0
8200,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",withdrawal reason,withdrawal reason,P3,Severe Cases,1
8201,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B1,Mild Cases,66
8202,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B2,Moderate Cases,7
8203,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B3,Severe Cases,11
8204,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B4,Total,84
8205,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B1,Mild Cases,69
8206,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B2,Moderate Cases,5
8207,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B3,Severe Cases,9
8208,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B4,Total,83
8209,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,135
8210,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,12
8211,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,20
8212,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,167
8213,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,0
8214,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,0
8215,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,0
8216,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,0
8217,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,0
8218,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,0
8219,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,0
8220,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,0
8221,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B1,Mild Cases,0
8222,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8223,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B3,Severe Cases,0
8224,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B4,Total,0
8225,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B1,Mild Cases,0
8226,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8227,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B3,Severe Cases,0
8228,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B4,Total,0
8229,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B1,Mild Cases,0
8230,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8231,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B3,Severe Cases,0
8232,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B4,Total,0
8233,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B1,Mild Cases,0
8234,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8235,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B3,Severe Cases,0
8236,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B4,Total,0
8237,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B1,Mild Cases,0
8238,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8239,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B3,Severe Cases,0
8240,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B4,Total,0
8241,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B1,Mild Cases,135
8242,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B2,Moderate Cases,12
8243,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B3,Severe Cases,20
8244,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B4,Total,167
8245,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B1,Mild Cases,0
8246,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8247,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B3,Severe Cases,0
8248,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B4,Total,0
8249,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",enrollment region,enrollment region,B1,Mild Cases,135
8250,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",enrollment region,enrollment region,B2,Moderate Cases,12
8251,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",enrollment region,enrollment region,B3,Severe Cases,20
8252,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,study_pop,"
      ",enrollment region,enrollment region,B4,Total,167
8253,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P1,Mild Cases,135
8254,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P2,Moderate Cases,12
8255,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P3,Severe Cases,20
8256,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P1,Mild Cases,135
8257,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P2,Moderate Cases,12
8258,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P3,Severe Cases,19
8259,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P1,Mild Cases,0
8260,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P2,Moderate Cases,0
8261,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P3,Severe Cases,1
8262,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,withdrawal reason,withdrawal reason,P1,Mild Cases,0
8263,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,withdrawal reason,withdrawal reason,P2,Moderate Cases,0
8264,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,withdrawal reason,withdrawal reason,P3,Severe Cases,1
8265,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B1,Mild Cases,66
8266,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B2,Moderate Cases,7
8267,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B3,Severe Cases,11
8268,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B4,Total,84
8269,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B1,Mild Cases,69
8270,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B2,Moderate Cases,5
8271,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B3,Severe Cases,9
8272,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B4,Total,83
8273,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,135
8274,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,12
8275,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,20
8276,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,167
8277,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,0
8278,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,0
8279,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,0
8280,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,0
8281,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,0
8282,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,0
8283,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,0
8284,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,0
8285,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8286,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8287,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8288,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B4,Total,0
8289,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8290,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8291,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8292,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B4,Total,0
8293,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8294,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8295,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8296,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B4,Total,0
8297,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8298,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8299,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8300,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B4,Total,0
8301,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8302,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8303,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8304,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B4,Total,0
8305,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B1,Mild Cases,135
8306,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B2,Moderate Cases,12
8307,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B3,Severe Cases,20
8308,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B4,Total,167
8309,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8310,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8311,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8312,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B4,Total,0
8313,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,enrollment region,enrollment region,B1,Mild Cases,135
8314,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,enrollment region,enrollment region,B2,Moderate Cases,12
8315,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,enrollment region,enrollment region,B3,Severe Cases,20
8316,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,sampling_method,Non-Probability Sample,enrollment region,enrollment region,B4,Total,167
8317,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,milestone,milestone,P1,Mild Cases,135
8318,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,milestone,milestone,P2,Moderate Cases,12
8319,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,milestone,milestone,P3,Severe Cases,20
8320,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,milestone,milestone,P1,Mild Cases,135
8321,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,milestone,milestone,P2,Moderate Cases,12
8322,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,milestone,milestone,P3,Severe Cases,19
8323,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,milestone,milestone,P1,Mild Cases,0
8324,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,milestone,milestone,P2,Moderate Cases,0
8325,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,milestone,milestone,P3,Severe Cases,1
8326,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Mild Cases,0
8327,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Moderate Cases,0
8328,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,withdrawal reason,withdrawal reason,P3,Severe Cases,1
8329,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Mild Cases,66
8330,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Moderate Cases,7
8331,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Severe Cases,11
8332,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,"sex: female, male","sex: female, male",B4,Total,84
8333,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Mild Cases,69
8334,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Moderate Cases,5
8335,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Severe Cases,9
8336,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,"sex: female, male","sex: female, male",B4,Total,83
8337,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,135
8338,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,12
8339,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,20
8340,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,167
8341,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,0
8342,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,0
8343,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,0
8344,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,0
8345,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,0
8346,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,0
8347,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,0
8348,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,0
8349,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8350,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8351,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8352,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B4,Total,0
8353,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8354,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8355,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8356,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B4,Total,0
8357,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8358,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8359,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8360,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B4,Total,0
8361,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8362,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8363,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8364,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B4,Total,0
8365,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8366,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8367,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8368,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B4,Total,0
8369,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Mild Cases,135
8370,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Moderate Cases,12
8371,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Severe Cases,20
8372,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B4,Total,167
8373,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8374,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8375,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8376,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B4,Total,0
8377,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,enrollment region,enrollment region,B1,Mild Cases,135
8378,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,enrollment region,enrollment region,B2,Moderate Cases,12
8379,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,enrollment region,enrollment region,B3,Severe Cases,20
8380,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,gender,All,enrollment region,enrollment region,B4,Total,167
8381,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,milestone,milestone,P1,Mild Cases,135
8382,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,milestone,milestone,P2,Moderate Cases,12
8383,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,milestone,milestone,P3,Severe Cases,20
8384,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,milestone,milestone,P1,Mild Cases,135
8385,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,milestone,milestone,P2,Moderate Cases,12
8386,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,milestone,milestone,P3,Severe Cases,19
8387,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,milestone,milestone,P1,Mild Cases,0
8388,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,milestone,milestone,P2,Moderate Cases,0
8389,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,milestone,milestone,P3,Severe Cases,1
8390,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,withdrawal reason,withdrawal reason,P1,Mild Cases,0
8391,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,withdrawal reason,withdrawal reason,P2,Moderate Cases,0
8392,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,withdrawal reason,withdrawal reason,P3,Severe Cases,1
8393,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,"sex: female, male","sex: female, male",B1,Mild Cases,66
8394,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,"sex: female, male","sex: female, male",B2,Moderate Cases,7
8395,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,"sex: female, male","sex: female, male",B3,Severe Cases,11
8396,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,"sex: female, male","sex: female, male",B4,Total,84
8397,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,"sex: female, male","sex: female, male",B1,Mild Cases,69
8398,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,"sex: female, male","sex: female, male",B2,Moderate Cases,5
8399,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,"sex: female, male","sex: female, male",B3,Severe Cases,9
8400,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,"sex: female, male","sex: female, male",B4,Total,83
8401,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,135
8402,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,12
8403,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,20
8404,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,167
8405,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,0
8406,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,0
8407,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,0
8408,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,0
8409,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,0
8410,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,0
8411,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,0
8412,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,0
8413,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8414,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8415,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8416,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B4,Total,0
8417,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8418,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8419,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8420,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B4,Total,0
8421,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8422,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8423,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8424,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B4,Total,0
8425,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8426,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8427,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8428,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B4,Total,0
8429,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8430,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8431,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8432,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B4,Total,0
8433,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B1,Mild Cases,135
8434,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B2,Moderate Cases,12
8435,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B3,Severe Cases,20
8436,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B4,Total,167
8437,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8438,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8439,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8440,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,race (nih/omb),race (nih/omb),B4,Total,0
8441,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,enrollment region,enrollment region,B1,Mild Cases,135
8442,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,enrollment region,enrollment region,B2,Moderate Cases,12
8443,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,enrollment region,enrollment region,B3,Severe Cases,20
8444,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,minimum_age,5 Years,enrollment region,enrollment region,B4,Total,167
8445,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,milestone,milestone,P1,Mild Cases,135
8446,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,milestone,milestone,P2,Moderate Cases,12
8447,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,milestone,milestone,P3,Severe Cases,20
8448,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,milestone,milestone,P1,Mild Cases,135
8449,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,milestone,milestone,P2,Moderate Cases,12
8450,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,milestone,milestone,P3,Severe Cases,19
8451,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,milestone,milestone,P1,Mild Cases,0
8452,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,milestone,milestone,P2,Moderate Cases,0
8453,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,milestone,milestone,P3,Severe Cases,1
8454,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Mild Cases,0
8455,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Moderate Cases,0
8456,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P3,Severe Cases,1
8457,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Mild Cases,66
8458,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Moderate Cases,7
8459,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Severe Cases,11
8460,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B4,Total,84
8461,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Mild Cases,69
8462,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Moderate Cases,5
8463,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Severe Cases,9
8464,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B4,Total,83
8465,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,135
8466,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,12
8467,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,20
8468,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,167
8469,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,0
8470,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,0
8471,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,0
8472,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,0
8473,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,0
8474,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,0
8475,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,0
8476,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,0
8477,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8478,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8479,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8480,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B4,Total,0
8481,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8482,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8483,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8484,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B4,Total,0
8485,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8486,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8487,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8488,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B4,Total,0
8489,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8490,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8491,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8492,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B4,Total,0
8493,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8494,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8495,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8496,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B4,Total,0
8497,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Mild Cases,135
8498,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Moderate Cases,12
8499,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Severe Cases,20
8500,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B4,Total,167
8501,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8502,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8503,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8504,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B4,Total,0
8505,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Mild Cases,135
8506,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Moderate Cases,12
8507,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Severe Cases,20
8508,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,maximum_age,N/A,enrollment region,enrollment region,B4,Total,167
8509,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,milestone,milestone,P1,Mild Cases,135
8510,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,milestone,milestone,P2,Moderate Cases,12
8511,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,milestone,milestone,P3,Severe Cases,20
8512,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,milestone,milestone,P1,Mild Cases,135
8513,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,milestone,milestone,P2,Moderate Cases,12
8514,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,milestone,milestone,P3,Severe Cases,19
8515,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,milestone,milestone,P1,Mild Cases,0
8516,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,milestone,milestone,P2,Moderate Cases,0
8517,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,milestone,milestone,P3,Severe Cases,1
8518,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Mild Cases,0
8519,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Moderate Cases,0
8520,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P3,Severe Cases,1
8521,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Mild Cases,66
8522,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Moderate Cases,7
8523,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Severe Cases,11
8524,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B4,Total,84
8525,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Mild Cases,69
8526,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Moderate Cases,5
8527,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Severe Cases,9
8528,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B4,Total,83
8529,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,135
8530,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,12
8531,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,20
8532,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,167
8533,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,0
8534,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,0
8535,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,0
8536,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,0
8537,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,0
8538,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,0
8539,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,0
8540,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,0
8541,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8542,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8543,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8544,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B4,Total,0
8545,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8546,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8547,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8548,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B4,Total,0
8549,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8550,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8551,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8552,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B4,Total,0
8553,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8554,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8555,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8556,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B4,Total,0
8557,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8558,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8559,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8560,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B4,Total,0
8561,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Mild Cases,135
8562,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Moderate Cases,12
8563,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Severe Cases,20
8564,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B4,Total,167
8565,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8566,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8567,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8568,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,race (nih/omb),race (nih/omb),B4,Total,0
8569,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Mild Cases,135
8570,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Moderate Cases,12
8571,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Severe Cases,20
8572,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,Total,167
8573,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,milestone,milestone,P1,Mild Cases,135
8574,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,milestone,milestone,P2,Moderate Cases,12
8575,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,milestone,milestone,P3,Severe Cases,20
8576,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,milestone,milestone,P1,Mild Cases,135
8577,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,milestone,milestone,P2,Moderate Cases,12
8578,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,milestone,milestone,P3,Severe Cases,19
8579,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,milestone,milestone,P1,Mild Cases,0
8580,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,milestone,milestone,P2,Moderate Cases,0
8581,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,milestone,milestone,P3,Severe Cases,1
8582,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,withdrawal reason,withdrawal reason,P1,Mild Cases,0
8583,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,withdrawal reason,withdrawal reason,P2,Moderate Cases,0
8584,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,withdrawal reason,withdrawal reason,P3,Severe Cases,1
8585,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B1,Mild Cases,66
8586,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B2,Moderate Cases,7
8587,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B3,Severe Cases,11
8588,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B4,Total,84
8589,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B1,Mild Cases,69
8590,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B2,Moderate Cases,5
8591,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B3,Severe Cases,9
8592,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B4,Total,83
8593,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,135
8594,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,12
8595,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,20
8596,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,167
8597,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,0
8598,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,0
8599,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,0
8600,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,0
8601,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,0
8602,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,0
8603,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,0
8604,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,0
8605,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8606,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8607,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8608,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B4,Total,0
8609,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8610,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8611,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8612,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B4,Total,0
8613,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8614,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8615,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8616,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B4,Total,0
8617,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8618,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8619,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8620,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B4,Total,0
8621,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8622,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8623,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8624,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B4,Total,0
8625,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B1,Mild Cases,135
8626,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B2,Moderate Cases,12
8627,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B3,Severe Cases,20
8628,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B4,Total,167
8629,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8630,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8631,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8632,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B4,Total,0
8633,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,enrollment region,enrollment region,B1,Mild Cases,135
8634,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,enrollment region,enrollment region,B2,Moderate Cases,12
8635,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,enrollment region,enrollment region,B3,Severe Cases,20
8636,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,observational_model,Cohort,enrollment region,enrollment region,B4,Total,167
8637,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,milestone,milestone,P1,Mild Cases,135
8638,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,milestone,milestone,P2,Moderate Cases,12
8639,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,milestone,milestone,P3,Severe Cases,20
8640,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,milestone,milestone,P1,Mild Cases,135
8641,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,milestone,milestone,P2,Moderate Cases,12
8642,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,milestone,milestone,P3,Severe Cases,19
8643,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,milestone,milestone,P1,Mild Cases,0
8644,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,milestone,milestone,P2,Moderate Cases,0
8645,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,milestone,milestone,P3,Severe Cases,1
8646,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,withdrawal reason,withdrawal reason,P1,Mild Cases,0
8647,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,withdrawal reason,withdrawal reason,P2,Moderate Cases,0
8648,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,withdrawal reason,withdrawal reason,P3,Severe Cases,1
8649,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B1,Mild Cases,66
8650,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B2,Moderate Cases,7
8651,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B3,Severe Cases,11
8652,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B4,Total,84
8653,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B1,Mild Cases,69
8654,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B2,Moderate Cases,5
8655,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B3,Severe Cases,9
8656,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B4,Total,83
8657,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,135
8658,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,12
8659,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,20
8660,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,167
8661,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,0
8662,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,0
8663,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,0
8664,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,0
8665,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,ethnicity (nih/omb),ethnicity (nih/omb),B1,Mild Cases,0
8666,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,ethnicity (nih/omb),ethnicity (nih/omb),B2,Moderate Cases,0
8667,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,ethnicity (nih/omb),ethnicity (nih/omb),B3,Severe Cases,0
8668,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,ethnicity (nih/omb),ethnicity (nih/omb),B4,Total,0
8669,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8670,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8671,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8672,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B4,Total,0
8673,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8674,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8675,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8676,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B4,Total,0
8677,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8678,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8679,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8680,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B4,Total,0
8681,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8682,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8683,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8684,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B4,Total,0
8685,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8686,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8687,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8688,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B4,Total,0
8689,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B1,Mild Cases,135
8690,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B2,Moderate Cases,12
8691,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B3,Severe Cases,20
8692,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B4,Total,167
8693,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B1,Mild Cases,0
8694,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B2,Moderate Cases,0
8695,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B3,Severe Cases,0
8696,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B4,Total,0
8697,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,enrollment region,enrollment region,B1,Mild Cases,135
8698,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,enrollment region,enrollment region,B2,Moderate Cases,12
8699,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,enrollment region,enrollment region,B3,Severe Cases,20
8700,18,"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19",Observational,study_design_info,time_perspective,Prospective,enrollment region,enrollment region,B4,Total,167
8701,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,milestone,milestone,P1,Hydroxychloroquine Arm,0
8702,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,milestone,milestone,P2,No Intervention Arm,1
8703,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,milestone,milestone,P1,Hydroxychloroquine Arm,0
8704,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,milestone,milestone,P2,No Intervention Arm,0
8705,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,milestone,milestone,P1,Hydroxychloroquine Arm,0
8706,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,milestone,milestone,P2,No Intervention Arm,1
8707,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Hydroxychloroquine Arm,0
8708,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,No Intervention Arm,1
8709,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,age,age,B1,Hydroxychloroquine Arm,0
8710,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,age,age,B2,No Intervention Arm,0
8711,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,age,age,B3,Total,0
8712,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,age,age,B1,Hydroxychloroquine Arm,0
8713,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,age,age,B2,No Intervention Arm,1
8714,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,age,age,B3,Total,1
8715,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,age,age,B1,Hydroxychloroquine Arm,0
8716,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,age,age,B2,No Intervention Arm,0
8717,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,age,age,B3,Total,0
8718,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Hydroxychloroquine Arm,0
8719,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,No Intervention Arm,0
8720,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,0
8721,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Hydroxychloroquine Arm,0
8722,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,No Intervention Arm,1
8723,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,1
8724,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,No Intervention Arm,1
8725,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Total,1
8726,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Hydroxychloroquine Arm,0
8727,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,No Intervention Arm,1
8728,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Hydroxychloroquine Arm,0
8729,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,No Intervention Arm,0
8730,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Hydroxychloroquine Arm,0
8731,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,No Intervention Arm,1
8732,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Hydroxychloroquine Arm,0
8733,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,No Intervention Arm,1
8734,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,age,age,B1,Hydroxychloroquine Arm,0
8735,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,age,age,B2,No Intervention Arm,0
8736,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,age,age,B3,Total,0
8737,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,age,age,B1,Hydroxychloroquine Arm,0
8738,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,age,age,B2,No Intervention Arm,1
8739,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,age,age,B3,Total,1
8740,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,age,age,B1,Hydroxychloroquine Arm,0
8741,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,age,age,B2,No Intervention Arm,0
8742,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,age,age,B3,Total,0
8743,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Hydroxychloroquine Arm,0
8744,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,No Intervention Arm,0
8745,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,0
8746,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Hydroxychloroquine Arm,0
8747,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,No Intervention Arm,1
8748,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,1
8749,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B2,No Intervention Arm,1
8750,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B3,Total,1
8751,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Hydroxychloroquine Arm,0
8752,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,No Intervention Arm,1
8753,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Hydroxychloroquine Arm,0
8754,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,No Intervention Arm,0
8755,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Hydroxychloroquine Arm,0
8756,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,No Intervention Arm,1
8757,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Hydroxychloroquine Arm,0
8758,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,No Intervention Arm,1
8759,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,age,age,B1,Hydroxychloroquine Arm,0
8760,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,age,age,B2,No Intervention Arm,0
8761,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,age,age,B3,Total,0
8762,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,age,age,B1,Hydroxychloroquine Arm,0
8763,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,age,age,B2,No Intervention Arm,1
8764,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,age,age,B3,Total,1
8765,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,age,age,B1,Hydroxychloroquine Arm,0
8766,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,age,age,B2,No Intervention Arm,0
8767,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,age,age,B3,Total,0
8768,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Hydroxychloroquine Arm,0
8769,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,No Intervention Arm,0
8770,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Total,0
8771,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Hydroxychloroquine Arm,0
8772,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,No Intervention Arm,1
8773,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Total,1
8774,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,No Intervention Arm,1
8775,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Total,1
8776,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,Hydroxychloroquine Arm,0
8777,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P2,No Intervention Arm,1
8778,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,Hydroxychloroquine Arm,0
8779,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P2,No Intervention Arm,0
8780,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,Hydroxychloroquine Arm,0
8781,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P2,No Intervention Arm,1
8782,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P1,Hydroxychloroquine Arm,0
8783,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P2,No Intervention Arm,1
8784,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,age,age,B1,Hydroxychloroquine Arm,0
8785,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,age,age,B2,No Intervention Arm,0
8786,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,age,age,B3,Total,0
8787,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,age,age,B1,Hydroxychloroquine Arm,0
8788,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,age,age,B2,No Intervention Arm,1
8789,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,age,age,B3,Total,1
8790,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,age,age,B1,Hydroxychloroquine Arm,0
8791,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,age,age,B2,No Intervention Arm,0
8792,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,age,age,B3,Total,0
8793,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B1,Hydroxychloroquine Arm,0
8794,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B2,No Intervention Arm,0
8795,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B3,Total,0
8796,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B1,Hydroxychloroquine Arm,0
8797,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B2,No Intervention Arm,1
8798,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B3,Total,1
8799,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,enrollment region,enrollment region,B2,No Intervention Arm,1
8800,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,enrollment region,enrollment region,B3,Total,1
8801,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,milestone,milestone,P1,Hydroxychloroquine Arm,0
8802,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,milestone,milestone,P2,No Intervention Arm,1
8803,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,milestone,milestone,P1,Hydroxychloroquine Arm,0
8804,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,milestone,milestone,P2,No Intervention Arm,0
8805,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,milestone,milestone,P1,Hydroxychloroquine Arm,0
8806,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,milestone,milestone,P2,No Intervention Arm,1
8807,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,withdrawal reason,withdrawal reason,P1,Hydroxychloroquine Arm,0
8808,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,withdrawal reason,withdrawal reason,P2,No Intervention Arm,1
8809,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,age,age,B1,Hydroxychloroquine Arm,0
8810,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,age,age,B2,No Intervention Arm,0
8811,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,age,age,B3,Total,0
8812,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,age,age,B1,Hydroxychloroquine Arm,0
8813,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,age,age,B2,No Intervention Arm,1
8814,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,age,age,B3,Total,1
8815,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,age,age,B1,Hydroxychloroquine Arm,0
8816,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,age,age,B2,No Intervention Arm,0
8817,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,age,age,B3,Total,0
8818,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,"sex: female, male","sex: female, male",B1,Hydroxychloroquine Arm,0
8819,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,"sex: female, male","sex: female, male",B2,No Intervention Arm,0
8820,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,"sex: female, male","sex: female, male",B3,Total,0
8821,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,"sex: female, male","sex: female, male",B1,Hydroxychloroquine Arm,0
8822,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,"sex: female, male","sex: female, male",B2,No Intervention Arm,1
8823,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,"sex: female, male","sex: female, male",B3,Total,1
8824,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,enrollment region,enrollment region,B2,No Intervention Arm,1
8825,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,allocation,Non-Randomized,enrollment region,enrollment region,B3,Total,1
8826,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Hydroxychloroquine Arm,0
8827,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,No Intervention Arm,1
8828,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Hydroxychloroquine Arm,0
8829,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,No Intervention Arm,0
8830,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Hydroxychloroquine Arm,0
8831,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,No Intervention Arm,1
8832,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Hydroxychloroquine Arm,0
8833,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,No Intervention Arm,1
8834,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B1,Hydroxychloroquine Arm,0
8835,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B2,No Intervention Arm,0
8836,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B3,Total,0
8837,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B1,Hydroxychloroquine Arm,0
8838,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B2,No Intervention Arm,1
8839,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B3,Total,1
8840,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B1,Hydroxychloroquine Arm,0
8841,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B2,No Intervention Arm,0
8842,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B3,Total,0
8843,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Hydroxychloroquine Arm,0
8844,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,No Intervention Arm,0
8845,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Total,0
8846,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Hydroxychloroquine Arm,0
8847,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,No Intervention Arm,1
8848,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Total,1
8849,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,No Intervention Arm,1
8850,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Total,1
8851,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,milestone,milestone,P1,Hydroxychloroquine Arm,0
8852,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,milestone,milestone,P2,No Intervention Arm,1
8853,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,milestone,milestone,P1,Hydroxychloroquine Arm,0
8854,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,milestone,milestone,P2,No Intervention Arm,0
8855,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,milestone,milestone,P1,Hydroxychloroquine Arm,0
8856,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,milestone,milestone,P2,No Intervention Arm,1
8857,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,withdrawal reason,withdrawal reason,P1,Hydroxychloroquine Arm,0
8858,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,withdrawal reason,withdrawal reason,P2,No Intervention Arm,1
8859,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,age,age,B1,Hydroxychloroquine Arm,0
8860,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,age,age,B2,No Intervention Arm,0
8861,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,age,age,B3,Total,0
8862,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,age,age,B1,Hydroxychloroquine Arm,0
8863,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,age,age,B2,No Intervention Arm,1
8864,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,age,age,B3,Total,1
8865,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,age,age,B1,Hydroxychloroquine Arm,0
8866,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,age,age,B2,No Intervention Arm,0
8867,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,age,age,B3,Total,0
8868,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,"sex: female, male","sex: female, male",B1,Hydroxychloroquine Arm,0
8869,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,"sex: female, male","sex: female, male",B2,No Intervention Arm,0
8870,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,"sex: female, male","sex: female, male",B3,Total,0
8871,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,"sex: female, male","sex: female, male",B1,Hydroxychloroquine Arm,0
8872,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,"sex: female, male","sex: female, male",B2,No Intervention Arm,1
8873,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,"sex: female, male","sex: female, male",B3,Total,1
8874,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,enrollment region,enrollment region,B2,No Intervention Arm,1
8875,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,primary_purpose,Prevention,enrollment region,enrollment region,B3,Total,1
8876,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Hydroxychloroquine Arm,0
8877,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,No Intervention Arm,1
8878,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Hydroxychloroquine Arm,0
8879,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,No Intervention Arm,0
8880,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Hydroxychloroquine Arm,0
8881,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,No Intervention Arm,1
8882,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Hydroxychloroquine Arm,0
8883,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,No Intervention Arm,1
8884,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),age,age,B1,Hydroxychloroquine Arm,0
8885,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),age,age,B2,No Intervention Arm,0
8886,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),age,age,B3,Total,0
8887,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),age,age,B1,Hydroxychloroquine Arm,0
8888,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),age,age,B2,No Intervention Arm,1
8889,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),age,age,B3,Total,1
8890,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),age,age,B1,Hydroxychloroquine Arm,0
8891,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),age,age,B2,No Intervention Arm,0
8892,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),age,age,B3,Total,0
8893,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,Hydroxychloroquine Arm,0
8894,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B2,No Intervention Arm,0
8895,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B3,Total,0
8896,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,Hydroxychloroquine Arm,0
8897,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B2,No Intervention Arm,1
8898,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B3,Total,1
8899,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,No Intervention Arm,1
8900,19,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Total,1
8901,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender,Male,milestone,milestone,P1,Standard Care,128
8902,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender,Male,milestone,milestone,P2,Proxalutamide + Standard Care,134
8903,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender,Male,milestone,milestone,P1,Standard Care,128
8904,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender,Male,milestone,milestone,P2,Proxalutamide + Standard Care,134
8905,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender,Male,milestone,milestone,P1,Standard Care,0
8906,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender,Male,milestone,milestone,P2,Proxalutamide + Standard Care,0
8907,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender,Male,"sex: female, male","sex: female, male",B1,Standard Care,0
8908,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender,Male,"sex: female, male","sex: female, male",B2,Proxalutamide + Standard Care,0
8909,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender,Male,"sex: female, male","sex: female, male",B3,Total,0
8910,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender,Male,"sex: female, male","sex: female, male",B1,Standard Care,128
8911,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender,Male,"sex: female, male","sex: female, male",B2,Proxalutamide + Standard Care,134
8912,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender,Male,"sex: female, male","sex: female, male",B3,Total,262
8913,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender,Male,enrollment region,enrollment region,B1,Standard Care,128
8914,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender,Male,enrollment region,enrollment region,B2,Proxalutamide + Standard Care,134
8915,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender,Male,enrollment region,enrollment region,B3,Total,262
8916,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender_based,Yes,milestone,milestone,P1,Standard Care,128
8917,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender_based,Yes,milestone,milestone,P2,Proxalutamide + Standard Care,134
8918,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender_based,Yes,milestone,milestone,P1,Standard Care,128
8919,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender_based,Yes,milestone,milestone,P2,Proxalutamide + Standard Care,134
8920,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender_based,Yes,milestone,milestone,P1,Standard Care,0
8921,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender_based,Yes,milestone,milestone,P2,Proxalutamide + Standard Care,0
8922,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender_based,Yes,"sex: female, male","sex: female, male",B1,Standard Care,0
8923,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender_based,Yes,"sex: female, male","sex: female, male",B2,Proxalutamide + Standard Care,0
8924,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender_based,Yes,"sex: female, male","sex: female, male",B3,Total,0
8925,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender_based,Yes,"sex: female, male","sex: female, male",B1,Standard Care,128
8926,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender_based,Yes,"sex: female, male","sex: female, male",B2,Proxalutamide + Standard Care,134
8927,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender_based,Yes,"sex: female, male","sex: female, male",B3,Total,262
8928,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender_based,Yes,enrollment region,enrollment region,B1,Standard Care,128
8929,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender_based,Yes,enrollment region,enrollment region,B2,Proxalutamide + Standard Care,134
8930,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,gender_based,Yes,enrollment region,enrollment region,B3,Total,262
8931,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Standard Care,128
8932,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Proxalutamide + Standard Care,134
8933,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Standard Care,128
8934,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Proxalutamide + Standard Care,134
8935,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Standard Care,0
8936,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Proxalutamide + Standard Care,0
8937,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Standard Care,0
8938,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Proxalutamide + Standard Care,0
8939,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,0
8940,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Standard Care,128
8941,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Proxalutamide + Standard Care,134
8942,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,262
8943,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,Standard Care,128
8944,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B2,Proxalutamide + Standard Care,134
8945,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B3,Total,262
8946,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Standard Care,128
8947,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Proxalutamide + Standard Care,134
8948,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Standard Care,128
8949,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Proxalutamide + Standard Care,134
8950,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Standard Care,0
8951,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Proxalutamide + Standard Care,0
8952,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Standard Care,0
8953,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Proxalutamide + Standard Care,0
8954,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Total,0
8955,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Standard Care,128
8956,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Proxalutamide + Standard Care,134
8957,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Total,262
8958,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Standard Care,128
8959,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Proxalutamide + Standard Care,134
8960,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Total,262
8961,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Standard Care,128
8962,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Proxalutamide + Standard Care,134
8963,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Standard Care,128
8964,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Proxalutamide + Standard Care,134
8965,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Standard Care,0
8966,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Proxalutamide + Standard Care,0
8967,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Standard Care,0
8968,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Proxalutamide + Standard Care,0
8969,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Total,0
8970,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Standard Care,128
8971,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Proxalutamide + Standard Care,134
8972,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Total,262
8973,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Standard Care,128
8974,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Proxalutamide + Standard Care,134
8975,20,Anti-Androgen Treatment for COVID-19,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Total,262
8976,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Standard Care,128
8977,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Proxalutamide + Standard Care,134
8978,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Standard Care,128
8979,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Proxalutamide + Standard Care,134
8980,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Standard Care,0
8981,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Proxalutamide + Standard Care,0
8982,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Standard Care,0
8983,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Proxalutamide + Standard Care,0
8984,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,0
8985,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Standard Care,128
8986,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Proxalutamide + Standard Care,134
8987,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,262
8988,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Standard Care,128
8989,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Proxalutamide + Standard Care,134
8990,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Total,262
8991,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Standard Care,128
8992,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Proxalutamide + Standard Care,134
8993,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Standard Care,128
8994,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Proxalutamide + Standard Care,134
8995,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Standard Care,0
8996,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Proxalutamide + Standard Care,0
8997,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Standard Care,0
8998,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Proxalutamide + Standard Care,0
8999,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Total,0
9000,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Standard Care,128
9001,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Proxalutamide + Standard Care,134
9002,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Total,262
9003,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Standard Care,128
9004,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Proxalutamide + Standard Care,134
9005,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Total,262
9006,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model_description,"This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.",milestone,milestone,P1,Standard Care,128
9007,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model_description,"This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.",milestone,milestone,P2,Proxalutamide + Standard Care,134
9008,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model_description,"This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.",milestone,milestone,P1,Standard Care,128
9009,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model_description,"This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.",milestone,milestone,P2,Proxalutamide + Standard Care,134
9010,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model_description,"This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.",milestone,milestone,P1,Standard Care,0
9011,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model_description,"This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.",milestone,milestone,P2,Proxalutamide + Standard Care,0
9012,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model_description,"This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.","sex: female, male","sex: female, male",B1,Standard Care,0
9013,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model_description,"This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.","sex: female, male","sex: female, male",B2,Proxalutamide + Standard Care,0
9014,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model_description,"This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.","sex: female, male","sex: female, male",B3,Total,0
9015,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model_description,"This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.","sex: female, male","sex: female, male",B1,Standard Care,128
9016,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model_description,"This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.","sex: female, male","sex: female, male",B2,Proxalutamide + Standard Care,134
9017,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model_description,"This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.","sex: female, male","sex: female, male",B3,Total,262
9018,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model_description,"This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.",enrollment region,enrollment region,B1,Standard Care,128
9019,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model_description,"This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.",enrollment region,enrollment region,B2,Proxalutamide + Standard Care,134
9020,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,intervention_model_description,"This study is designed as a prospective, interventional, placebo controlled, double-blinded, randomized parallel assignment study.",enrollment region,enrollment region,B3,Total,262
9021,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Standard Care,128
9022,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Proxalutamide + Standard Care,134
9023,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Standard Care,128
9024,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Proxalutamide + Standard Care,134
9025,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Standard Care,0
9026,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Proxalutamide + Standard Care,0
9027,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Standard Care,0
9028,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Proxalutamide + Standard Care,0
9029,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Total,0
9030,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Standard Care,128
9031,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Proxalutamide + Standard Care,134
9032,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Total,262
9033,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Standard Care,128
9034,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Proxalutamide + Standard Care,134
9035,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Total,262
9036,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",milestone,milestone,P1,Standard Care,128
9037,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",milestone,milestone,P2,Proxalutamide + Standard Care,134
9038,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",milestone,milestone,P1,Standard Care,128
9039,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",milestone,milestone,P2,Proxalutamide + Standard Care,134
9040,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",milestone,milestone,P1,Standard Care,0
9041,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",milestone,milestone,P2,Proxalutamide + Standard Care,0
9042,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","sex: female, male","sex: female, male",B1,Standard Care,0
9043,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","sex: female, male","sex: female, male",B2,Proxalutamide + Standard Care,0
9044,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","sex: female, male","sex: female, male",B3,Total,0
9045,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","sex: female, male","sex: female, male",B1,Standard Care,128
9046,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","sex: female, male","sex: female, male",B2,Proxalutamide + Standard Care,134
9047,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","sex: female, male","sex: female, male",B3,Total,262
9048,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",enrollment region,enrollment region,B1,Standard Care,128
9049,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",enrollment region,enrollment region,B2,Proxalutamide + Standard Care,134
9050,20,Anti-Androgen Treatment for COVID-19,Interventional,study_design_info,masking,"Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)",enrollment region,enrollment region,B3,Total,262
9051,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,milestone,milestone,P1,EXO-1,10
9052,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,milestone,milestone,P2,EXO-2,10
9053,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,milestone,milestone,P3,Placebo,10
9054,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,milestone,milestone,P1,EXO-1,10
9055,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,milestone,milestone,P2,EXO-2,10
9056,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,milestone,milestone,P3,Placebo,10
9057,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,milestone,milestone,P1,EXO-1,0
9058,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,milestone,milestone,P2,EXO-2,0
9059,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,milestone,milestone,P3,Placebo,0
9060,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,age,age,B1,EXO-1,0
9061,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,age,age,B2,EXO-2,0
9062,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,age,age,B3,Placebo,0
9063,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,age,age,B4,Total,0
9064,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,age,age,B1,EXO-1,10
9065,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,age,age,B2,EXO-2,10
9066,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,age,age,B3,Placebo,10
9067,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,age,age,B4,Total,30
9068,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,age,age,B1,EXO-1,0
9069,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,age,age,B2,EXO-2,0
9070,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,age,age,B3,Placebo,0
9071,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,age,age,B4,Total,0
9072,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,EXO-1,6
9073,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,EXO-2,8
9074,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Placebo,5
9075,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B4,Total,19
9076,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,EXO-1,4
9077,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,EXO-2,2
9078,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Placebo,5
9079,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B4,Total,11
9080,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,EXO-1,10
9081,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,EXO-2,10
9082,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Placebo,10
9083,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,gender,All,enrollment region,enrollment region,B4,Total,30
9084,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,EXO-1,10
9085,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,EXO-2,10
9086,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P3,Placebo,10
9087,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,EXO-1,10
9088,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,EXO-2,10
9089,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P3,Placebo,10
9090,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,EXO-1,0
9091,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,EXO-2,0
9092,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P3,Placebo,0
9093,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,age,age,B1,EXO-1,0
9094,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,age,age,B2,EXO-2,0
9095,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,age,age,B3,Placebo,0
9096,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,age,age,B4,Total,0
9097,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,age,age,B1,EXO-1,10
9098,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,age,age,B2,EXO-2,10
9099,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,age,age,B3,Placebo,10
9100,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,age,age,B4,Total,30
9101,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,age,age,B1,EXO-1,0
9102,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,age,age,B2,EXO-2,0
9103,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,age,age,B3,Placebo,0
9104,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,age,age,B4,Total,0
9105,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,EXO-1,6
9106,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,EXO-2,8
9107,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Placebo,5
9108,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B4,Total,19
9109,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,EXO-1,4
9110,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,EXO-2,2
9111,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Placebo,5
9112,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B4,Total,11
9113,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,EXO-1,10
9114,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B2,EXO-2,10
9115,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B3,Placebo,10
9116,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B4,Total,30
9117,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,milestone,milestone,P1,EXO-1,10
9118,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,milestone,milestone,P2,EXO-2,10
9119,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,milestone,milestone,P3,Placebo,10
9120,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,milestone,milestone,P1,EXO-1,10
9121,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,milestone,milestone,P2,EXO-2,10
9122,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,milestone,milestone,P3,Placebo,10
9123,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,milestone,milestone,P1,EXO-1,0
9124,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,milestone,milestone,P2,EXO-2,0
9125,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,milestone,milestone,P3,Placebo,0
9126,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,age,age,B1,EXO-1,0
9127,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,age,age,B2,EXO-2,0
9128,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,age,age,B3,Placebo,0
9129,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,age,age,B4,Total,0
9130,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,age,age,B1,EXO-1,10
9131,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,age,age,B2,EXO-2,10
9132,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,age,age,B3,Placebo,10
9133,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,age,age,B4,Total,30
9134,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,age,age,B1,EXO-1,0
9135,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,age,age,B2,EXO-2,0
9136,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,age,age,B3,Placebo,0
9137,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,age,age,B4,Total,0
9138,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,"sex: female, male","sex: female, male",B1,EXO-1,6
9139,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,"sex: female, male","sex: female, male",B2,EXO-2,8
9140,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,"sex: female, male","sex: female, male",B3,Placebo,5
9141,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,"sex: female, male","sex: female, male",B4,Total,19
9142,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,"sex: female, male","sex: female, male",B1,EXO-1,4
9143,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,"sex: female, male","sex: female, male",B2,EXO-2,2
9144,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,"sex: female, male","sex: female, male",B3,Placebo,5
9145,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,"sex: female, male","sex: female, male",B4,Total,11
9146,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,enrollment region,enrollment region,B1,EXO-1,10
9147,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,enrollment region,enrollment region,B2,EXO-2,10
9148,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,enrollment region,enrollment region,B3,Placebo,10
9149,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,maximum_age,65 Years,enrollment region,enrollment region,B4,Total,30
9150,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,EXO-1,10
9151,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,EXO-2,10
9152,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P3,Placebo,10
9153,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,EXO-1,10
9154,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,EXO-2,10
9155,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P3,Placebo,10
9156,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,EXO-1,0
9157,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,EXO-2,0
9158,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P3,Placebo,0
9159,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,age,age,B1,EXO-1,0
9160,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,age,age,B2,EXO-2,0
9161,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,age,age,B3,Placebo,0
9162,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,age,age,B4,Total,0
9163,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,age,age,B1,EXO-1,10
9164,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,age,age,B2,EXO-2,10
9165,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,age,age,B3,Placebo,10
9166,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,age,age,B4,Total,30
9167,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,age,age,B1,EXO-1,0
9168,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,age,age,B2,EXO-2,0
9169,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,age,age,B3,Placebo,0
9170,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,age,age,B4,Total,0
9171,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,EXO-1,6
9172,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,EXO-2,8
9173,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Placebo,5
9174,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B4,Total,19
9175,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,EXO-1,4
9176,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,EXO-2,2
9177,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Placebo,5
9178,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B4,Total,11
9179,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,EXO-1,10
9180,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,EXO-2,10
9181,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Placebo,10
9182,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B4,Total,30
9183,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,EXO-1,10
9184,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,EXO-2,10
9185,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P3,Placebo,10
9186,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,EXO-1,10
9187,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,EXO-2,10
9188,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P3,Placebo,10
9189,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,EXO-1,0
9190,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,EXO-2,0
9191,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P3,Placebo,0
9192,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,age,age,B1,EXO-1,0
9193,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,age,age,B2,EXO-2,0
9194,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,age,age,B3,Placebo,0
9195,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,age,age,B4,Total,0
9196,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,age,age,B1,EXO-1,10
9197,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,age,age,B2,EXO-2,10
9198,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,age,age,B3,Placebo,10
9199,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,age,age,B4,Total,30
9200,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,age,age,B1,EXO-1,0
9201,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,age,age,B2,EXO-2,0
9202,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,age,age,B3,Placebo,0
9203,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,age,age,B4,Total,0
9204,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,EXO-1,6
9205,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,EXO-2,8
9206,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Placebo,5
9207,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B4,Total,19
9208,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,EXO-1,4
9209,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,EXO-2,2
9210,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Placebo,5
9211,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B4,Total,11
9212,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,EXO-1,10
9213,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,EXO-2,10
9214,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Placebo,10
9215,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B4,Total,30
9216,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,EXO-1,10
9217,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,EXO-2,10
9218,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P3,Placebo,10
9219,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,EXO-1,10
9220,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,EXO-2,10
9221,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P3,Placebo,10
9222,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,EXO-1,0
9223,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,EXO-2,0
9224,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P3,Placebo,0
9225,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B1,EXO-1,0
9226,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B2,EXO-2,0
9227,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B3,Placebo,0
9228,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B4,Total,0
9229,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B1,EXO-1,10
9230,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B2,EXO-2,10
9231,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B3,Placebo,10
9232,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B4,Total,30
9233,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B1,EXO-1,0
9234,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B2,EXO-2,0
9235,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B3,Placebo,0
9236,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B4,Total,0
9237,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,EXO-1,6
9238,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,EXO-2,8
9239,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Placebo,5
9240,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B4,Total,19
9241,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,EXO-1,4
9242,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,EXO-2,2
9243,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Placebo,5
9244,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B4,Total,11
9245,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,EXO-1,10
9246,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,EXO-2,10
9247,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Placebo,10
9248,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B4,Total,30
9249,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",milestone,milestone,P1,EXO-1,10
9250,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",milestone,milestone,P2,EXO-2,10
9251,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",milestone,milestone,P3,Placebo,10
9252,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",milestone,milestone,P1,EXO-1,10
9253,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",milestone,milestone,P2,EXO-2,10
9254,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",milestone,milestone,P3,Placebo,10
9255,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",milestone,milestone,P1,EXO-1,0
9256,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",milestone,milestone,P2,EXO-2,0
9257,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",milestone,milestone,P3,Placebo,0
9258,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",age,age,B1,EXO-1,0
9259,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",age,age,B2,EXO-2,0
9260,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",age,age,B3,Placebo,0
9261,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",age,age,B4,Total,0
9262,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",age,age,B1,EXO-1,10
9263,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",age,age,B2,EXO-2,10
9264,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",age,age,B3,Placebo,10
9265,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",age,age,B4,Total,30
9266,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",age,age,B1,EXO-1,0
9267,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",age,age,B2,EXO-2,0
9268,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",age,age,B3,Placebo,0
9269,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",age,age,B4,Total,0
9270,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.","sex: female, male","sex: female, male",B1,EXO-1,6
9271,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.","sex: female, male","sex: female, male",B2,EXO-2,8
9272,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.","sex: female, male","sex: female, male",B3,Placebo,5
9273,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.","sex: female, male","sex: female, male",B4,Total,19
9274,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.","sex: female, male","sex: female, male",B1,EXO-1,4
9275,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.","sex: female, male","sex: female, male",B2,EXO-2,2
9276,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.","sex: female, male","sex: female, male",B3,Placebo,5
9277,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.","sex: female, male","sex: female, male",B4,Total,11
9278,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",enrollment region,enrollment region,B1,EXO-1,10
9279,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",enrollment region,enrollment region,B2,EXO-2,10
9280,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",enrollment region,enrollment region,B3,Placebo,10
9281,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,intervention_model_description,"The trial has three groups, each with 10 subjects (n=30). All eligible study subjects will be randomized, double-blinded, to either the two treatment groups or placebo group.",enrollment region,enrollment region,B4,Total,30
9282,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P1,EXO-1,10
9283,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P2,EXO-2,10
9284,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P3,Placebo,10
9285,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P1,EXO-1,10
9286,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P2,EXO-2,10
9287,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P3,Placebo,10
9288,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P1,EXO-1,0
9289,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P2,EXO-2,0
9290,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P3,Placebo,0
9291,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,age,age,B1,EXO-1,0
9292,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,age,age,B2,EXO-2,0
9293,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,age,age,B3,Placebo,0
9294,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,age,age,B4,Total,0
9295,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,age,age,B1,EXO-1,10
9296,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,age,age,B2,EXO-2,10
9297,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,age,age,B3,Placebo,10
9298,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,age,age,B4,Total,30
9299,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,age,age,B1,EXO-1,0
9300,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,age,age,B2,EXO-2,0
9301,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,age,age,B3,Placebo,0
9302,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,age,age,B4,Total,0
9303,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B1,EXO-1,6
9304,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B2,EXO-2,8
9305,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B3,Placebo,5
9306,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B4,Total,19
9307,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B1,EXO-1,4
9308,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B2,EXO-2,2
9309,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B3,Placebo,5
9310,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B4,Total,11
9311,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,enrollment region,enrollment region,B1,EXO-1,10
9312,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,enrollment region,enrollment region,B2,EXO-2,10
9313,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,enrollment region,enrollment region,B3,Placebo,10
9314,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,primary_purpose,Other,enrollment region,enrollment region,B4,Total,30
9315,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",milestone,milestone,P1,EXO-1,10
9316,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",milestone,milestone,P2,EXO-2,10
9317,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",milestone,milestone,P3,Placebo,10
9318,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",milestone,milestone,P1,EXO-1,10
9319,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",milestone,milestone,P2,EXO-2,10
9320,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",milestone,milestone,P3,Placebo,10
9321,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",milestone,milestone,P1,EXO-1,0
9322,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",milestone,milestone,P2,EXO-2,0
9323,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",milestone,milestone,P3,Placebo,0
9324,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",age,age,B1,EXO-1,0
9325,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",age,age,B2,EXO-2,0
9326,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",age,age,B3,Placebo,0
9327,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",age,age,B4,Total,0
9328,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",age,age,B1,EXO-1,10
9329,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",age,age,B2,EXO-2,10
9330,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",age,age,B3,Placebo,10
9331,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",age,age,B4,Total,30
9332,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",age,age,B1,EXO-1,0
9333,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",age,age,B2,EXO-2,0
9334,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",age,age,B3,Placebo,0
9335,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",age,age,B4,Total,0
9336,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)","sex: female, male","sex: female, male",B1,EXO-1,6
9337,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)","sex: female, male","sex: female, male",B2,EXO-2,8
9338,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)","sex: female, male","sex: female, male",B3,Placebo,5
9339,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)","sex: female, male","sex: female, male",B4,Total,19
9340,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)","sex: female, male","sex: female, male",B1,EXO-1,4
9341,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)","sex: female, male","sex: female, male",B2,EXO-2,2
9342,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)","sex: female, male","sex: female, male",B3,Placebo,5
9343,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)","sex: female, male","sex: female, male",B4,Total,11
9344,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",enrollment region,enrollment region,B1,EXO-1,10
9345,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",enrollment region,enrollment region,B2,EXO-2,10
9346,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",enrollment region,enrollment region,B3,Placebo,10
9347,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking,"Double (Participant, Care Provider)",enrollment region,enrollment region,B4,Total,30
9348,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",milestone,milestone,P1,EXO-1,10
9349,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",milestone,milestone,P2,EXO-2,10
9350,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",milestone,milestone,P3,Placebo,10
9351,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",milestone,milestone,P1,EXO-1,10
9352,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",milestone,milestone,P2,EXO-2,10
9353,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",milestone,milestone,P3,Placebo,10
9354,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",milestone,milestone,P1,EXO-1,0
9355,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",milestone,milestone,P2,EXO-2,0
9356,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",milestone,milestone,P3,Placebo,0
9357,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",age,age,B1,EXO-1,0
9358,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",age,age,B2,EXO-2,0
9359,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",age,age,B3,Placebo,0
9360,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",age,age,B4,Total,0
9361,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",age,age,B1,EXO-1,10
9362,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",age,age,B2,EXO-2,10
9363,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",age,age,B3,Placebo,10
9364,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",age,age,B4,Total,30
9365,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",age,age,B1,EXO-1,0
9366,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",age,age,B2,EXO-2,0
9367,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",age,age,B3,Placebo,0
9368,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",age,age,B4,Total,0
9369,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.","sex: female, male","sex: female, male",B1,EXO-1,6
9370,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.","sex: female, male","sex: female, male",B2,EXO-2,8
9371,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.","sex: female, male","sex: female, male",B3,Placebo,5
9372,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.","sex: female, male","sex: female, male",B4,Total,19
9373,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.","sex: female, male","sex: female, male",B1,EXO-1,4
9374,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.","sex: female, male","sex: female, male",B2,EXO-2,2
9375,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.","sex: female, male","sex: female, male",B3,Placebo,5
9376,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.","sex: female, male","sex: female, male",B4,Total,11
9377,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",enrollment region,enrollment region,B1,EXO-1,10
9378,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",enrollment region,enrollment region,B2,EXO-2,10
9379,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",enrollment region,enrollment region,B3,Placebo,10
9380,21,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Interventional,study_design_info,masking_description,"Two main groups will be provided with exosomes in a specially provided solution, the third group (control) will receive the same solution without exosomes. Due to exosomes are nanoparticles and requires special methods and devices to be detected the hospital staff and patients have no way to check which group receives exosomes.",enrollment region,enrollment region,B4,Total,30
9381,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,milestone,milestone,P1,Control Group,180
9382,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,milestone,milestone,P2,Intervention Group,360
9383,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,milestone,milestone,P1,Control Group,151
9384,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,milestone,milestone,P2,Intervention Group,349
9385,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,milestone,milestone,P1,Control Group,29
9386,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,milestone,milestone,P2,Intervention Group,11
9387,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Control Group,10
9388,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Intervention Group,5
9389,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Control Group,4
9390,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Intervention Group,1
9391,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Control Group,11
9392,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Intervention Group,2
9393,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Control Group,4
9394,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Intervention Group,3
9395,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,age,age,B1,Supportive Arm,0
9396,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,age,age,B2,HCQ Arm,0
9397,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,age,age,B3,Total,0
9398,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,age,age,B1,Supportive Arm,180
9399,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,age,age,B2,HCQ Arm,360
9400,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,age,age,B3,Total,540
9401,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,age,age,B1,Supportive Arm,0
9402,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,age,age,B2,HCQ Arm,0
9403,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,age,age,B3,Total,0
9404,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Supportive Arm,10
9405,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,HCQ Arm,24
9406,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,34
9407,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Supportive Arm,170
9408,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,HCQ Arm,336
9409,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,506
9410,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Supportive Arm,180
9411,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,HCQ Arm,360
9412,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Total,540
9413,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Control Group,180
9414,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Intervention Group,360
9415,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Control Group,151
9416,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Intervention Group,349
9417,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Control Group,29
9418,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Intervention Group,11
9419,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Control Group,10
9420,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Intervention Group,5
9421,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Control Group,4
9422,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Intervention Group,1
9423,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Control Group,11
9424,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Intervention Group,2
9425,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Control Group,4
9426,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Intervention Group,3
9427,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,age,age,B1,Supportive Arm,0
9428,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,age,age,B2,HCQ Arm,0
9429,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,age,age,B3,Total,0
9430,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,age,age,B1,Supportive Arm,180
9431,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,age,age,B2,HCQ Arm,360
9432,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,age,age,B3,Total,540
9433,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,age,age,B1,Supportive Arm,0
9434,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,age,age,B2,HCQ Arm,0
9435,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,age,age,B3,Total,0
9436,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Supportive Arm,10
9437,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,HCQ Arm,24
9438,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,34
9439,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Supportive Arm,170
9440,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,HCQ Arm,336
9441,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,506
9442,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,Supportive Arm,180
9443,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B2,HCQ Arm,360
9444,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B3,Total,540
9445,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,milestone,milestone,P1,Control Group,180
9446,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,milestone,milestone,P2,Intervention Group,360
9447,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,milestone,milestone,P1,Control Group,151
9448,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,milestone,milestone,P2,Intervention Group,349
9449,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,milestone,milestone,P1,Control Group,29
9450,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,milestone,milestone,P2,Intervention Group,11
9451,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,withdrawal reason,withdrawal reason,P1,Control Group,10
9452,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,withdrawal reason,withdrawal reason,P2,Intervention Group,5
9453,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,withdrawal reason,withdrawal reason,P1,Control Group,4
9454,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,withdrawal reason,withdrawal reason,P2,Intervention Group,1
9455,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,withdrawal reason,withdrawal reason,P1,Control Group,11
9456,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,withdrawal reason,withdrawal reason,P2,Intervention Group,2
9457,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,withdrawal reason,withdrawal reason,P1,Control Group,4
9458,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,withdrawal reason,withdrawal reason,P2,Intervention Group,3
9459,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,age,age,B1,Supportive Arm,0
9460,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,age,age,B2,HCQ Arm,0
9461,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,age,age,B3,Total,0
9462,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,age,age,B1,Supportive Arm,180
9463,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,age,age,B2,HCQ Arm,360
9464,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,age,age,B3,Total,540
9465,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,age,age,B1,Supportive Arm,0
9466,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,age,age,B2,HCQ Arm,0
9467,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,age,age,B3,Total,0
9468,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,"sex: female, male","sex: female, male",B1,Supportive Arm,10
9469,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,"sex: female, male","sex: female, male",B2,HCQ Arm,24
9470,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,"sex: female, male","sex: female, male",B3,Total,34
9471,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,"sex: female, male","sex: female, male",B1,Supportive Arm,170
9472,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,"sex: female, male","sex: female, male",B2,HCQ Arm,336
9473,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,"sex: female, male","sex: female, male",B3,Total,506
9474,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,enrollment region,enrollment region,B1,Supportive Arm,180
9475,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,enrollment region,enrollment region,B2,HCQ Arm,360
9476,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,maximum_age,80 Years,enrollment region,enrollment region,B3,Total,540
9477,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Control Group,180
9478,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Intervention Group,360
9479,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Control Group,151
9480,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Intervention Group,349
9481,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Control Group,29
9482,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Intervention Group,11
9483,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Control Group,10
9484,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Intervention Group,5
9485,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Control Group,4
9486,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Intervention Group,1
9487,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Control Group,11
9488,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Intervention Group,2
9489,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Control Group,4
9490,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Intervention Group,3
9491,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,age,age,B1,Supportive Arm,0
9492,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,age,age,B2,HCQ Arm,0
9493,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,age,age,B3,Total,0
9494,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,age,age,B1,Supportive Arm,180
9495,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,age,age,B2,HCQ Arm,360
9496,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,age,age,B3,Total,540
9497,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,age,age,B1,Supportive Arm,0
9498,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,age,age,B2,HCQ Arm,0
9499,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,age,age,B3,Total,0
9500,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Supportive Arm,10
9501,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,HCQ Arm,24
9502,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Total,34
9503,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Supportive Arm,170
9504,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,HCQ Arm,336
9505,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Total,506
9506,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Supportive Arm,180
9507,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,HCQ Arm,360
9508,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Total,540
9509,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Control Group,180
9510,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Intervention Group,360
9511,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Control Group,151
9512,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Intervention Group,349
9513,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Control Group,29
9514,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Intervention Group,11
9515,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Control Group,10
9516,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Intervention Group,5
9517,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Control Group,4
9518,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Intervention Group,1
9519,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Control Group,11
9520,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Intervention Group,2
9521,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Control Group,4
9522,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Intervention Group,3
9523,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,age,age,B1,Supportive Arm,0
9524,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,age,age,B2,HCQ Arm,0
9525,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,age,age,B3,Total,0
9526,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,age,age,B1,Supportive Arm,180
9527,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,age,age,B2,HCQ Arm,360
9528,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,age,age,B3,Total,540
9529,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,age,age,B1,Supportive Arm,0
9530,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,age,age,B2,HCQ Arm,0
9531,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,age,age,B3,Total,0
9532,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Supportive Arm,10
9533,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,HCQ Arm,24
9534,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,34
9535,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Supportive Arm,170
9536,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,HCQ Arm,336
9537,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,506
9538,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Supportive Arm,180
9539,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,HCQ Arm,360
9540,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Total,540
9541,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Control Group,180
9542,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Intervention Group,360
9543,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Control Group,151
9544,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Intervention Group,349
9545,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Control Group,29
9546,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Intervention Group,11
9547,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Control Group,10
9548,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Intervention Group,5
9549,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Control Group,4
9550,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Intervention Group,1
9551,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Control Group,11
9552,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Intervention Group,2
9553,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Control Group,4
9554,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Intervention Group,3
9555,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B1,Supportive Arm,0
9556,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B2,HCQ Arm,0
9557,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B3,Total,0
9558,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B1,Supportive Arm,180
9559,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B2,HCQ Arm,360
9560,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B3,Total,540
9561,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B1,Supportive Arm,0
9562,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B2,HCQ Arm,0
9563,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,age,age,B3,Total,0
9564,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Supportive Arm,10
9565,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,HCQ Arm,24
9566,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Total,34
9567,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Supportive Arm,170
9568,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,HCQ Arm,336
9569,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Total,506
9570,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Supportive Arm,180
9571,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,HCQ Arm,360
9572,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Total,540
9573,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",milestone,milestone,P1,Control Group,180
9574,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",milestone,milestone,P2,Intervention Group,360
9575,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",milestone,milestone,P1,Control Group,151
9576,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",milestone,milestone,P2,Intervention Group,349
9577,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",milestone,milestone,P1,Control Group,29
9578,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",milestone,milestone,P2,Intervention Group,11
9579,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",withdrawal reason,withdrawal reason,P1,Control Group,10
9580,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",withdrawal reason,withdrawal reason,P2,Intervention Group,5
9581,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",withdrawal reason,withdrawal reason,P1,Control Group,4
9582,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",withdrawal reason,withdrawal reason,P2,Intervention Group,1
9583,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",withdrawal reason,withdrawal reason,P1,Control Group,11
9584,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",withdrawal reason,withdrawal reason,P2,Intervention Group,2
9585,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",withdrawal reason,withdrawal reason,P1,Control Group,4
9586,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",withdrawal reason,withdrawal reason,P2,Intervention Group,3
9587,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",age,age,B1,Supportive Arm,0
9588,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",age,age,B2,HCQ Arm,0
9589,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",age,age,B3,Total,0
9590,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",age,age,B1,Supportive Arm,180
9591,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",age,age,B2,HCQ Arm,360
9592,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",age,age,B3,Total,540
9593,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",age,age,B1,Supportive Arm,0
9594,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",age,age,B2,HCQ Arm,0
9595,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",age,age,B3,Total,0
9596,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled","sex: female, male","sex: female, male",B1,Supportive Arm,10
9597,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled","sex: female, male","sex: female, male",B2,HCQ Arm,24
9598,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled","sex: female, male","sex: female, male",B3,Total,34
9599,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled","sex: female, male","sex: female, male",B1,Supportive Arm,170
9600,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled","sex: female, male","sex: female, male",B2,HCQ Arm,336
9601,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled","sex: female, male","sex: female, male",B3,Total,506
9602,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",enrollment region,enrollment region,B1,Supportive Arm,180
9603,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",enrollment region,enrollment region,B2,HCQ Arm,360
9604,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,intervention_model_description,"Randomization rules were designed by Dr. Wasim Alamgir together with principal investigators and implemented by an independent statistician who was not involved in data analysis. Stratified random sampling was applied to stratify all eligible patients according to age, gender and comorbidities. Computerized random number generator was used and allocation was done in 2:1 sequence. Cards with each group assignment number randomly generated by computer were placed in sequentially numbered envelopes that were opened as the patients were enrolled",enrollment region,enrollment region,B3,Total,540
9605,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Control Group,180
9606,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Intervention Group,360
9607,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Control Group,151
9608,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Intervention Group,349
9609,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Control Group,29
9610,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Intervention Group,11
9611,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Control Group,10
9612,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Intervention Group,5
9613,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Control Group,4
9614,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Intervention Group,1
9615,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Control Group,11
9616,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Intervention Group,2
9617,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Control Group,4
9618,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Intervention Group,3
9619,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,age,age,B1,Supportive Arm,0
9620,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,age,age,B2,HCQ Arm,0
9621,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,age,age,B3,Total,0
9622,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,age,age,B1,Supportive Arm,180
9623,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,age,age,B2,HCQ Arm,360
9624,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,age,age,B3,Total,540
9625,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,age,age,B1,Supportive Arm,0
9626,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,age,age,B2,HCQ Arm,0
9627,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,age,age,B3,Total,0
9628,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Supportive Arm,10
9629,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,HCQ Arm,24
9630,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Total,34
9631,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Supportive Arm,170
9632,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,HCQ Arm,336
9633,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Total,506
9634,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Supportive Arm,180
9635,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,HCQ Arm,360
9636,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Total,540
9637,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Control Group,180
9638,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,Intervention Group,360
9639,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Control Group,151
9640,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,Intervention Group,349
9641,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Control Group,29
9642,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,Intervention Group,11
9643,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Control Group,10
9644,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Intervention Group,5
9645,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Control Group,4
9646,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Intervention Group,1
9647,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Control Group,11
9648,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Intervention Group,2
9649,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Control Group,4
9650,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Intervention Group,3
9651,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),age,age,B1,Supportive Arm,0
9652,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),age,age,B2,HCQ Arm,0
9653,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),age,age,B3,Total,0
9654,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),age,age,B1,Supportive Arm,180
9655,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),age,age,B2,HCQ Arm,360
9656,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),age,age,B3,Total,540
9657,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),age,age,B1,Supportive Arm,0
9658,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),age,age,B2,HCQ Arm,0
9659,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),age,age,B3,Total,0
9660,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,Supportive Arm,10
9661,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B2,HCQ Arm,24
9662,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B3,Total,34
9663,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,Supportive Arm,170
9664,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B2,HCQ Arm,336
9665,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B3,Total,506
9666,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Supportive Arm,180
9667,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,HCQ Arm,360
9668,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Total,540
9669,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",milestone,milestone,P1,Control Group,180
9670,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",milestone,milestone,P2,Intervention Group,360
9671,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",milestone,milestone,P1,Control Group,151
9672,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",milestone,milestone,P2,Intervention Group,349
9673,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",milestone,milestone,P1,Control Group,29
9674,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",milestone,milestone,P2,Intervention Group,11
9675,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",withdrawal reason,withdrawal reason,P1,Control Group,10
9676,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",withdrawal reason,withdrawal reason,P2,Intervention Group,5
9677,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",withdrawal reason,withdrawal reason,P1,Control Group,4
9678,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",withdrawal reason,withdrawal reason,P2,Intervention Group,1
9679,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",withdrawal reason,withdrawal reason,P1,Control Group,11
9680,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",withdrawal reason,withdrawal reason,P2,Intervention Group,2
9681,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",withdrawal reason,withdrawal reason,P1,Control Group,4
9682,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",withdrawal reason,withdrawal reason,P2,Intervention Group,3
9683,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",age,age,B1,Supportive Arm,0
9684,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",age,age,B2,HCQ Arm,0
9685,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",age,age,B3,Total,0
9686,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",age,age,B1,Supportive Arm,180
9687,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",age,age,B2,HCQ Arm,360
9688,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",age,age,B3,Total,540
9689,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",age,age,B1,Supportive Arm,0
9690,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",age,age,B2,HCQ Arm,0
9691,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",age,age,B3,Total,0
9692,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.","sex: female, male","sex: female, male",B1,Supportive Arm,10
9693,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.","sex: female, male","sex: female, male",B2,HCQ Arm,24
9694,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.","sex: female, male","sex: female, male",B3,Total,34
9695,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.","sex: female, male","sex: female, male",B1,Supportive Arm,170
9696,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.","sex: female, male","sex: female, male",B2,HCQ Arm,336
9697,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.","sex: female, male","sex: female, male",B3,Total,506
9698,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",enrollment region,enrollment region,B1,Supportive Arm,180
9699,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",enrollment region,enrollment region,B2,HCQ Arm,360
9700,22,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Interventional,study_design_info,masking_description,"Neither patients, nor investigators, nor statisticians were masked to treatment assignment. Lab staff who performed sampling for PCR, basic blood tests and other routine measurement were unaware of treatment information.",enrollment region,enrollment region,B3,Total,540
9701,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,gender,All,milestone,milestone,P1,Ivermectin and Doxycycline,200
9702,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,gender,All,milestone,milestone,P2,Placebo,200
9703,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,gender,All,milestone,milestone,P1,Ivermectin and Doxycycline,183
9704,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,gender,All,milestone,milestone,P2,Placebo,180
9705,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,gender,All,milestone,milestone,P1,Ivermectin and Doxycycline,17
9706,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,gender,All,milestone,milestone,P2,Placebo,20
9707,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,15
9708,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Placebo,17
9709,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,0
9710,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Placebo,3
9711,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,2
9712,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Placebo,0
9713,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Ivermectin and Doxycycline,77
9714,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Placebo,88
9715,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,165
9716,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Ivermectin and Doxycycline,123
9717,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Placebo,112
9718,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,235
9719,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Ivermectin and Doxycycline,200
9720,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Placebo,200
9721,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Ivermectin and Doxycycline,183
9722,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Placebo,180
9723,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Ivermectin and Doxycycline,17
9724,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Placebo,20
9725,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,15
9726,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Placebo,17
9727,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,0
9728,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Placebo,3
9729,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,2
9730,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Placebo,0
9731,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Ivermectin and Doxycycline,77
9732,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Placebo,88
9733,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,165
9734,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Ivermectin and Doxycycline,123
9735,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Placebo,112
9736,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,235
9737,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Ivermectin and Doxycycline,200
9738,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Placebo,200
9739,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Ivermectin and Doxycycline,183
9740,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Placebo,180
9741,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Ivermectin and Doxycycline,17
9742,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Placebo,20
9743,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,15
9744,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Placebo,17
9745,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,0
9746,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Placebo,3
9747,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,2
9748,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Placebo,0
9749,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Ivermectin and Doxycycline,77
9750,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Placebo,88
9751,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Total,165
9752,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Ivermectin and Doxycycline,123
9753,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Placebo,112
9754,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Total,235
9755,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Ivermectin and Doxycycline,200
9756,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Placebo,200
9757,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Ivermectin and Doxycycline,183
9758,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Placebo,180
9759,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Ivermectin and Doxycycline,17
9760,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Placebo,20
9761,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,15
9762,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Placebo,17
9763,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,0
9764,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Placebo,3
9765,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,2
9766,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Placebo,0
9767,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Ivermectin and Doxycycline,77
9768,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Placebo,88
9769,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Total,165
9770,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Ivermectin and Doxycycline,123
9771,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Placebo,112
9772,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Total,235
9773,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Ivermectin and Doxycycline,200
9774,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Placebo,200
9775,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Ivermectin and Doxycycline,183
9776,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Placebo,180
9777,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Ivermectin and Doxycycline,17
9778,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Placebo,20
9779,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,15
9780,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Placebo,17
9781,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,0
9782,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Placebo,3
9783,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,2
9784,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Placebo,0
9785,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Ivermectin and Doxycycline,77
9786,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Placebo,88
9787,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,165
9788,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Ivermectin and Doxycycline,123
9789,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Placebo,112
9790,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,235
9791,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Ivermectin and Doxycycline,200
9792,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Placebo,200
9793,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Ivermectin and Doxycycline,183
9794,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Placebo,180
9795,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Ivermectin and Doxycycline,17
9796,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Placebo,20
9797,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,15
9798,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Placebo,17
9799,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,0
9800,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Placebo,3
9801,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,2
9802,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Placebo,0
9803,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Ivermectin and Doxycycline,77
9804,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Placebo,88
9805,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Total,165
9806,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Ivermectin and Doxycycline,123
9807,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Placebo,112
9808,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Total,235
9809,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model_description,Patient will be randomized 1:1 to placaebo with standard care and combined doxycycline and ivermectin with standard care.,milestone,milestone,P1,Ivermectin and Doxycycline,200
9810,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model_description,Patient will be randomized 1:1 to placaebo with standard care and combined doxycycline and ivermectin with standard care.,milestone,milestone,P2,Placebo,200
9811,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model_description,Patient will be randomized 1:1 to placaebo with standard care and combined doxycycline and ivermectin with standard care.,milestone,milestone,P1,Ivermectin and Doxycycline,183
9812,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model_description,Patient will be randomized 1:1 to placaebo with standard care and combined doxycycline and ivermectin with standard care.,milestone,milestone,P2,Placebo,180
9813,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model_description,Patient will be randomized 1:1 to placaebo with standard care and combined doxycycline and ivermectin with standard care.,milestone,milestone,P1,Ivermectin and Doxycycline,17
9814,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model_description,Patient will be randomized 1:1 to placaebo with standard care and combined doxycycline and ivermectin with standard care.,milestone,milestone,P2,Placebo,20
9815,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model_description,Patient will be randomized 1:1 to placaebo with standard care and combined doxycycline and ivermectin with standard care.,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,15
9816,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model_description,Patient will be randomized 1:1 to placaebo with standard care and combined doxycycline and ivermectin with standard care.,withdrawal reason,withdrawal reason,P2,Placebo,17
9817,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model_description,Patient will be randomized 1:1 to placaebo with standard care and combined doxycycline and ivermectin with standard care.,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,0
9818,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model_description,Patient will be randomized 1:1 to placaebo with standard care and combined doxycycline and ivermectin with standard care.,withdrawal reason,withdrawal reason,P2,Placebo,3
9819,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model_description,Patient will be randomized 1:1 to placaebo with standard care and combined doxycycline and ivermectin with standard care.,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,2
9820,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model_description,Patient will be randomized 1:1 to placaebo with standard care and combined doxycycline and ivermectin with standard care.,withdrawal reason,withdrawal reason,P2,Placebo,0
9821,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model_description,Patient will be randomized 1:1 to placaebo with standard care and combined doxycycline and ivermectin with standard care.,"sex: female, male","sex: female, male",B1,Ivermectin and Doxycycline,77
9822,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model_description,Patient will be randomized 1:1 to placaebo with standard care and combined doxycycline and ivermectin with standard care.,"sex: female, male","sex: female, male",B2,Placebo,88
9823,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model_description,Patient will be randomized 1:1 to placaebo with standard care and combined doxycycline and ivermectin with standard care.,"sex: female, male","sex: female, male",B3,Total,165
9824,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model_description,Patient will be randomized 1:1 to placaebo with standard care and combined doxycycline and ivermectin with standard care.,"sex: female, male","sex: female, male",B1,Ivermectin and Doxycycline,123
9825,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model_description,Patient will be randomized 1:1 to placaebo with standard care and combined doxycycline and ivermectin with standard care.,"sex: female, male","sex: female, male",B2,Placebo,112
9826,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,intervention_model_description,Patient will be randomized 1:1 to placaebo with standard care and combined doxycycline and ivermectin with standard care.,"sex: female, male","sex: female, male",B3,Total,235
9827,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Ivermectin and Doxycycline,200
9828,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Placebo,200
9829,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Ivermectin and Doxycycline,183
9830,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Placebo,180
9831,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Ivermectin and Doxycycline,17
9832,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Placebo,20
9833,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,15
9834,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Placebo,17
9835,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,0
9836,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Placebo,3
9837,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,2
9838,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Placebo,0
9839,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Ivermectin and Doxycycline,77
9840,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Placebo,88
9841,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Total,165
9842,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Ivermectin and Doxycycline,123
9843,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Placebo,112
9844,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Total,235
9845,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P1,Ivermectin and Doxycycline,200
9846,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P2,Placebo,200
9847,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P1,Ivermectin and Doxycycline,183
9848,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P2,Placebo,180
9849,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P1,Ivermectin and Doxycycline,17
9850,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking,"Double (Participant, Investigator)",milestone,milestone,P2,Placebo,20
9851,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking,"Double (Participant, Investigator)",withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,15
9852,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking,"Double (Participant, Investigator)",withdrawal reason,withdrawal reason,P2,Placebo,17
9853,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking,"Double (Participant, Investigator)",withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,0
9854,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking,"Double (Participant, Investigator)",withdrawal reason,withdrawal reason,P2,Placebo,3
9855,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking,"Double (Participant, Investigator)",withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,2
9856,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking,"Double (Participant, Investigator)",withdrawal reason,withdrawal reason,P2,Placebo,0
9857,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B1,Ivermectin and Doxycycline,77
9858,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B2,Placebo,88
9859,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B3,Total,165
9860,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B1,Ivermectin and Doxycycline,123
9861,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B2,Placebo,112
9862,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking,"Double (Participant, Investigator)","sex: female, male","sex: female, male",B3,Total,235
9863,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking_description,Double blind (The participant and the clinicians/data collectors will be unaware of the treatment the participant receives).The drugs will be labelled with a random code number,milestone,milestone,P1,Ivermectin and Doxycycline,200
9864,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking_description,Double blind (The participant and the clinicians/data collectors will be unaware of the treatment the participant receives).The drugs will be labelled with a random code number,milestone,milestone,P2,Placebo,200
9865,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking_description,Double blind (The participant and the clinicians/data collectors will be unaware of the treatment the participant receives).The drugs will be labelled with a random code number,milestone,milestone,P1,Ivermectin and Doxycycline,183
9866,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking_description,Double blind (The participant and the clinicians/data collectors will be unaware of the treatment the participant receives).The drugs will be labelled with a random code number,milestone,milestone,P2,Placebo,180
9867,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking_description,Double blind (The participant and the clinicians/data collectors will be unaware of the treatment the participant receives).The drugs will be labelled with a random code number,milestone,milestone,P1,Ivermectin and Doxycycline,17
9868,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking_description,Double blind (The participant and the clinicians/data collectors will be unaware of the treatment the participant receives).The drugs will be labelled with a random code number,milestone,milestone,P2,Placebo,20
9869,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking_description,Double blind (The participant and the clinicians/data collectors will be unaware of the treatment the participant receives).The drugs will be labelled with a random code number,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,15
9870,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking_description,Double blind (The participant and the clinicians/data collectors will be unaware of the treatment the participant receives).The drugs will be labelled with a random code number,withdrawal reason,withdrawal reason,P2,Placebo,17
9871,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking_description,Double blind (The participant and the clinicians/data collectors will be unaware of the treatment the participant receives).The drugs will be labelled with a random code number,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,0
9872,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking_description,Double blind (The participant and the clinicians/data collectors will be unaware of the treatment the participant receives).The drugs will be labelled with a random code number,withdrawal reason,withdrawal reason,P2,Placebo,3
9873,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking_description,Double blind (The participant and the clinicians/data collectors will be unaware of the treatment the participant receives).The drugs will be labelled with a random code number,withdrawal reason,withdrawal reason,P1,Ivermectin and Doxycycline,2
9874,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking_description,Double blind (The participant and the clinicians/data collectors will be unaware of the treatment the participant receives).The drugs will be labelled with a random code number,withdrawal reason,withdrawal reason,P2,Placebo,0
9875,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking_description,Double blind (The participant and the clinicians/data collectors will be unaware of the treatment the participant receives).The drugs will be labelled with a random code number,"sex: female, male","sex: female, male",B1,Ivermectin and Doxycycline,77
9876,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking_description,Double blind (The participant and the clinicians/data collectors will be unaware of the treatment the participant receives).The drugs will be labelled with a random code number,"sex: female, male","sex: female, male",B2,Placebo,88
9877,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking_description,Double blind (The participant and the clinicians/data collectors will be unaware of the treatment the participant receives).The drugs will be labelled with a random code number,"sex: female, male","sex: female, male",B3,Total,165
9878,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking_description,Double blind (The participant and the clinicians/data collectors will be unaware of the treatment the participant receives).The drugs will be labelled with a random code number,"sex: female, male","sex: female, male",B1,Ivermectin and Doxycycline,123
9879,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking_description,Double blind (The participant and the clinicians/data collectors will be unaware of the treatment the participant receives).The drugs will be labelled with a random code number,"sex: female, male","sex: female, male",B2,Placebo,112
9880,23,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Interventional,study_design_info,masking_description,Double blind (The participant and the clinicians/data collectors will be unaware of the treatment the participant receives).The drugs will be labelled with a random code number,"sex: female, male","sex: female, male",B3,Total,235
9881,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",milestone,milestone,P1,Adult Patients Hospitalized With COVID-19,81
9882,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",milestone,milestone,P1,Adult Patients Hospitalized With COVID-19,81
9883,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",milestone,milestone,P1,Adult Patients Hospitalized With COVID-19,0
9884,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",age,age,B1,Adult Patients Hospitalized With COVID-19,0
9885,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",age,age,B1,Adult Patients Hospitalized With COVID-19,71
9886,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",age,age,B1,Adult Patients Hospitalized With COVID-19,10
9887,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B1,Adult Patients Hospitalized With COVID-19,44
9888,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ","sex: female, male","sex: female, male",B1,Adult Patients Hospitalized With COVID-19,37
9889,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9890,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9891,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9892,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,4
9893,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,77
9894,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9895,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9896,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",enrollment region,enrollment region,B1,Adult Patients Hospitalized With COVID-19,10
9897,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",enrollment region,enrollment region,B1,Adult Patients Hospitalized With COVID-19,71
9898,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",baseline severity according to the national early warning score (news score),baseline severity according to the national early warning score (news score),B1,Adult Patients Hospitalized With COVID-19,30
9899,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",baseline severity according to the national early warning score (news score),baseline severity according to the national early warning score (news score),B1,Adult Patients Hospitalized With COVID-19,28
9900,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",baseline severity according to the national early warning score (news score),baseline severity according to the national early warning score (news score),B1,Adult Patients Hospitalized With COVID-19,23
9901,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,14
9902,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,25
9903,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,25
9904,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,17
9905,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",mechanical ventilation,mechanical ventilation,B1,Adult Patients Hospitalized With COVID-19,39
9906,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,study_pop,"
      ",mechanical ventilation,mechanical ventilation,B1,Adult Patients Hospitalized With COVID-19,42
9907,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P1,Adult Patients Hospitalized With COVID-19,81
9908,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P1,Adult Patients Hospitalized With COVID-19,81
9909,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,milestone,milestone,P1,Adult Patients Hospitalized With COVID-19,0
9910,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,age,age,B1,Adult Patients Hospitalized With COVID-19,0
9911,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,age,age,B1,Adult Patients Hospitalized With COVID-19,71
9912,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,age,age,B1,Adult Patients Hospitalized With COVID-19,10
9913,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B1,Adult Patients Hospitalized With COVID-19,44
9914,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,"sex: female, male","sex: female, male",B1,Adult Patients Hospitalized With COVID-19,37
9915,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9916,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9917,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9918,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,4
9919,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,77
9920,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9921,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9922,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,enrollment region,enrollment region,B1,Adult Patients Hospitalized With COVID-19,10
9923,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,enrollment region,enrollment region,B1,Adult Patients Hospitalized With COVID-19,71
9924,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,baseline severity according to the national early warning score (news score),baseline severity according to the national early warning score (news score),B1,Adult Patients Hospitalized With COVID-19,30
9925,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,baseline severity according to the national early warning score (news score),baseline severity according to the national early warning score (news score),B1,Adult Patients Hospitalized With COVID-19,28
9926,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,baseline severity according to the national early warning score (news score),baseline severity according to the national early warning score (news score),B1,Adult Patients Hospitalized With COVID-19,23
9927,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,14
9928,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,25
9929,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,25
9930,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,17
9931,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,mechanical ventilation,mechanical ventilation,B1,Adult Patients Hospitalized With COVID-19,39
9932,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,sampling_method,Non-Probability Sample,mechanical ventilation,mechanical ventilation,B1,Adult Patients Hospitalized With COVID-19,42
9933,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,milestone,milestone,P1,Adult Patients Hospitalized With COVID-19,81
9934,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,milestone,milestone,P1,Adult Patients Hospitalized With COVID-19,81
9935,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,milestone,milestone,P1,Adult Patients Hospitalized With COVID-19,0
9936,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,age,age,B1,Adult Patients Hospitalized With COVID-19,0
9937,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,age,age,B1,Adult Patients Hospitalized With COVID-19,71
9938,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,age,age,B1,Adult Patients Hospitalized With COVID-19,10
9939,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Adult Patients Hospitalized With COVID-19,44
9940,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Adult Patients Hospitalized With COVID-19,37
9941,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9942,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9943,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9944,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,4
9945,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,77
9946,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9947,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9948,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,enrollment region,enrollment region,B1,Adult Patients Hospitalized With COVID-19,10
9949,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,enrollment region,enrollment region,B1,Adult Patients Hospitalized With COVID-19,71
9950,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,baseline severity according to the national early warning score (news score),baseline severity according to the national early warning score (news score),B1,Adult Patients Hospitalized With COVID-19,30
9951,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,baseline severity according to the national early warning score (news score),baseline severity according to the national early warning score (news score),B1,Adult Patients Hospitalized With COVID-19,28
9952,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,baseline severity according to the national early warning score (news score),baseline severity according to the national early warning score (news score),B1,Adult Patients Hospitalized With COVID-19,23
9953,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,14
9954,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,25
9955,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,25
9956,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,17
9957,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,mechanical ventilation,mechanical ventilation,B1,Adult Patients Hospitalized With COVID-19,39
9958,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,gender,All,mechanical ventilation,mechanical ventilation,B1,Adult Patients Hospitalized With COVID-19,42
9959,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,milestone,milestone,P1,Adult Patients Hospitalized With COVID-19,81
9960,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,milestone,milestone,P1,Adult Patients Hospitalized With COVID-19,81
9961,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,milestone,milestone,P1,Adult Patients Hospitalized With COVID-19,0
9962,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,age,age,B1,Adult Patients Hospitalized With COVID-19,0
9963,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,age,age,B1,Adult Patients Hospitalized With COVID-19,71
9964,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,age,age,B1,Adult Patients Hospitalized With COVID-19,10
9965,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Adult Patients Hospitalized With COVID-19,44
9966,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Adult Patients Hospitalized With COVID-19,37
9967,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9968,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9969,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9970,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,4
9971,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,77
9972,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9973,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9974,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,Adult Patients Hospitalized With COVID-19,10
9975,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,Adult Patients Hospitalized With COVID-19,71
9976,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,baseline severity according to the national early warning score (news score),baseline severity according to the national early warning score (news score),B1,Adult Patients Hospitalized With COVID-19,30
9977,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,baseline severity according to the national early warning score (news score),baseline severity according to the national early warning score (news score),B1,Adult Patients Hospitalized With COVID-19,28
9978,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,baseline severity according to the national early warning score (news score),baseline severity according to the national early warning score (news score),B1,Adult Patients Hospitalized With COVID-19,23
9979,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,14
9980,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,25
9981,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,25
9982,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,17
9983,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,mechanical ventilation,mechanical ventilation,B1,Adult Patients Hospitalized With COVID-19,39
9984,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,minimum_age,18 Years,mechanical ventilation,mechanical ventilation,B1,Adult Patients Hospitalized With COVID-19,42
9985,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,milestone,milestone,P1,Adult Patients Hospitalized With COVID-19,81
9986,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,milestone,milestone,P1,Adult Patients Hospitalized With COVID-19,81
9987,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,milestone,milestone,P1,Adult Patients Hospitalized With COVID-19,0
9988,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,age,age,B1,Adult Patients Hospitalized With COVID-19,0
9989,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,age,age,B1,Adult Patients Hospitalized With COVID-19,71
9990,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,age,age,B1,Adult Patients Hospitalized With COVID-19,10
9991,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Adult Patients Hospitalized With COVID-19,44
9992,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Adult Patients Hospitalized With COVID-19,37
9993,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9994,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9995,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9996,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,4
9997,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,77
9998,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
9999,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
10000,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Adult Patients Hospitalized With COVID-19,10
10001,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Adult Patients Hospitalized With COVID-19,71
10002,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,baseline severity according to the national early warning score (news score),baseline severity according to the national early warning score (news score),B1,Adult Patients Hospitalized With COVID-19,30
10003,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,baseline severity according to the national early warning score (news score),baseline severity according to the national early warning score (news score),B1,Adult Patients Hospitalized With COVID-19,28
10004,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,baseline severity according to the national early warning score (news score),baseline severity according to the national early warning score (news score),B1,Adult Patients Hospitalized With COVID-19,23
10005,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,14
10006,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,25
10007,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,25
10008,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,17
10009,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,mechanical ventilation,mechanical ventilation,B1,Adult Patients Hospitalized With COVID-19,39
10010,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,eligibility,maximum_age,N/A,mechanical ventilation,mechanical ventilation,B1,Adult Patients Hospitalized With COVID-19,42
10011,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,milestone,milestone,P1,Adult Patients Hospitalized With COVID-19,81
10012,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,milestone,milestone,P1,Adult Patients Hospitalized With COVID-19,81
10013,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,milestone,milestone,P1,Adult Patients Hospitalized With COVID-19,0
10014,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,age,age,B1,Adult Patients Hospitalized With COVID-19,0
10015,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,age,age,B1,Adult Patients Hospitalized With COVID-19,71
10016,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,age,age,B1,Adult Patients Hospitalized With COVID-19,10
10017,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B1,Adult Patients Hospitalized With COVID-19,44
10018,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,"sex: female, male","sex: female, male",B1,Adult Patients Hospitalized With COVID-19,37
10019,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
10020,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
10021,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
10022,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,4
10023,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,77
10024,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
10025,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
10026,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,enrollment region,enrollment region,B1,Adult Patients Hospitalized With COVID-19,10
10027,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,enrollment region,enrollment region,B1,Adult Patients Hospitalized With COVID-19,71
10028,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,baseline severity according to the national early warning score (news score),baseline severity according to the national early warning score (news score),B1,Adult Patients Hospitalized With COVID-19,30
10029,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,baseline severity according to the national early warning score (news score),baseline severity according to the national early warning score (news score),B1,Adult Patients Hospitalized With COVID-19,28
10030,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,baseline severity according to the national early warning score (news score),baseline severity according to the national early warning score (news score),B1,Adult Patients Hospitalized With COVID-19,23
10031,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,14
10032,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,25
10033,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,25
10034,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,17
10035,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,mechanical ventilation,mechanical ventilation,B1,Adult Patients Hospitalized With COVID-19,39
10036,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,observational_model,Cohort,mechanical ventilation,mechanical ventilation,B1,Adult Patients Hospitalized With COVID-19,42
10037,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,milestone,milestone,P1,Adult Patients Hospitalized With COVID-19,81
10038,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,milestone,milestone,P1,Adult Patients Hospitalized With COVID-19,81
10039,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,milestone,milestone,P1,Adult Patients Hospitalized With COVID-19,0
10040,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,age,age,B1,Adult Patients Hospitalized With COVID-19,0
10041,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,age,age,B1,Adult Patients Hospitalized With COVID-19,71
10042,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,age,age,B1,Adult Patients Hospitalized With COVID-19,10
10043,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B1,Adult Patients Hospitalized With COVID-19,44
10044,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,"sex: female, male","sex: female, male",B1,Adult Patients Hospitalized With COVID-19,37
10045,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
10046,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
10047,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
10048,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,4
10049,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,77
10050,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
10051,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,race (nih/omb),race (nih/omb),B1,Adult Patients Hospitalized With COVID-19,0
10052,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,enrollment region,enrollment region,B1,Adult Patients Hospitalized With COVID-19,10
10053,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,enrollment region,enrollment region,B1,Adult Patients Hospitalized With COVID-19,71
10054,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,baseline severity according to the national early warning score (news score),baseline severity according to the national early warning score (news score),B1,Adult Patients Hospitalized With COVID-19,30
10055,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,baseline severity according to the national early warning score (news score),baseline severity according to the national early warning score (news score),B1,Adult Patients Hospitalized With COVID-19,28
10056,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,baseline severity according to the national early warning score (news score),baseline severity according to the national early warning score (news score),B1,Adult Patients Hospitalized With COVID-19,23
10057,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,14
10058,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,25
10059,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,25
10060,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,respiratory support type,respiratory support type,B1,Adult Patients Hospitalized With COVID-19,17
10061,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,mechanical ventilation,mechanical ventilation,B1,Adult Patients Hospitalized With COVID-19,39
10062,24,Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19,Observational,study_design_info,time_perspective,Prospective,mechanical ventilation,mechanical ventilation,B1,Adult Patients Hospitalized With COVID-19,42
10063,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,gender,All,milestone,milestone,P1,Favipiravir (Areplivir),100
10064,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,gender,All,milestone,milestone,P2,Standard of Care,100
10065,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,gender,All,milestone,milestone,P1,Favipiravir (Areplivir),96
10066,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,gender,All,milestone,milestone,P2,Standard of Care,100
10067,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,gender,All,milestone,milestone,P1,Favipiravir (Areplivir),4
10068,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,gender,All,milestone,milestone,P2,Standard of Care,0
10069,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),2
10070,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Standard of Care,0
10071,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),1
10072,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Standard of Care,0
10073,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),1
10074,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Standard of Care,0
10075,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Favipiravir (Areplivir),49
10076,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Standard of Care,54
10077,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,103
10078,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Favipiravir (Areplivir),51
10079,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Standard of Care,46
10080,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,97
10081,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Favipiravir (Areplivir),100
10082,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Standard of Care,100
10083,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Total,200
10084,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Favipiravir (Areplivir),100
10085,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Standard of Care,100
10086,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Favipiravir (Areplivir),96
10087,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Standard of Care,100
10088,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Favipiravir (Areplivir),4
10089,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Standard of Care,0
10090,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),2
10091,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Standard of Care,0
10092,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),1
10093,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Standard of Care,0
10094,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),1
10095,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Standard of Care,0
10096,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Favipiravir (Areplivir),49
10097,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Standard of Care,54
10098,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,103
10099,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Favipiravir (Areplivir),51
10100,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Standard of Care,46
10101,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,97
10102,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,Favipiravir (Areplivir),100
10103,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B2,Standard of Care,100
10104,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B3,Total,200
10105,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,maximum_age,80 Years,milestone,milestone,P1,Favipiravir (Areplivir),100
10106,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,maximum_age,80 Years,milestone,milestone,P2,Standard of Care,100
10107,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,maximum_age,80 Years,milestone,milestone,P1,Favipiravir (Areplivir),96
10108,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,maximum_age,80 Years,milestone,milestone,P2,Standard of Care,100
10109,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,maximum_age,80 Years,milestone,milestone,P1,Favipiravir (Areplivir),4
10110,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,maximum_age,80 Years,milestone,milestone,P2,Standard of Care,0
10111,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,maximum_age,80 Years,withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),2
10112,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,maximum_age,80 Years,withdrawal reason,withdrawal reason,P2,Standard of Care,0
10113,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,maximum_age,80 Years,withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),1
10114,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,maximum_age,80 Years,withdrawal reason,withdrawal reason,P2,Standard of Care,0
10115,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,maximum_age,80 Years,withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),1
10116,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,maximum_age,80 Years,withdrawal reason,withdrawal reason,P2,Standard of Care,0
10117,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,maximum_age,80 Years,"sex: female, male","sex: female, male",B1,Favipiravir (Areplivir),49
10118,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,maximum_age,80 Years,"sex: female, male","sex: female, male",B2,Standard of Care,54
10119,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,maximum_age,80 Years,"sex: female, male","sex: female, male",B3,Total,103
10120,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,maximum_age,80 Years,"sex: female, male","sex: female, male",B1,Favipiravir (Areplivir),51
10121,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,maximum_age,80 Years,"sex: female, male","sex: female, male",B2,Standard of Care,46
10122,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,maximum_age,80 Years,"sex: female, male","sex: female, male",B3,Total,97
10123,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,maximum_age,80 Years,enrollment region,enrollment region,B1,Favipiravir (Areplivir),100
10124,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,maximum_age,80 Years,enrollment region,enrollment region,B2,Standard of Care,100
10125,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,maximum_age,80 Years,enrollment region,enrollment region,B3,Total,200
10126,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Favipiravir (Areplivir),100
10127,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Standard of Care,100
10128,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Favipiravir (Areplivir),96
10129,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Standard of Care,100
10130,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P1,Favipiravir (Areplivir),4
10131,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,healthy_volunteers,No,milestone,milestone,P2,Standard of Care,0
10132,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),2
10133,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Standard of Care,0
10134,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),1
10135,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Standard of Care,0
10136,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),1
10137,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,healthy_volunteers,No,withdrawal reason,withdrawal reason,P2,Standard of Care,0
10138,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Favipiravir (Areplivir),49
10139,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Standard of Care,54
10140,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Total,103
10141,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B1,Favipiravir (Areplivir),51
10142,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B2,Standard of Care,46
10143,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,healthy_volunteers,No,"sex: female, male","sex: female, male",B3,Total,97
10144,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B1,Favipiravir (Areplivir),100
10145,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B2,Standard of Care,100
10146,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,eligibility,healthy_volunteers,No,enrollment region,enrollment region,B3,Total,200
10147,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Favipiravir (Areplivir),100
10148,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Standard of Care,100
10149,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Favipiravir (Areplivir),96
10150,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Standard of Care,100
10151,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Favipiravir (Areplivir),4
10152,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Standard of Care,0
10153,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),2
10154,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Standard of Care,0
10155,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),1
10156,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Standard of Care,0
10157,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),1
10158,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Standard of Care,0
10159,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Favipiravir (Areplivir),49
10160,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Standard of Care,54
10161,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,103
10162,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Favipiravir (Areplivir),51
10163,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Standard of Care,46
10164,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,97
10165,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Favipiravir (Areplivir),100
10166,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Standard of Care,100
10167,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Total,200
10168,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Favipiravir (Areplivir),100
10169,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Standard of Care,100
10170,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Favipiravir (Areplivir),96
10171,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Standard of Care,100
10172,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Favipiravir (Areplivir),4
10173,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Standard of Care,0
10174,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),2
10175,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Standard of Care,0
10176,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),1
10177,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Standard of Care,0
10178,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),1
10179,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Standard of Care,0
10180,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Favipiravir (Areplivir),49
10181,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Standard of Care,54
10182,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Total,103
10183,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Favipiravir (Areplivir),51
10184,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Standard of Care,46
10185,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Total,97
10186,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Favipiravir (Areplivir),100
10187,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Standard of Care,100
10188,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Total,200
10189,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Favipiravir (Areplivir),100
10190,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Standard of Care,100
10191,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Favipiravir (Areplivir),96
10192,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Standard of Care,100
10193,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Favipiravir (Areplivir),4
10194,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Standard of Care,0
10195,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),2
10196,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Standard of Care,0
10197,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),1
10198,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Standard of Care,0
10199,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),1
10200,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Standard of Care,0
10201,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Favipiravir (Areplivir),49
10202,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Standard of Care,54
10203,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Total,103
10204,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Favipiravir (Areplivir),51
10205,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Standard of Care,46
10206,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Total,97
10207,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Favipiravir (Areplivir),100
10208,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Standard of Care,100
10209,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Total,200
10210,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Favipiravir (Areplivir),100
10211,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,Standard of Care,100
10212,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Favipiravir (Areplivir),96
10213,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,Standard of Care,100
10214,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Favipiravir (Areplivir),4
10215,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,Standard of Care,0
10216,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),2
10217,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Standard of Care,0
10218,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),1
10219,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Standard of Care,0
10220,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Favipiravir (Areplivir),1
10221,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Standard of Care,0
10222,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,Favipiravir (Areplivir),49
10223,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B2,Standard of Care,54
10224,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B3,Total,103
10225,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,Favipiravir (Areplivir),51
10226,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B2,Standard of Care,46
10227,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B3,Total,97
10228,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Favipiravir (Areplivir),100
10229,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Standard of Care,100
10230,25,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Total,200
10231,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,milestone,milestone,P1,Control Group,30
10232,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,milestone,milestone,P2,Study Group,36
10233,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,milestone,milestone,P1,Control Group,30
10234,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,milestone,milestone,P2,Study Group,30
10235,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,milestone,milestone,P1,Control Group,0
10236,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,milestone,milestone,P2,Study Group,6
10237,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Control Group,0
10238,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P2,Study Group,6
10239,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Control Group,11
10240,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Study Group,9
10241,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,20
10242,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Control Group,19
10243,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B2,Study Group,21
10244,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B3,Total,40
10245,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Control Group,0
10246,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Study Group,0
10247,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,0
10248,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Control Group,0
10249,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Study Group,0
10250,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,0
10251,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Control Group,0
10252,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Study Group,0
10253,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,0
10254,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Control Group,0
10255,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Study Group,0
10256,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,0
10257,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Control Group,0
10258,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Study Group,0
10259,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,0
10260,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Control Group,0
10261,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Study Group,0
10262,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,0
10263,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Control Group,30
10264,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B2,Study Group,30
10265,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B3,Total,60
10266,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Control Group,30
10267,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,enrollment region,enrollment region,B2,Study Group,30
10268,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,gender,All,enrollment region,enrollment region,B3,Total,60
10269,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Control Group,30
10270,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Study Group,36
10271,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Control Group,30
10272,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Study Group,30
10273,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P1,Control Group,0
10274,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,milestone,milestone,P2,Study Group,6
10275,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P1,Control Group,0
10276,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,withdrawal reason,withdrawal reason,P2,Study Group,6
10277,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Control Group,11
10278,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Study Group,9
10279,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,20
10280,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B1,Control Group,19
10281,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B2,Study Group,21
10282,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,"sex: female, male","sex: female, male",B3,Total,40
10283,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Control Group,0
10284,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Study Group,0
10285,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,0
10286,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Control Group,0
10287,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Study Group,0
10288,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,0
10289,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Control Group,0
10290,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Study Group,0
10291,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,0
10292,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Control Group,0
10293,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Study Group,0
10294,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,0
10295,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Control Group,0
10296,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Study Group,0
10297,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,0
10298,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Control Group,0
10299,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Study Group,0
10300,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,0
10301,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B1,Control Group,30
10302,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B2,Study Group,30
10303,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,race (nih/omb),race (nih/omb),B3,Total,60
10304,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B1,Control Group,30
10305,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B2,Study Group,30
10306,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,minimum_age,18 Years,enrollment region,enrollment region,B3,Total,60
10307,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Control Group,30
10308,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Study Group,36
10309,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Control Group,30
10310,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Study Group,30
10311,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Control Group,0
10312,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P2,Study Group,6
10313,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Control Group,0
10314,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P2,Study Group,6
10315,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Control Group,11
10316,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Study Group,9
10317,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Total,20
10318,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Control Group,19
10319,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B2,Study Group,21
10320,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B3,Total,40
10321,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Control Group,0
10322,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Study Group,0
10323,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Total,0
10324,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Control Group,0
10325,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Study Group,0
10326,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Total,0
10327,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Control Group,0
10328,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Study Group,0
10329,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Total,0
10330,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Control Group,0
10331,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Study Group,0
10332,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Total,0
10333,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Control Group,0
10334,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Study Group,0
10335,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Total,0
10336,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Control Group,0
10337,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Study Group,0
10338,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Total,0
10339,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Control Group,30
10340,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B2,Study Group,30
10341,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B3,Total,60
10342,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Control Group,30
10343,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B2,Study Group,30
10344,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B3,Total,60
10345,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,Control Group,30
10346,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P2,Study Group,36
10347,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,Control Group,30
10348,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P2,Study Group,30
10349,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,Control Group,0
10350,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P2,Study Group,6
10351,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P1,Control Group,0
10352,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P2,Study Group,6
10353,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B1,Control Group,11
10354,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B2,Study Group,9
10355,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B3,Total,20
10356,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B1,Control Group,19
10357,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B2,Study Group,21
10358,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B3,Total,40
10359,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,Control Group,0
10360,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B2,Study Group,0
10361,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B3,Total,0
10362,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,Control Group,0
10363,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B2,Study Group,0
10364,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B3,Total,0
10365,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,Control Group,0
10366,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B2,Study Group,0
10367,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B3,Total,0
10368,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,Control Group,0
10369,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B2,Study Group,0
10370,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B3,Total,0
10371,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,Control Group,0
10372,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B2,Study Group,0
10373,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B3,Total,0
10374,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,Control Group,0
10375,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B2,Study Group,0
10376,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B3,Total,0
10377,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,Control Group,30
10378,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B2,Study Group,30
10379,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B3,Total,60
10380,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,enrollment region,enrollment region,B1,Control Group,30
10381,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,enrollment region,enrollment region,B2,Study Group,30
10382,26,Ivermectin for Severe COVID-19 Management,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,enrollment region,enrollment region,B3,Total,60
10383,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Control Group,30
10384,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Study Group,36
10385,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Control Group,30
10386,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Study Group,30
10387,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P1,Control Group,0
10388,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,milestone,milestone,P2,Study Group,6
10389,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P1,Control Group,0
10390,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,withdrawal reason,withdrawal reason,P2,Study Group,6
10391,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Control Group,11
10392,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Study Group,9
10393,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,20
10394,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B1,Control Group,19
10395,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B2,Study Group,21
10396,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,"sex: female, male","sex: female, male",B3,Total,40
10397,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Control Group,0
10398,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Study Group,0
10399,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Total,0
10400,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Control Group,0
10401,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Study Group,0
10402,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Total,0
10403,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Control Group,0
10404,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Study Group,0
10405,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Total,0
10406,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Control Group,0
10407,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Study Group,0
10408,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Total,0
10409,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Control Group,0
10410,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Study Group,0
10411,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Total,0
10412,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Control Group,0
10413,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Study Group,0
10414,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Total,0
10415,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B1,Control Group,30
10416,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B2,Study Group,30
10417,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,race (nih/omb),race (nih/omb),B3,Total,60
10418,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B1,Control Group,30
10419,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B2,Study Group,30
10420,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,allocation,Randomized,enrollment region,enrollment region,B3,Total,60
10421,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Control Group,30
10422,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Study Group,36
10423,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Control Group,30
10424,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Study Group,30
10425,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P1,Control Group,0
10426,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,milestone,milestone,P2,Study Group,6
10427,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P1,Control Group,0
10428,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,withdrawal reason,withdrawal reason,P2,Study Group,6
10429,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Control Group,11
10430,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Study Group,9
10431,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Total,20
10432,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B1,Control Group,19
10433,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B2,Study Group,21
10434,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,"sex: female, male","sex: female, male",B3,Total,40
10435,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Control Group,0
10436,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Study Group,0
10437,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Total,0
10438,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Control Group,0
10439,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Study Group,0
10440,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Total,0
10441,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Control Group,0
10442,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Study Group,0
10443,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Total,0
10444,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Control Group,0
10445,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Study Group,0
10446,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Total,0
10447,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Control Group,0
10448,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Study Group,0
10449,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Total,0
10450,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Control Group,0
10451,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Study Group,0
10452,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Total,0
10453,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B1,Control Group,30
10454,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B2,Study Group,30
10455,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,race (nih/omb),race (nih/omb),B3,Total,60
10456,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B1,Control Group,30
10457,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B2,Study Group,30
10458,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model,Parallel Assignment,enrollment region,enrollment region,B3,Total,60
10459,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",milestone,milestone,P1,Control Group,30
10460,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",milestone,milestone,P2,Study Group,36
10461,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",milestone,milestone,P1,Control Group,30
10462,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",milestone,milestone,P2,Study Group,30
10463,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",milestone,milestone,P1,Control Group,0
10464,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",milestone,milestone,P2,Study Group,6
10465,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",withdrawal reason,withdrawal reason,P1,Control Group,0
10466,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",withdrawal reason,withdrawal reason,P2,Study Group,6
10467,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group","sex: female, male","sex: female, male",B1,Control Group,11
10468,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group","sex: female, male","sex: female, male",B2,Study Group,9
10469,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group","sex: female, male","sex: female, male",B3,Total,20
10470,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group","sex: female, male","sex: female, male",B1,Control Group,19
10471,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group","sex: female, male","sex: female, male",B2,Study Group,21
10472,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group","sex: female, male","sex: female, male",B3,Total,40
10473,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",race (nih/omb),race (nih/omb),B1,Control Group,0
10474,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",race (nih/omb),race (nih/omb),B2,Study Group,0
10475,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",race (nih/omb),race (nih/omb),B3,Total,0
10476,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",race (nih/omb),race (nih/omb),B1,Control Group,0
10477,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",race (nih/omb),race (nih/omb),B2,Study Group,0
10478,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",race (nih/omb),race (nih/omb),B3,Total,0
10479,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",race (nih/omb),race (nih/omb),B1,Control Group,0
10480,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",race (nih/omb),race (nih/omb),B2,Study Group,0
10481,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",race (nih/omb),race (nih/omb),B3,Total,0
10482,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",race (nih/omb),race (nih/omb),B1,Control Group,0
10483,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",race (nih/omb),race (nih/omb),B2,Study Group,0
10484,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",race (nih/omb),race (nih/omb),B3,Total,0
10485,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",race (nih/omb),race (nih/omb),B1,Control Group,0
10486,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",race (nih/omb),race (nih/omb),B2,Study Group,0
10487,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",race (nih/omb),race (nih/omb),B3,Total,0
10488,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",race (nih/omb),race (nih/omb),B1,Control Group,0
10489,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",race (nih/omb),race (nih/omb),B2,Study Group,0
10490,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",race (nih/omb),race (nih/omb),B3,Total,0
10491,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",race (nih/omb),race (nih/omb),B1,Control Group,30
10492,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",race (nih/omb),race (nih/omb),B2,Study Group,30
10493,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",race (nih/omb),race (nih/omb),B3,Total,60
10494,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",enrollment region,enrollment region,B1,Control Group,30
10495,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",enrollment region,enrollment region,B2,Study Group,30
10496,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,intervention_model_description,"Patients who were hospitalised with a pre-diagnosis of severe COVID-19 pneumonia and thereafter diagnosis of COVID-19 was also confirmed microbiologically with polymerase chain reaction (PCR) positivity in respiratory tract samples were included into the study. They were randomized to the study and control group, respectively. Single numbered patients were accepted as study group and double numbered patients as control group",enrollment region,enrollment region,B3,Total,60
10497,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Control Group,30
10498,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Study Group,36
10499,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Control Group,30
10500,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Study Group,30
10501,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P1,Control Group,0
10502,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,milestone,milestone,P2,Study Group,6
10503,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P1,Control Group,0
10504,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,withdrawal reason,withdrawal reason,P2,Study Group,6
10505,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Control Group,11
10506,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Study Group,9
10507,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Total,20
10508,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B1,Control Group,19
10509,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B2,Study Group,21
10510,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,"sex: female, male","sex: female, male",B3,Total,40
10511,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Control Group,0
10512,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Study Group,0
10513,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Total,0
10514,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Control Group,0
10515,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Study Group,0
10516,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Total,0
10517,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Control Group,0
10518,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Study Group,0
10519,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Total,0
10520,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Control Group,0
10521,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Study Group,0
10522,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Total,0
10523,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Control Group,0
10524,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Study Group,0
10525,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Total,0
10526,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Control Group,0
10527,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Study Group,0
10528,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Total,0
10529,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B1,Control Group,30
10530,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B2,Study Group,30
10531,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,race (nih/omb),race (nih/omb),B3,Total,60
10532,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B1,Control Group,30
10533,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B2,Study Group,30
10534,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,primary_purpose,Treatment,enrollment region,enrollment region,B3,Total,60
10535,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Control Group,30
10536,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,Study Group,36
10537,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Control Group,30
10538,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,Study Group,30
10539,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Control Group,0
10540,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P2,Study Group,6
10541,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Control Group,0
10542,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P2,Study Group,6
10543,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,Control Group,11
10544,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B2,Study Group,9
10545,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B3,Total,20
10546,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,Control Group,19
10547,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B2,Study Group,21
10548,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B3,Total,40
10549,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,Control Group,0
10550,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B2,Study Group,0
10551,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B3,Total,0
10552,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,Control Group,0
10553,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B2,Study Group,0
10554,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B3,Total,0
10555,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,Control Group,0
10556,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B2,Study Group,0
10557,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B3,Total,0
10558,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,Control Group,0
10559,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B2,Study Group,0
10560,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B3,Total,0
10561,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,Control Group,0
10562,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B2,Study Group,0
10563,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B3,Total,0
10564,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,Control Group,0
10565,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B2,Study Group,0
10566,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B3,Total,0
10567,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,Control Group,30
10568,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B2,Study Group,30
10569,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B3,Total,60
10570,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Control Group,30
10571,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B2,Study Group,30
10572,26,Ivermectin for Severe COVID-19 Management,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B3,Total,60
10573,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,gender,All,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,850
10574,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,gender,All,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,813
10575,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,gender,All,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,37
10576,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,gender,All,withdrawal reason,withdrawal reason,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,37
10577,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,gender,All,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10578,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,gender,All,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10579,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,gender,All,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10580,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,553
10581,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,gender,All,"sex: female, male","sex: female, male",B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,260
10582,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10583,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10584,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10585,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10586,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10587,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10588,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,gender,All,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10589,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,gender,All,enrollment region,enrollment region,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10590,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,minimum_age,23 Years,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,850
10591,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,minimum_age,23 Years,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,813
10592,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,minimum_age,23 Years,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,37
10593,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,minimum_age,23 Years,withdrawal reason,withdrawal reason,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,37
10594,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,minimum_age,23 Years,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10595,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,minimum_age,23 Years,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10596,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,minimum_age,23 Years,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10597,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,minimum_age,23 Years,"sex: female, male","sex: female, male",B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,553
10598,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,minimum_age,23 Years,"sex: female, male","sex: female, male",B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,260
10599,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,minimum_age,23 Years,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10600,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,minimum_age,23 Years,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10601,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,minimum_age,23 Years,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10602,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,minimum_age,23 Years,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10603,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,minimum_age,23 Years,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10604,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,minimum_age,23 Years,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10605,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,minimum_age,23 Years,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10606,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,minimum_age,23 Years,enrollment region,enrollment region,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10607,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,850
10608,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,813
10609,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,maximum_age,N/A,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,37
10610,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,maximum_age,N/A,withdrawal reason,withdrawal reason,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,37
10611,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,maximum_age,N/A,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10612,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,maximum_age,N/A,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10613,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,maximum_age,N/A,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10614,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,553
10615,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,maximum_age,N/A,"sex: female, male","sex: female, male",B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,260
10616,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10617,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10618,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10619,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10620,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10621,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10622,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,maximum_age,N/A,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10623,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,maximum_age,N/A,enrollment region,enrollment region,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10624,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,850
10625,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,813
10626,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,37
10627,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,withdrawal reason,withdrawal reason,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,37
10628,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10629,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10630,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10631,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,553
10632,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,"sex: female, male","sex: female, male",B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,260
10633,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10634,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10635,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10636,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10637,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10638,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10639,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10640,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,eligibility,healthy_volunteers,Accepts Healthy Volunteers,enrollment region,enrollment region,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10641,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,allocation,N/A,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,850
10642,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,allocation,N/A,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,813
10643,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,allocation,N/A,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,37
10644,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,allocation,N/A,withdrawal reason,withdrawal reason,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,37
10645,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,allocation,N/A,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10646,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,allocation,N/A,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10647,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,allocation,N/A,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10648,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,allocation,N/A,"sex: female, male","sex: female, male",B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,553
10649,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,allocation,N/A,"sex: female, male","sex: female, male",B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,260
10650,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,allocation,N/A,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10651,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,allocation,N/A,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10652,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,allocation,N/A,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10653,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,allocation,N/A,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10654,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,allocation,N/A,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10655,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,allocation,N/A,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10656,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,allocation,N/A,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10657,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,allocation,N/A,enrollment region,enrollment region,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10658,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model,Single Group Assignment,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,850
10659,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model,Single Group Assignment,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,813
10660,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model,Single Group Assignment,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,37
10661,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model,Single Group Assignment,withdrawal reason,withdrawal reason,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,37
10662,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model,Single Group Assignment,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10663,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model,Single Group Assignment,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10664,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model,Single Group Assignment,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10665,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model,Single Group Assignment,"sex: female, male","sex: female, male",B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,553
10666,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model,Single Group Assignment,"sex: female, male","sex: female, male",B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,260
10667,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model,Single Group Assignment,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10668,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model,Single Group Assignment,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10669,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model,Single Group Assignment,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10670,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model,Single Group Assignment,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10671,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model,Single Group Assignment,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10672,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model,Single Group Assignment,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10673,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model,Single Group Assignment,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10674,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model,Single Group Assignment,enrollment region,enrollment region,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10675,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model_description,Dental professionals,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,850
10676,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model_description,Dental professionals,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,813
10677,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model_description,Dental professionals,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,37
10678,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model_description,Dental professionals,withdrawal reason,withdrawal reason,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,37
10679,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model_description,Dental professionals,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10680,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model_description,Dental professionals,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10681,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model_description,Dental professionals,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10682,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model_description,Dental professionals,"sex: female, male","sex: female, male",B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,553
10683,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model_description,Dental professionals,"sex: female, male","sex: female, male",B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,260
10684,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model_description,Dental professionals,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10685,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model_description,Dental professionals,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10686,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model_description,Dental professionals,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10687,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model_description,Dental professionals,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10688,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model_description,Dental professionals,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10689,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model_description,Dental professionals,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10690,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model_description,Dental professionals,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10691,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,intervention_model_description,Dental professionals,enrollment region,enrollment region,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10692,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,850
10693,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,813
10694,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,primary_purpose,Other,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,37
10695,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,primary_purpose,Other,withdrawal reason,withdrawal reason,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,37
10696,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,primary_purpose,Other,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10697,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,primary_purpose,Other,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10698,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,primary_purpose,Other,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10699,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,553
10700,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,primary_purpose,Other,"sex: female, male","sex: female, male",B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,260
10701,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,primary_purpose,Other,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10702,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,primary_purpose,Other,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10703,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,primary_purpose,Other,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10704,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,primary_purpose,Other,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10705,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,primary_purpose,Other,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10706,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,primary_purpose,Other,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10707,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,primary_purpose,Other,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10708,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,primary_purpose,Other,enrollment region,enrollment region,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10709,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,850
10710,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,813
10711,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking,None (Open Label),milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,37
10712,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking,None (Open Label),withdrawal reason,withdrawal reason,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,37
10713,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking,None (Open Label),age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10714,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking,None (Open Label),age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10715,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking,None (Open Label),age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10716,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,553
10717,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking,None (Open Label),"sex: female, male","sex: female, male",B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,260
10718,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10719,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10720,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10721,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10722,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10723,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10724,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking,None (Open Label),race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10725,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking,None (Open Label),enrollment region,enrollment region,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10726,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking_description,Dental professionals working in public and university hospitals,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,850
10727,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking_description,Dental professionals working in public and university hospitals,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,813
10728,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking_description,Dental professionals working in public and university hospitals,milestone,milestone,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,37
10729,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking_description,Dental professionals working in public and university hospitals,withdrawal reason,withdrawal reason,P1,Analysing the Psychosocial Effects of COVID-19 Pandemic,37
10730,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking_description,Dental professionals working in public and university hospitals,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10731,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking_description,Dental professionals working in public and university hospitals,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10732,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking_description,Dental professionals working in public and university hospitals,age,age,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10733,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking_description,Dental professionals working in public and university hospitals,"sex: female, male","sex: female, male",B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,553
10734,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking_description,Dental professionals working in public and university hospitals,"sex: female, male","sex: female, male",B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,260
10735,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking_description,Dental professionals working in public and university hospitals,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10736,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking_description,Dental professionals working in public and university hospitals,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10737,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking_description,Dental professionals working in public and university hospitals,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10738,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking_description,Dental professionals working in public and university hospitals,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10739,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking_description,Dental professionals working in public and university hospitals,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
10740,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking_description,Dental professionals working in public and university hospitals,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10741,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking_description,Dental professionals working in public and university hospitals,race (nih/omb),race (nih/omb),B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,0
10742,27,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Interventional,study_design_info,masking_description,Dental professionals working in public and university hospitals,enrollment region,enrollment region,B1,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals,813
